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Introduction
The Primary Care Reimbursement Service (PCRS) 
supports the delivery of primary health care by providing 
reimbursement services to Primary Care Contractors 
(General Practitioners, Pharmacists, Dentists and 
Optometrists/Ophthalmologists), for the provision of health 
services to members of the public in their own community.
In 2009 over 2.69 million people used the services of Primary 
Care Contractors for which reimbursement was provided by 
the PCRS. Over 73 million transactions, with an associated 
expenditure of more than €2.642 billion, were processed 
by PCRS during the year. With the current national and 
international economic climate it is anticipated that demand 
on these services will continue to grow.
The Demand Led Schemes are the state funded General 
Practitioner, Pharmacy, Dental, Ophthalmic, and other 
special payments which account for approximately 18% of 
the HSE’s overall budget. The Schemes are – the General 
Medical Services (GMS) (i.e. Medical Cards/GP Visit Cards), 
Drugs Payment, Long Term Illness, Dental Treatment 
Services, European Economic Area, High Tech Drugs, 
Primary Childhood Immunisation, Health (Amendment) 
Act 1996, Methadone Treatment and HSE Community 
Ophthalmic Services.
In November 2009 the PCRS took over executive 
responsibility for the Demand Led Primary Care Schemes 
nationally. This new responsibility includes approval, 
review and reimbursement of all claims for services and 
refunds and overall responsibility for all associated budgets. 
While executive responsibility has transferred to PCRS, 
the transition and streamlining of the Schemes is taking 
place over a phased period so that the project can be 
continuously monitored and evaluated, and if required 
modified to deliver optimal results, for both the patients 
and the HSE.
Recent Trends
The current economic climate continues to present 
challenges for service moving forward. Expenditure budgets 
are being reduced and the number of people on the Live 
Register continues to grow, with associated increased uptake 
of the Demand Led Schemes.
Since January 2005 the number of eligible medical card 
holders has increased by some 322,833. The rate of increase 
has been particularly acute in this scheme in 2009, with an 
additional 126,440 eligible persons granted Medical Cards, 
an increase of 9.35% over 2008. As of 31st December 
2009, the total number of eligible Medical Card holders 
was 1,478,560, which is approximately 35% of the total 
population. There is also sustained growth in the number 
of Long Term Illness items claimed in 2009, up 8.02% 
against 2008.
Expenditure has also continued to grow, up by more than 
6.15% from 2008 to 2009 (€2.642 billion compared with 
€2.489 billion).
Outlook
The sharp growth in numbers eligible for services is 
expected to continue throughout 2010 and funding to 
meet this level of demand is not assured, resulting in a 
challenging environment for service providers in terms of 
both finance and human resources. Continued focus will 
be given to driving further efficiencies in order to address 
these challenges.
The specific Value for Money (VfM) projects set out 
previously to ensure continued efficiencies have moved 
apace during 2009 with the major project to centralise the 
processing of all Medical Cards being one of the primary 
focuses in this area.
In 2008, the Government introduced a new Medical Card 
Scheme for persons aged 70 years and over. The processing 
of applications under the new scheme was centralised to 
the national office at PCRS in January 2009.
Later on in the year the second phase of the centralisation 
project commenced. This phase involved transferring the 
processing of renewals and applications for medical cards 
from the North West Dublin and Dublin North Central 
Local Health Offices to the Central Office at the PCRS.
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The next phase of the project is to go live and process all 
new applications in the Central Office from a given date 
following a consultative process with staff representatives 
and in line with the recent agreement on pay and reform in 
the public service. This phase also includes the introduction 
of a national on-line Medical Card application process. 
Taking cognisance of the fact that this is a critical change 
project which must move ahead, there are many benefits 
accruing in the final phase, e.g. better customer service, full 
implementation on a given date will provide more clarity 
to all concerned (Clients, TDs, Primary Care Contractors, 
HSE staff etc.), will free up staff for redeployment to 
key frontline services more quickly, and will result in the 
provision of better Customer Relations Management 
services to the patient.
In the period since the central office started working on this 
project, a significant number of patient and staff friendly 
initiatives have been introduced. As the centralisation 
process continues, more initiatives will be introduced. 
The current initiatives will continue to be enhanced as 
we receive feedback and continue to engage closer with 
advocacy groups, staff and public representative and primary 
care contractors to provide improved services to patients 
in a more efficient way.
Significant progress has been made to date in this national 
project in providing an improved service to the public at 
less cost to the State. By the end of 2009 the centralised 
office at PCRS has, in addition to providing new customer 
focused initiatives and delivering all of its normal workload, 
processed over 68,681 Medical Card applications and 
reviews.
In addition to the changes introduced and the processing 
and making of payments on a national basis to General 
Practitioners, Pharmacists, Dentists and Optometrists/
Ophthalmologists, the PCRS continues to compile statistics 
and trend analyses which are provided to customers, the 
Government, stakeholders, members of the public and 
other areas within the HSE.
I would like to take this opportunity to once again thank 
everybody in the organisation for their important individual 
contribution and commitment, and their team efforts, in 
the delivery of these vital support services through a year in 
which significant change management was also taking place.
This dedication and commitment ultimately enables 
members of the public to access the health services that 
they need in their own community. I would also like to 
acknowledge the contribution of the Chief Executive 
Officer, the Directors and the support of the HSE Board 
throughout 2009.
The goodwill and co-operation received from all of our 
customers, General Practitioners, Pharmacists, Dentists and 
Optometrists/Ophthalmologists, is very much appreciated. 
I look forward to continuing to build on our success and 
striving to improve the services to our customers even 
further.
Patrick Burke 
Primary Care Reimbursement Service
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Almost all payments for services provided in the community 
by General Practitioners, Community Pharmacies, 
Dentists and Optometrists/Ophthalmologists are made 
by the Primary Care Reimbursement Service. Payments 
in the Year 2009 were in excess of €2.642bn. Estimated 
payments by the Primary Care Reimbursement Service 
for 2010 are €2.543bn
Claim data is processed and payments are made by the 
Primary Care Reimbursement Service under the following 
Schemes/Payment Arrangements:
General Medical Services (GMS)
Persons who are unable without undue hardship to arrange 
general practitioner medical and surgical services for 
themselves and their dependants.
Drugs, medicines and appliances supplied under the 
Scheme are provided through Community Pharmacies. 
In most cases the Doctor gives a completed prescription 
form to a person, who takes it to any pharmacy that has an 
agreement with the Health Service Executive to dispense 
GMS prescription forms. In rural areas the Doctor may 
dispense for those persons who opt to have their medicines 
dispensed by him/her. All GMS claims are processed and 
paid by the Primary Care Reimbursement Service. 
Drugs Payment Scheme (DPS)
Under the Drugs Payment Scheme persons who are 
ordinarily resident in the State and who do not have a 
current medical card can benefit – an individual or family 
has now to pay no more than €100 in a calendar month for 
approved drugs, medicines and appliances for themselves 
or their families. In order to benefit under this Scheme a 
person must register themselves and their dependants with 
their Local Health Office. Items currently reimbursable 
under the Drugs Payment Scheme are those listed on 
the HSE Website. Other items which were reimbursable 
under the DCS and Refund of Drugs Schemes continue, in 
certain circumstances, to be reimbursable under the Drugs 
Payment Scheme. DPS claims are processed and paid by 
the Primary Care Reimbursement Service. 
Long Term Illness Scheme (LTI)
On approval by the Health Service Executive persons 
who suffer from one or more of a schedule of illnesses are 
entitled to obtain, without charge, irrespective of income, 
necessary drugs/medicines and/or appliances under the 
LTI Scheme. All LTI claims are processed and paid by the 
Primary Care Reimbursement Service.
Dental Treatment Services Scheme (DTSS)
Under the Dental Treatment Services Scheme GMS 
eligible adults have access to a range of treatments and 
clinical procedures comprised of Routine Treatments and 
Full Upper and Lower Dentures. Routine Treatments are 
now available for all eligible persons. Dentists may also 
prescribe a range of medicines to eligible persons. All claims 
under the DTSS are processed and paid by the Primary 
Care Reimbursement Service. 
European Economic Area (EEA)
Residents from one of the other states of the European 
Economic Area, with established eligibility, who require 
emergency general practitioner services while on a temporary 
visit to the State are entitled to receive from a General 
Practitioner a GMS prescription form for necessary 
medication and to have such medication dispensed in a 
Pharmacy that has entered into an agreement with the 
Health Service Executive within the State. EEA claims 
are paid by the Primary Care Reimbursement Service. 
Community Based Services – Payment Arrangements
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High Tech Drugs (HTD)
Arrangements are in place for the supply and dispensing 
of High Tech medicines through Community Pharmacies. 
Such medicines are generally only prescribed or initiated 
in hospital and would include items such as anti-rejection 
drugs for transplant patients or medicines used in 
conjunction with chemotherapy or growth hormones. The 
medicines are purchased by the Health Service Executive 
and supplied through Community Pharmacies for which 
Pharmacists are paid a patient care fee: the cost of the 
medicines and patient care fees are paid by the Primary 
Care Reimbursement Service.
Primary Childhood Immunisation Scheme
A National Primary Childhood Immunisation Scheme 
provides for immunisation of the total child population with 
the aim of eliminating, as far as possible, such conditions 
as Diphtheria, Polio, Measles, Mumps, Rubella and more 
recently Meningococcal C Meningitis. Payments under 
this Scheme to Doctors in the Midland, Mid-Western, 
Southern and Western HSE Areas are made by the Primary 
Care Reimbursement Service.
Health (Amendment) Act 1996
Under the Health (Amendment) Act 1996 certain health 
services are made available without charge to persons 
who have contracted Hepatitis C directly or indirectly 
from the use of Human Immunoglobulin - Anti D or the 
receipt within the State of another blood product or blood 
transfusion. General Practitioner services, pharmaceutical 
services, dental services and optometric/ophthalmic services 
provided under the Act are paid for by the Primary Care 
Reimbursement Service.
Methadone Treatment Scheme
Methadone is prescribed and dispensed by Doctors and 
Pharmacists for approved clients under the Methadone 
Treatment Scheme – capitation fees payable to participating 
Doctors and Community Pharmacists and claims by 
pharmacies for the ingredient cost of the Methadone 
dispensed and the associated dispensing fees are processed 
and paid by the Primary Care Reimbursement Service.
Health Services Executive Community 
Ophthalmic Services Scheme (HSE-COS)
Under the Health Service Executive Community 
Ophthalmic Services Scheme, adult medical card holders 
and their dependants are entitled, free of charge, to eye 
examinations and necessary spectacles/appliances. Claims 
by Optometrists/Ophthalmologists are paid by the Primary 
Care Reimbursement Service. Claims for spectacles provided 
under the Children’s Scheme are also paid by the Primary 
Care Reimbursement Service.
Immunisations for certain GMS Eligible Persons
Agreement was reached between the Department of Health 
& Children and the Irish Medical Organisation on fee 
rates to be applied to certain immunisations for GMS 
eligible persons. The immunisations encompassed by the 
agreement are:- Pneumococcal, Influenza, Hepatitis B 
and the combined Pneumococcal/Influenza. The Health 
Service Executive facilitated claiming for any of these 
immunisations by extending the range of codes for ‘Special 
Items of Service’.
General Practitioner Visit Card (GPVC)
Certain people in Ireland who do not qualify for a medical 
card may apply to the Health Service Executive for a GP 
Visit Card. GP Visit Cards allow individuals and families 
who qualify, to visit their General Practitioner for free. All 
GP claims are processed and paid by the Primary Care 
Reimbursement Service.
Discretionary Hardship Arrangements
Medical Card patients, for whom Non GMS Reimbursable 
Items have been prescribed, may make application to the 
HSE Local Health Office (LHO) for approval to have such 
items dispensed by a Community Pharmacist. Previously, 
the LHO reimbursed Community Pharmacists directly in 
respect of such prescribed items. In July 2009 the payment 
function for these items transferred to the PCRS. 
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Summary Statement of Activity During the Year
l Payments in the Year were in excess of €2,642.99m.
l Claim data is processed and payments are made by 
the PCRS under the following Schemes:
n General Medical Services (GMS);
n Drugs Payment (DP); 
n Long Term Illness (LTI);
n Dental Treatment Services (DTS);
n European Economic Area (EEA);
n High Tech Drugs (HTD);
n Primary Childhood Immunisation;
n Health (Amendment) Act 1996;
n Methadone Treatment;
n Health Service Executive Community 
Ophthalmic Services (HSE-COS).
l At year end there were more than 3.29m persons 
registered as being eligible to benefit under the 
General Medical Services, Drugs Payment, Long 
Term Illness, Dental Treatment and Health Service 
Executive Community Ophthalmic Services Schemes.
l More than 94% of eligible GMS persons availed of 
GP, Pharmaceutical, Dental or Ophthalmic services 
provided by more than 6,418 Doctors, Pharmacists, 
Dentists and Optometrists/Ophthalmologists.
l More than 67m prescription items were paid for by 
the PCRS – an increase of over 2.3m items on 2008.
l Fees and allowances paid to Doctors totalled €499.67m.
l Payments to Pharmacies totalled €1,694.73m:
n GMS €1,260.24m;
n DP €263.47m;
n LTI €139.76m;
n EEA €1.96m;
n Patient Care Fees under the HTD Scheme 
€15.94m;
n The Health (Amendment) Act 1996, 
Methadone Treatment Scheme, DTS 
prescriptions and Pharmacy Training  
Grants €13.36m.
l Payments to Dentists under the DTS totalled  €86.83m.
l Payments to Optometrists/Ophthalmologists under 
the HSE-COS totalled €23.80m.
l Payments to Wholesalers under the HTD Scheme 
totalled €315.36m. 
l Administration costs in the accounting period of 2009 
were €19.72m.
l Claims processed are in respect of services provided 
in the community and availed of by almost 63.66% 
of the population.
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l Fees to Doctors include an amount of €9.84m in respect 
of the Primary Childhood Immunisation Scheme, 
€0.22m in respect of the Health (Amendment) Act 
1996, €6.03m in respect of the Methadone Treatment 
Scheme.
l Allowances paid to Doctors include an amount of 
€5.54m paid as superannuation to Retired District 
Medical Officers and their dependants.
l Payments to Pharmacists include an amount of €1.80m 
in respect of drugs/medicines dispensed under the 
Health (Amendment) Act 1996, an amount of €10.56m 
in respect of the cost of Methadone dispensed under 
the Methadone Treatment Scheme and an amount of 
€0.79m in respect of DTS prescriptions.
l Payments to Dentists include an amount of €62,114 in 
respect of treatments under the Health (Amendment) 
Act 1996.
l Payments to Optometrists/Ophthalmologists, include 
an amount of €72,238 in respect of treatments under 
the Health (Amendment) Act 1996.
l The corresponding figures for 2008 are:- 
n Total of Payments €2,489.38m.
n Doctors’ Fees €338.57m and Doctors’ 
Allowances €136.60m.
n Pharmacists’ Fees and Mark-Up €408.29m, 
Drugs and Medicines €1,204.96m.
n Payments to Dentists under the DTS Scheme 
were €65.42m.
n Payments to Optometrists/Opthalmologists 
€22.40m.
n Investment in General Practice Development 
was €4.60m.
n High Tech Drugs Scheme – Payment to 
Wholesalers €275.39m, Patient Care Fees 
€15.28m.
n Administration €17.87m.
The Year 2009
Doctors Fees  €357.80m 
 Allowances €141.87m
Pharmacists Fees and Mark-Up  €405.02m
 Drugs and Medicines €1,273.77m
Dentists   €86.83m
High Tech Drugs Scheme Payment to Wholesalers  €315.36m 
Patient Care Fees paid to Pharmacists €15.94m
Optometrists/Ophthalmologists  €23.80m
Administration  €19.72m
Investment in General Practice Development  €2.88m
Total of Payments for the year €2,642.99m
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Number of Agreements
Doctors 2,663 Pharmacists 1,630 Dentists  1,570 Optometrists 555
The number of agreements between The Health Service Executive and General Practitioners for the provision of services to GMS persons 
reflects the policy position agreed between the Department of Health & Children and the Irish Medical Organisation on entry to the GMS. 
In December 2009 there were 2,663 such agreements. 
Number of Agreements as at 31st December 2009
Health Service Executive Doctors Pharmacists Dentists Optometrists
East Coast Area 283 141 125 41
South West Area 343 203 189 76
Northern Area 298 189 160 50
Midland 151 100 76 46
Mid-Western 234 149 136 45
North Eastern 193 150 103 62
North Western 159 98 78 33
South Eastern 264 181 152 65
Southern 452 251 341 70
Western 286 168 210 67
National *2,663 #1,630 + 1,570 555 
Corresponding figures for 2008 2,599 1,620 1,349 535
*527 GPs who do not hold GMS agreements and who were registered as providing services under the Primary Childhood Immunisation Scheme, the Health 
(Amendment) Act 1996, Heartwatch and the Methadone Treatment Scheme at year end are included above.
#12 Pharmacies who do not hold GMS agreements and who were registered as providing services under non GMS schemes at year end are included above.
+188 Dentists who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
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Persons who are unable without undue hardship to arrange General 
Practitioner medical and surgical services plus dental and optometric 
services for themselves and their dependants are provided with 
such services free of charge under the GMS Scheme. An eligible 
person is entitled to select a Doctor of his/her choice, from among 
those Doctors who have entered into agreements with the Health 
Service Executive. Drugs, medicines and appliances prescribed by 
participating Doctors for their GMS patients are provided through 
Community Pharmacies. Dental and ophthalmic services are provided 
by Dentists and Optometrists/Ophthalmologists who have contracted 
with the Health Service Executive. GMS prescription forms may be 
dispensed in any Pharmacy that has an agreement with the Health 
Service Executive to dispense GMS prescription forms. In rural areas, 
where a Doctor has a centre of practice three miles or more from the 
nearest Community Pharmacy participating in the Scheme, the Doctor 
dispenses for those persons served from the centre who opt to have 
their medicines dispensed by him/her. The number of eligible GMS 
persons at year end included 44,839 persons who were entitled and 
had opted to have their medicines dispensed by their GPs.
Under the terms of the Drugs Payment Scheme persons who do not 
have a medical card may apply for a Drugs Payment Scheme card on 
an individual or on a family unit basis. Prescribed medicines, which are 
reimbursable under the GMS, costing in excess of a specified amount 
per month, currently €100 per family, is claimed by the Pharmacy and 
is paid by the Primary Care Reimbursement Service.
On approval by the Health Service Executive, persons who suffer from 
one or more of a schedule of illnesses are entitled to obtain, without 
charge, irrespective of income, necessary drugs/medicines and/or 
appliances under the LTI Scheme. The Primary Care Reimbursement 
Service makes payments on behalf of the Health Service Executive 
for LTI claims submitted by Pharmacies.
Persons Eligible for Services
GMS 1,478,560 GPVC 98,325 DP 1,587,448 LTI 127,636
Number of Eligible Persons as at 31st December 2009
Health Service Executive GMS GPVC DP LTI
Eastern Areas 408,060 18,052 539,188 63,906
Midland 95,925 6,543 101,708 7,453
Mid-Western 131,955 7,718 159,029 8,647
North Eastern 141,500 11,366 147,811 10,241
North Western 117,908 9,157 63,000 7,207
South Eastern 189,845 13,789 149,983 13,602
Southern 220,608 19,882 266,122 9,259
Western 172,759 11,818 160,607 7,321
National 1,478,560 98,325 1,587,448 127,636
% of Population 34.87% 2.32% 37.44% 3.01%
Corresponding figures for 2008 1,352,120 85,546 1,624,413 120,407
GMS – General Medical Services Scheme. GPVC – GP Visit Card Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme.
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Payments to Doctors
Payments to General Practitioners are categorised as fees and/or 
allowances. For the majority of GPs who operate under the 1989 
agreement the principle fee is the capitation per person which is weighted 
for gender, age and distance from a Doctor’s centre of practice – capitation 
fees totalled €225,954,778 in 2009 – a decrease of  €4,908,112 on 2008. 
Fees totalling €769,487 were paid to 10 GPs who continue to provide 
services under the Fee-Per-Item of service agreements.
Apart from ‘Out-of-Hours’ fees and fees for a range of special services 
the cost of services provided in normal hours by GPs for GMS persons, 
including the prescribing of necessary medicines, is encompassed by 
the capitation fee. All GMS persons can avail of full GP services and 
in many cases they can benefit from specialist clinics provided by GPs 
for issues such as Women’s Health, Family Planning and Asthma.
In addition to a capitation fee an outside normal hours fee is payable 
for non routine consultations when an eligible GMS person is seen 
by their GP or another GP acting on his/her behalf from 5pm in the 
evening to 9am on the following morning (Monday to Friday) and 
all hours on Saturdays, Sundays and Bank Holidays. The number of 
‘Out-of-Hours’ claims increased to 837,143 in 2009 compared with 
817,691 in 2008 – and the cost of such claims increased to €49,507,291 
from €46,401,447 in 2008. Special fees are payable for a range of 18 
services such as excisions, suturing, vaccinations, catheterization, family 
planning etc. The most frequent claimed special service in 2009 was 
Influenza Vaccination (349,890) followed by Excisions (103,183) and 
E.C.G. treatments (76,757) – there was a total of more than 713,658 
special services provided in 2009 – special fees totalling €28,653,853 
were paid in 2009.
Annual and Study Leave together with locum, nursing and secretarial 
support plus other practice support payments account for most of the 
€141,865,756 allowances paid in the year. The total paid in 2008 was 
€136,600,570.
Total of Payments to Doctors by Health Service Executive
Health Service Executive 2009
East Coast Area €30,608,922
South West Area €55,875,871
Northern Area €49,996,553
Midland €33,533,961
Mid-Western €43,749,789
North Eastern €45,304,954 
North Western €37,720,543 
South Eastern €61,771,075
Southern €81,990,163 
Western €59,113,528
National €499,665,359
Corresponding figure for 2008 €475,174,715
The total of payments to Doctors includes payments of: €9,844,411 under the Primary Childhood Immunisation Scheme; €217,499 to Doctors who provided 
services under the Health (Amendment) Act 1996; Heartwatch €1,538,150; National Cancer Screening Service €15,295,162 and €6,032,984 under the 
Methadone Treatment Scheme.
Total Payments accumulated by Regional Health Area
Dublin North East €95,301,507
Dublin Mid-Leinster €120,018,754
South €143,761,238
West €140,583,860
Fees €357.80m Allowances €141.87m
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Volume of Claims by Doctors
Fee-Per-Item 59,632
Special Type 261,884
Special Service 713,658
Out-of-Hours 837,143
National – Number of Claims – 2009
Number of Claims in each Health Service Executive Area
Health Service Executive Fee-Per-Item Special Type Special Service Out-of-Hours
East Coast Area - 11,630 44,013 32,706
South West Area 20,230 34,671 66,827 81,815
Northern Area 3,621 27,793 63,792 45,482
Midland - 22,184 50,157 68,574
Mid-Western 14,480 25,367 59,184 69,117
North Eastern - 16,317 58,436 10,169
North Western - 14,855 59,780 68,358
South Eastern 2,976 22,553 94,588 135,943
Southern 18,325 52,624 117,688 215,184
Western - 33,890 99,193 109,795
National 59,632 261,884 713,658 837,143
Corresponding figures for 2008 67,083 242,073 679,948 817,691
A majority of Doctors are paid an annual capitation fee for each eligible 
person – the rate of payment is determined by the age/gender of the 
person and distance between each person’s residence and the centre of 
practice of their Doctor-of-Choice. A minority of Doctors (10) who 
have continued to provide services under the Fee-Per-Item of Service 
agreement are paid a fee for each Doctor/Patient contact. 
A Special Type Consultation (STC) fee is payable when a GMS eligible 
person is unable to contact their registered Doctor and is seen as an 
emergency case by another. General Practitioners qualify for payment 
of ‘special fees’ for the special items of service separately identified 
under the Capitation agreement and the Fee-Per-Item agreement.
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Payments to Pharmacies 
Total of Payments to Pharmacies by Health Service Executive
Health Service Executive GMS € DP € LTI € *EEA €
East Coast Area 79,438,939 26,567,370 15,830,612 72,098
South Western Area 143,609,194 42,370,859 21,601,891 112,322
Northern Area 142,601,176 38,960,741 23,491,235 73,396
Midland 86,460,595 15,954,793 8,003,509 106,003
Mid-Western 115,957,501 20,067,259 8,608,387 231,847
North Eastern 108,692,171 21,739,038 12,947,603 139,049
North Western 80,798,442 8,722,729 8,994,083 242,507
South Eastern 163,291,281 25,373,805 14,174,555 199,920
Southern 201,087,419 40,040,494 16,577,276 433,731
Western 138,307,897 20,131,101 9,530,021 346,740
National 1,260,244,615 259,928,189 139,759,172 1,957,613
Corresponding figures for 2008 €1,145,291,632 €311,898,446 €137,898,995 €2,245,995
*EEA – Payment to Pharmacies to cover the cost of GMS prescriptions dispensed for residents from the European Economic Area.
Pharmacies were also paid in respect of the drugs/medicines dispensed under: Health (Amendment) Act 1996 – €1,801,926; Methadone Treatment Scheme – €10,558,156; DTS Scheme – €786,133; Pharmacy 
Training Grant – €213,110 and Patient Care Fees totalling €15,938,159 under the High Tech Drugs Scheme (Payments to Wholesalers under the High Tech Drugs Scheme amounted to €315,355,866).
Included in the above GMS figures is an amount of €3,684,770 which was was paid in respect of non GMS Reimbursable Items dispensed under Discretionary Hardship Arrangements.
In 2009 The National Maternity Hospital was paid €1,118,797 and The Rotunda Hospital was paid €2,427,120 in respect of Fertility Treatment. These figures are not included in the above table.
Total Payments accumulated by Regional Health Area
GMS € DP € LTI € *EEA €
Dublin North East 251,293,347 60,699,779 36,438,838 212,445
Dublin Mid-Leinster 309,508,728 84,893,022 45,436,012 290,423
South 364,378,700 65,414,299 30,751,831 633,651
West 335,063,840 48,921,089 27,132,491 821,094
GMS €1,260.24m DP €263.47m LTI €139.76m  EEA €1.96m
A GMS person who is provided with a properly completed GMS 
prescription form by his/her GP can choose to have such prescription 
forms dispensed in any of the Pharmacies who have entered into 
agreements with the Health Service Executive for the provision of 
services under Section 59 of the Health Act, 1970.
In 2009 there were 16.3m prescription forms containing over 50m 
prescription items dispensed at a cost of over €1,260,244,615 i.e. an 
average cost of €24.56 per dispensed item. More than 94% of all eligible 
GMS persons were prescribed for in the year. The average cost of 
medicines per GMS person in 2009 was €907.85.
Payments made to Pharmacies under the GMS and DTS Schemes are 
inclusive of the ingredient cost of medicines, dispensing fees and VAT.
Under DP, LTI and EEA Schemes Pharmacies are reimbursed the 
ingredient cost of items dispensed, dispensing fees, mark-up and VAT. 
For details please see page 28.
The cost of the High Tech Drugs Scheme was €331.29m – at year 
end there were 53,515 persons registered under this Scheme – Patient 
Care Fees totalled €15.94m and payments for drugs and medicines 
totalled €315.36m.
In the year the Health Service Executive processed claims valued at 
€441.93m on drugs acting on the ‘cardiovascular system’ (GMS €291.07, 
DP €120.97m and LTI €29.89m). The second highest cost category 
was drugs acting on the ‘nervous system’ €360.29m (GMS €268.53m, 
DP €72.28m, LTI €19.48m). The third highest amount paid was for 
drugs acting on the ‘alimentary tract and metabolism system’ €299.47m 
(GMS €194.94m, DP €65.56m, LTI €38.97m).
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Volume of Claims by Pharmacies
National – Number of Items – 2009
EEA 0.09m
HTD 0.36m
Other 0.43m
LTI 2.86m
DP 13.37m
GMS 50.72m
Number of Items in each Health Service Executive Area
Health Service Executive GMS DP LTI EEA HTD *Other
East Coast Area 3,252,646 1,370,170 309,292 3,069 31,387 38,819
South West Area 5,995,036 2,037,467 473,330 5,111 50,400 124,711
Northern Area 5,683,891 1,886,789 428,838 3,509 39,763 108,820
Midland 3,464,279 846,125 172,423 4,609 22,431 18,434
Mid-Western 4,783,532 1,080,867 188,257 10,139 29,475 23,093
North Eastern 4,423,611 1,172,765 265,117 5,407 29,703 23,304
North Western 3,211,631 461,296 184,643 10,878 23,654 7,967
South Eastern 6,546,461 1,421,492 313,172 8,732 39,991 28,683
Southern 8,093,563 2,038,348 328,991 19,539 54,503 36,104
Western 5,267,269 1,057,206 191,298 14,527 36,058 23,366
National 50,721,919 13,372,525 2,855,361 85,520 357,365 433,301
Corresponding figures for 2008 48,211,863 13,907,438 2,643,424 91,822 315,256 395,697
* This group includes: 63,379 claim items in respect of the Health (Amendment) Act 1996; 259,486 items under the Methadone Treatment Scheme and 110,436 prescription items 
under the DTS Scheme.
GMS – General Medical Services Scheme. DP – Drugs Payment Scheme. LTI – Long Term Illness Scheme. EEA – European Economic Area. HTD – High Tech Drugs Scheme. 
Other – Methadone Treatment Scheme, Health (Amendment) Act 1996 and Dental Treatment Services Scheme.
GMS prescription forms processed for payment in the year totalled 
16.3m – the total of prescribed items was more than 50.7m – these 
accounted for approximately 74.78% of all items paid for by the Primary 
Care Reimbursement Service in 2009.
Approximately 38.08% of GMS forms contained a single item – more 
than 19.06% contained 2 items – the average number of items per form 
was 3.11 (2008 – 3.08).
GMS dispensed items paid for by the Primary Care Reimbursement 
Service in 2009 increased by more than 2,510,056 – the decrease in 
the number of DP items was less than 534,913 – the overall increase 
in the number of pharmacy claims processed by the Primary Care 
Reimbursement Service in the year was more than 2.3m.
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Payments to Dentists 
Dentists were paid a total of €86,772,492 in 2009, in respect of treatments 
provided for more than 343,067 GMS persons under the DTS Scheme.
The following treatments were available to all eligible GMS persons.
ROUTINE: Routine treatments are categorised as either ‘Above the 
Line’ or ‘Below the Line’;
 ‘Above the Line’ treatments are uncomplicated procedures 
viz. Amalgam; Extractions; 
 ‘Below the Line’ treatments are advanced procedures 
viz. Protracted Periodontal; Prosthetics.
‘Below the Line’ treatments – prior Health Service Executive approval 
for a specific course of treatment under this category is required.  Full 
denture treatment is available, with prior Health Service Executive 
approval, to all edentulous GMS persons over 16 years. 
Above the line €60.63m Below the line €26.15m
Payments to Dentists in each Health Service Executive Area
Health Service Executive 2009
Eastern Areas €22,497,276
Midland €5,611,711
Mid-Western €7,432,999
North Eastern €7,990,868
North Western €4,805,003
South Eastern €11,598,690
Southern €15,045,005 
Western €11,790,940
National €86,772,492
Corresponding figure for 2008 €65,364,364 
Dentists were also paid a total of €62,114 in 2009 in respect of treatments under the Health (Amendment) Act 1996.
Total Payments accumulated by Regional Health Area
Dublin North East €17,146,142
Dublin Mid-Leinster €18,953,713
South €26,643,695
West €24,028,942
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Volume of Claims by Dentists
National – Volume of Treatments – 2009
Above the Line  1,439,431
Below the Line 145,167
Volume of Treatments by Dentists in each Health Service Executive Area
Health Service Executive +Above the Line +Below the Line No. of persons treated 
under DTS
Eastern Areas 402,760 29,986 90,772
Midland 89,879 10,060 22,281
Mid-Western 119,984 15,466 30,997
North Eastern 127,435 14,711 30,330
North Western 84,965 6,108 22,219
South Eastern 177,103 23,680 43,678
Southern 258,768 24,635 60,277
Western 178,537 20,521 42,513
National 1,439,431 145,167 343,067
Corresponding figures for 2008 1,084,517 111,428 271,731
ROUTINE – Routine treatments are categorised as either ‘Above the Line’ or ‘Below the Line’:
 ‘Above the Line’ (ATL) treatments are uncomplicated procedures;
 ‘Below the Line’ (BTL) treatments are advanced procedures.
+ The most frequently used ATL service was Amalgam Restoration, which was used by 148,575 patients followed by Oral Examination.  In the BTL category the most 
frequently used service was Prosthetics followed by Protracted Periodontal and Radiographs.
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Payments to Optometrists/Ophthalmologists
Under the Health Service Executive Community Ophthalmic Services 
Scheme, Optometric/Ophthalmic services are provided to adult medical 
card holders, which include free eye examinations and necessary 
spectacles/appliances.
Payments in respect of spectacles provided under the Children’s Scheme 
are also made by the Primary Care Reimbursement Service on behalf 
of the majority of Health Service Executive Areas.
Payments in respect of eye examinations and necessary spectacles/
appliances are provided under the Teenager’s Scheme for eligible medical 
card holders on behalf of certain Health Service Executive Areas.
In the 12-month period to the end of December 2009 claims were 
received on behalf of 238,844 GMS persons for 564,606 treatments 
costing €22,184,541.
Eye examinations by Optometrists/Ophthalmologists totalled 242,336; 
complete spectacles (distance, reading and bi-focals) provided under the 
Scheme totalled 322,270. The balance of treatments included replacement 
lenses and frames, tinted lenses, prisms and contact lenses. A breakdown 
of treatments and payments in each Health Service Executive Area is 
shown hereunder.
Payments to Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive 2009
Eastern Areas €6,204,743
Midland €1,647,247
Mid-Western €2,111,555
North Eastern €1,553,308
North Western €1,638,602 
South Eastern €3,247,259
Southern €3,464,502 
Western €2,317,325
National €22,184,541
Corresponding figure for 2008 €20,997,766
Opticians were also paid in respect of: Health (Amendment) Act 1996 €72,238; Optical services for Teenagers €195,744; Optical services for Children 
€1,348,185.
Total Payments accumulated by Regional Health Area
Dublin North East €3,508,064
Dublin Mid-Leinster €5,897,233
South €6,711,762
West €6,067,482
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Volume of Treatments by Optometrists/Ophthalmologists
National – Volume of Treatments – 2009
Eye Exams 242,336
Appliances 322,270
Volume of Treatments by Optometrists/Ophthalmologists in each Health Service Executive Area
Health Service Executive Eye Exams Appliances Volume of 
Treatments
No. of Persons 
Treated
Eastern Areas 67,626 84,744 152,370 65,184
Midland 17,461 23,092 40,553 16,678
Mid-Western 22,435 31,870 54,305 22,793
North Eastern 16,870 23,483 40,353 17,517
North Western 19,122 24,898 44,020 19,413
South Eastern 34,548 50,731 85,279 36,115
Southern 38,894 48,732 87,626 35,941
Western 25,380 34,720 60,100 25,203
National 242,336 322,270 564,606 238,844
Corresponding figures for 2008 225,403 304,879 530,282 222,567
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Cost per Person
National 2009
GMS €1,245.79
LTI €2,126.23
DP €391.97
DTS €252.93
HSE-COS €92.88
Cost per Person in each Health Service Executive Area
Health Service 
Executive
GMS LTI DP DTS HSE-COS
Doctor
Cost
€
Pharmacy
Cost
€
Total
Cost
€
Pharmacy
Cost
€
Net Cost
Per 
Claimant
€
Per 
Person
Treated
€
Per 
Adult
Treated
€
Eastern Areas 334.39 896.72 1,231.11 2,243.64 442.50 247.84 95.16
Midland 349.89 943.28 1,293.17 2,010.43 377.56 251.86 98.77
Mid-Western 331.55 936.25 1,267.80 1,855.26 349.58 239.80 92.64
North Eastern 320.18 884.91 1,205.09 2,173.88 358.62 263.46 88.67
North Western 319.92 787.19 1,107.11 2,212.57 349.37 216.23 84.41
South Eastern 325.38 908.98 1,234.36 2,020.89 364.80 265.55 89.91
Southern 371.65 975.65 1,347.30 2,100.78 383.07 249.60 96.39
Western 342.17 900.00 1,242.17 1,894.64 335.73 277.35 91.95
National €337.94 €907.85 €1,245.79 €2,126.23 €391.97 €252.93 €92.88
Corresponding figures for 2008 €352.67 €932.63 €1,285.30 €2,191.17 €453.61 €240.55 €94.34
The Doctor cost above does not include superannuation paid to retired DMOs.
The above table shows the actual cost per person in respect of those who availed of services under each Scheme in 2009.
Medical and pharmaceutical services delivered to GMS persons decreased in cost from €1,285.30 in 2008 to €1,245.79 in 2009 a decrease of €39.51 
per person – the cost of medical services per person decreased in cost from €352.67 in 2008 to €337.94 a decrease of 4.18% – the cost per person of 
pharmaceutical services decreased from €932.63 in 2008 to €907.85 in 2009 a decrease of 2.66%.
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Major Therapeutic Classification of Drugs, Medicines and Appliances – General Medical Services Scheme
National 2009
C - 23.10%
N - 21.31%
A - 15.47%
R - 9.30%
V - 7.81%
Other - 23.01%
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 194.94 15.47
B Blood and Blood Forming Organs 56.99 4.52
C Cardiovascular System 291.07 23.10
D Dermatologicals 23.29 1.85
G Genito Urinary System and Sex Hormones 48.13 3.82
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 13.46 1.07
J Anti-infectives for Systemic Use 40.27 3.19
L Antineoplastic and Immunomodulating Agents 11.32 0.90
M Musculo-Skeletal System 72.75 5.77
N Nervous System 268.53 21.31
P Antiparasitic Products, Insecticides and Repellents 1.02 0.08
R Respiratory System 117.19 9.30
S Sensory Organs 22.85 1.81
V Clinical Nutritional Products 44.13 3.50
Diagnostic Products 22.25 1.77
Ostomy Appliances 13.26 1.05
Urinary Appliances 7.02 0.56
Needles/Syringes/Lancets 5.24 0.41
Other Therapeutic Products 2.66 0.21
Dressings 1.65 0.13
Allergens 0.00 0.00
Miscellaneous 2.23 0.18
Total €1,260.25m 100%
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Major Therapeutic Classification of Drugs, Medicines and Appliances – Drugs Payment Scheme
Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 65.56 14.52
B Blood and Blood Forming Organs 17.06 3.78
C Cardiovascular System 120.97 26.78
D Dermatologicals 16.48 3.65
G Genito Urinary System and Sex Hormones 27.16 6.01
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 4.67 1.03
J Anti-infectives for Systemic Use 17.04 3.77
L Antineoplastic and Immunomodulating Agents 6.52 1.44
M Musculo-Skeletal System 27.50 6.09
N Nervous System 72.28 16.00
P Antiparasitic Products, Insecticides and Repellents 1.62 0.36
R Respiratory System 50.67 11.22
S Sensory Organs 5.75 1.27
V Clinical Nutritional Products 8.15 1.80
Ostomy Appliances 5.46 1.21
Urinary Appliances 1.89 0.42
Diagnostic Products 1.33 0.29
Dressings 0.37 0.08
Needles/Syringes/Lancets 0.34 0.08
Other Therapeutic Products 0.45 0.10
Allergens 0.10 0.02
Miscellaneous 0.34 0.08
Total €451.71m 100%
Note:  The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.
National 2009
C - 26.78%
A - 14.52%
N - 16.00%
R - 11.22%
V - 4.08%
Other - 27.40%
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Major Therapeutic Classification €m %
A Alimentary Tract and Metabolism 38.97 27.88
B Blood and Blood Forming Organs 3.41 2.44
C Cardiovascular System 29.89 21.38
D Dermatologicals 0.15 0.11
G Genito Urinary System and Sex Hormones 1.61 1.15
H Systemic Hormonal Preps. excl. Sex Hormones and Insulins 0.81 0.58
J Anti-infectives for Systemic Use 1.87 1.34
L Antineoplastic and Immunomodulating Agents 0.08 0.06
M Musculo-Skeletal System 0.64 0.46
N Nervous System 19.48 13.94
P Antiparasitic Products, Insecticides and Repellents 0.00 0.00
R Respiratory System 0.67 0.48
S Sensory Organs 0.30 0.21
V Diagnostic Products 25.27 18.09
Clinical Nutritional Products 6.58 4.71
Needles/Syringes/Lancets/Swabs 7.42 5.31
Urinary Appliances 1.23 0.88
Nutritional/Ancillary Devices 0.58 0.41
Dressings 0.22 0.16
Ostomy Appliances 0.18 0.13
Other Therapeutic Products 0.09 0.06
Miscellaneous 0.31 0.22
Total €139.76m 100%
Major Therapeutic Classification of Drugs, Medicines and Appliances – Long Term Illness Scheme
National 2009
V - 29.97%
A - 27.88%
C - 21.38%
N - 13.94%
Other - 6.83%
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2009 2008 2007 2006 2005
Number of Eligible Persons in December 1,478,560 1,352,120 1,276,178 1,221,695 1,155,727
Doctors (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €466,737 €459,476 €427,418 €391,029 €403,071
Doctors’ Payment per Person €337.94 €352.67 €349.03 €314.85 €343.35
Pharmacies (000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Prescriptions €1,245,935 €1,129,494 €1,032,178 €924,995 €816,304
Ingredient Cost €962,305 €881,425 €824,323 €743,943 €653,251
Dispensing Fee €257,968 €225,697 €188,163 €163,537 €147,860
VAT €25,662 €22,372 €19,692 €17,516 €15,193
Number of Forms 16,333 15,648 14,780 13,932 13,227
Number of Items 50,722 48,212 44,358 40,569 37,428
Cost per Form €76.28 €72.18 €69.84 €66.39 €61.71
Cost per Item €24.56 €23.43 €23.27 €22.80 €21.81
Ingredient Cost per Item €18.97 €18.28 €18.58 €18.34 €17.45
Items per Form 3.11 3.08 3.00 2.91 2.83
(000’s) (000’s) (000’s) (000’s) (000’s)
Total Cost of Stock Orders €14,309 €15,797 €16,231 €15,230 €15,139
Ingredient Cost €11,044 €12,188 €12,559 €11,777 €11,714
Pharmacy Fees €2,761 €3,047 €3,140 €2,944 €2,927
VAT €504 €562 €532 €509 €498
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Cost of Medicines €1,260,244 €1,145,292 €1,048,409 €940,225 €831,443
*Pharmacy Payment per Person €907.85 €932.63 €856.14 €809.04 €750.04
(000’s) (000’s) (000’s) (000’s) (000’s)
Overall Payments €1,726,981 €1,604,768 €1,475,827 €1,331,254 €1,234,514
*Overall Payment per Person €1,245.79 €1,285.30 €1,205.17 €1,123.89 €1,093.39
Doctors’ payment per person is exclusive of superannuation paid to retired DMOs.
* These figures are based on the actual number of persons who availed of services.
Summary of Statistical Information relating to the GMS Scheme for each of the five years 2005-2009
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2009 2008 2007 2006 2005
LTI Scheme
Number of Eligible Persons in December 127,636 120,407 112,580 106,307 99,280
*Number of Claimants 65,731 62,934 59,040 53,082 53,006
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,855 2,643 2,353 2,165 1,929
Total Cost €139,759 €137,899 €124,458 €115,461 €100,547
Cost per Item €48.95 €52.17 €52.90 €53.32 €52.12
*Cost per Claimant €2,126.23 €2,191.17 €2,108.03 €2,175.15 €1,896.89
DP Scheme
Number of Eligible Persons in December 1,587,448 1,624,413 1,583,738 1,525,657 1,478,650
*Number of Claimants 663,127 687,587 667,782 597,835 526,052
(000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 13,373 13,907 13,430 11,872 10,582
Gross Cost €451,707 €506,806 €491,186 €442,924 €388,021
Net Cost €259,928 €311,898 €307,334 €283,108 €244,486
Gross Cost per Item €33.78 €36.44 €36.57 €37.31 €36.67
*Net Cost per Claimant €391.97 €453.61 €460.23 €473.56 €464.76
* These figures are based on the actual number of persons who availed of services under each Scheme.
Summary of Statistical Information relating to the LTI /DP Schemes for each of the five years 2005-2009
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Fees and Allowances under Capitation Agreement as at 31st December 2009
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles Over 10 Miles
Ages Male € Female € Male € Female € Male € Female € Male € Female € Male € Female €
Under 5 years 76.98 75.09 81.07 79.19 87.11 85.27 93.09 91.25 100.48 98.63
5-15 44.68 45.19 46.38 46.88 48.87 49.43 51.29 51.81 54.33 54.80
16-44 57.03 93.26 59.23 95.46 62.49 98.70 65.68 101.37 69.60 105.81
45-64 113.91 125.17 119.19 130.45 126.98 138.21 134.65 145.93 144.22 155.43
65-69 120.00 133.87 134.67 148.56 156.46 170.34 177.85 191.75 204.46 218.37
Above rates inclusive of supplementary Out-of-Hours Fee.
The Capitation rate is €280.31 per annum for persons aged 70 years and over in the community issued with a medical card. 
A Capitation rate of €896.07 per annum will apply to anyone aged 70 years and over in a private nursing home (approved by the Health Service 
Executive) for continuous periods in excess of five weeks. 
Out-of-Hours Payment
Surgery €46.59
Domiciliary
Up to 3 miles €46.59
3-5 miles €62.17
5-7 miles €69.98
7-10 miles €77.68
Over 10 miles €93.24
Additional Fee €36.37
*Special Items of Service
(i) to (ix) €29.14
(x) and (xi) €43.73
(xii) €72.88
(xiii) €49.05
(xiv) €78.49
(xv) and (xvi) €42.75
(xvii) €64.12
(xviii) €154.13
+ Mileage
Temporary Residents
Surgery €46.59
Domiciliary
Up to 3 miles €46.59
3-5 miles €62.17
5-7 miles €69.98
7-10 miles €77.68
Over 10 miles €93.24
Rural Dispensing Fee €15.41
Fee for Second Medical Opinion €31.09
Practice Payments for Rural Areas
Rural Practice Allowance  
Per Annum €19,055.31
Practice Support
Allowance for Practice Secretary  
up to a maximum Per Annum of €25,591.70
Allowance for Practice Nurse  
up to a maximum Per Annum of €40,215.55
Allowance for Practice Manager  
up to a maximum Per Annum of €32,903.63
Contributions to Locum Expenses
(Subject to the conditions of the Agreement)
Annual Leave
Up to a maximum of 
€1,622.39 per week
Sick Leave
Up to a maximum of 
€1,622.39 per week
Study Leave
Adoptive Leave
Maternity Leave
Paternity Leave
Up to a maximum of 
€231.77 per day
Contributions to Medical  
Indemnity Insurance
Calculation of contribution is related to GMS 
panel numbers and net premium.
Asylum Seekers
A one off superannuable registration fee of 
€179.25 per relevant patient will be paid to 
Doctors in respect of each such patient on their 
GMS Scheme panels.
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging  
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting 
of a Diaphragm.
(viii) Removal of Adherent 
Foreign Bodies from the 
Conjunctival Surface of the Eye.
(ix) Removal of Lodged or Impacted 
Foreign Bodies from the Ear, Nose 
and Throat.
(x) Nebuliser Treatment  
in the case of Acute Asthmatic 
Attack. 
(xi) Bladder Catheterization.
(xii) Attendance at case conferences 
(in cases where such are 
convened by the HSE).
(xiii) Advice and Fitting  
of a Diaphragm.
(xiv) Counselling and  
Fitting of an IUCD.
(xv) Pneumococcal Vaccination.
(xvi) Influenza Vaccination.
(xvii) Pneumococcal/Influenza 
Vaccination.
(xviii) Hepatitis B Vaccination.
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Surgery Consultations
Day Normal Hours €12.83
Late Outside Normal Hours other than (Night) €18.25
Night Midnight to 8.00 a.m. €36.09
Domiciliary Consultations
Day Normal Hours
Urban €18.93
Up to 3 miles €18.93
3-5 miles €24.79
5-7 miles €33.30
7-10 miles €41.76
Over 10 miles €52.22
Late Outside Normal Hours
Urban €24.79
Up to 3 miles €24.79
3-5 miles €32.08
5-7 miles €41.76
7-10 miles €55.48
Over 10 miles €65.05
Night Midnight to 8.00 a.m.
Urban €48.61
Up to 3 miles €48.61
3-5 miles €62.49
5-7 miles €79.05
7-10 miles €88.20
Over 10 miles €95.75
Emergency Fee/EEA Fee (Additional to Standard Fee)
Dispensing Fee €15.26
Rural Practitioner’s Allowance
Per Annum €8,276.04
Locum and Practice Expense Allowance
Per Annum €1,611.12
Sessional Rate – Homes for the Aged
Per 3 Hour Session €85.99
* Special Items of Service
(i) to (vii) €26.36
(viii) and (ix) €42.75
(x) €64.12
(xi) €154.13
Immunisation Fees
(i) Registration of child with a GP €40.84
(ii) Complete course of immunisation  
against PT/DT, Hib, Polio and MMR
€136.08
(iii) 95% uptake bonus €65.54
Health (Amendment) Act 1996
Surgery Fee €35.87
Domiciliary Fee €47.31
Methadone Treatment Scheme
Level 1 Contractor €159.97
Level 2 Contractor €176.43
Fees and Allowances under the Fee-Per-Item Agreement and Fees under the Immunisation Scheme, Health 
(Amendment) Act 1996 and Methadone Treatment Scheme as at 31st December 2009
* Special Items of Service. 
(i) Excisions/Cryotherapy/ 
Diathermy of Skin Lesions.
(ii) Suturing of Cuts and 
Lacerations.
(iii) Draining of Hydroceles.
(iv) Treatment and Plugging 
of Dental and Nasal 
Haemorrhages.
(v) Recognised Vein Treatment.
(vi) ECG Tests and their 
Interpretation.
(vii) Instruction in the fitting  
of a Diaphragm.
(viii) Pneumococcal Vaccination.
(ix) Influenza Vaccination.
(x) Pneumococcal/Influenza 
Vaccination.
(xi) Hepatitis B Vaccination.
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GMS Scheme €
*Fee-Per-Item
-   for each of the first 1,667 items dispensed by the Community Pharmacy Contractor in a month 5.00
-   for each of the next 833 items dispensed by the Community Pharmacy Contractor in that month 4.50
-   for each other item dispensed by the Community Pharmacy Contractor in that month 3.50
Extemporaneous Fee 6.53
Extemporaneous dispensing and compounding of
-   Powders 19.60
-   Ointments and Creams 13.07
Non-Dispensing – exercise of professional judgement 3.27
Phased Dispensing – each part of phased dispensing 3.27
*A Fee-Per-Item is also payable on prescription forms issued by Dentists under the DTS Scheme.
Supplies to Dispensing Doctors
Pharmacies supplying Dispensing Doctors are reimbursed on the basis of the reimbursement price with the addition of 25% on cost.
DP/LTI/EEA Schemes and Health (Amendment) Act 1996
*The Fee-Per-Item structure shown for the GMS Scheme above includes the items dispensed in these four Schemes. 
Reimbursement of ingredient cost plus 20% mark-up on ingredient cost plus Fee-Per-Item. 
20% mark-up on Incontinence products and Dressings under DP Scheme, 50% mark-up on all other Non Drug Items.
Extemporaneously dispensed preparations are reimbursed according to Statutory Instrument S.I. No. 249 of 2009. In the case of the Drugs Payment 
Scheme the PCRS makes payments to Pharmacies in respect of authorised Patients whose monthly costs of prescribed drugs and medicines are in 
excess of the specified monthly amount (currently €100) payable to the Pharmacy by an individual or family.
High Tech Medicines Scheme
Patient Care Fee: €62.03 per month.
Methadone Treatment Scheme
Patient Care Fee: Up to a Maximum of €62.00 per month.
Scale of Fees Payable to Participating Pharmacists as at 31st December 2009
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Scale of Fees Payable under the Dental Treatment Services Scheme as at 31st December 2009
Treatment Type Routine 
€
Oral Examination 33.00
Prophylaxis 31.00
Restoration (Amalgam) 50.06
Restoration (Composite) 6 anterior teeth only 51.88
Exodontics (Extraction under local anaesthetic) 39.50
Surgical Extraction – Maximum 3 units:
Fee payable for each 15 minute unit 35.00
Maximum 105.00
1st Stage Endodontic Treatment (Anterior teeth only) 57.30
Denture Repairs
1st Item of Repair 47.86
Each Subsequent Item 15.34
Maximum 78.54
Apicectomy/Amputation of Roots * Dentist Estimate
Endodontics (Anterior teeth only) * Dentist Estimate
Protracted Periodontal Treatment * Dentist Estimate
Radiographs
1 Film 24.70
2 or more Films 37.40
Panoramic 41.45
Miscellaneous
(e.g. Abcess, Haemorrhage, Dressings etc.) 22.65
Prosthetics
Full Upper or Lower Denture 326.22
(Other than Edentulous Persons)
Partial Upper or Lower Acrylic Denture 239.27
Complete Upper or Lower Reline 130.59
Complete Upper and Lower Reline 217.38
Full Upper and Lower Denture (Edentulous Persons Only) 478.74
* Dentist Estimates are subject to agreement between a Dentist and the Health Service Executive Area.
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As at 31st December 2009 €
Examinations
Eye Examination Ophthalmic Optician 22.51
Eye Examination Ophthalmologist/
Ophthalmic Medical Practitioner 25.55
Medical Eye Examination by Ophthalmologist 51.11
Eye Examination for Contact Lenses (Grant) 68.44 (H)
Eye Examination Ophthalmic (Dilation) 45.03
Appliances
Single Vision Complete Appliances
Spectacles – Distance 42.07
Spectacles – Reading 42.07
Spectacles – Uncollected 29.32
Contact Lenses (Pair) 42.07
Contact Lenses Standard or Disposable per pair (Grant) 64.34 (H)
Single Vision Spectacles – with Glass Lenses Distance 122.18 (H)
Single Vision Spectacles – with Glass Lenses Reading 122.18 (H)
Single Vision Spectacles – with Plastic Lenses Distance 131.27 (H)
Single Vision Spectacles – with Plastic Lenses Reading 131.27 (H)
Single Vision Lenses to Own Frame
Replacement Distance Lens (1) to own frame 16.35
Replacement Distance Lenses (2) to own frame 32.71
Replacement Reading Lens (1) to own frame 16.35
Replacement Reading Lenses (2) to own frame 32.71
Single Vision Lenses to Non-Standard Frame
Single Vision Lens (1) (Glass) Distance 23.54 (H)
Single Vision Lenses (2) (Glass) Distance 47.10 (H)
Single Vision Lens (1) (Glass) Reading 23.54 (H)
Single Vision Lenses (2) (Glass) Reading 47.10 (H)
Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme
€
Single Vision Lens (1) (Plastic) Distance 26.84 (H)
Single Vision Lenses (2) (Plastic) Distance 53.67 (H)
Single Vision Lens (1) (Plastic) Reading 26.84 (H)
Single Vision Lenses (2) (Plastic) Reading 53.67 (H)
Additional Specification for Lenses to All Spectacle Types
Special grant towards additional specification for lens (1)
– applies to all spectacle types 81.81 (H)
Special grant towards additional specification for lenses (2)
– applies to all spectacle types 163.62 (H)
Other Items – Single Vision
Lenticular Lens (1 Surface) 11.64
Lenticular Lenses (2 Surfaces) 23.28
Lenticular Lenses (3 Surfaces) 34.92
Lenticular Lenses (4 Surfaces) 46.56
Tinted Lens (1) 7.43
Tinted Lenses (2) 14.87
Tinted Lenses (3) 22.30
Tinted Lenses (4) 29.74
Prism (1) 6.30
Prisms (2) 12.60
Prisms (3) 18.90
Prisms (4) 25.20
Prisms (5) 31.50
Prisms (6) 37.80
Prisms (7) 44.10
Prisms (8) 50.40
Dioptric powers higher than 8.00 (1) Lens 6.17
Dioptric powers higher than 8.00 (2) Lenses 12.34
Dioptric powers higher than 8.00 (3) Lenses 18.52
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
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Scale of Fees Payable under the Health Service Executive Community Ophthalmic Services Scheme continued
As at 31st December 2009 €
Dioptric powers higher than 8.00 (4) Lenses 24.69
Anti-Reflective Coating on Plastic Lens (1) 18.14 (H)
Anti-Reflective Coating on Plastic Lenses (2) 36.28 (H)
Dioptric powers higher than 6.00 (Plastic) (1) Lens 15.43
Dioptric powers higher than 6.00 (Plastic) (2) Lenses 30.86
Dioptric powers higher than 6.00 (Plastic) (3) Lenses 46.29
Dioptric powers higher than 6.00 (Plastic) (4) Lenses 61.72
Plastic Lens (1) for children as prescribed 4.70
Plastic Lenses (2) for children as prescribed 9.39
Plastic Lens (1) Adult 4.55 (H)
Plastic Lenses (2) Adult 9.10 (H)
Bifocals
Spectacles Bifocal Complete 83.70
Fused Bifocal Spectacles 163.01 (H)
Varifocals Spectacles – Glass or Plastic 250.80 (H)
Bifocal Lenses
Replacement Bifocal Lens (1) to own frame 37.21
Replacement Bifocal Lenses (2) to own frame 74.42
Bifocal Lens (1) To Non-Standard Frames 47.89 (H)
€
Bifocal Lenses (2) to Non-Standard Frames 95.78 (H)
Varifocal Lens (1) (Grant) 94.82 (H)
Varifocal Lenses (2) (Grant) 189.64 (H)
Other Items – Bifocals
Sphere over 6.00 and up to 9.00 extra charge (1) Lens 4.17
Sphere over 6.00 and up to 9.00 extra charge (2) Lenses 8.33
Sphere over 9.00 extra charge (1) Lens 9.26
Sphere over 9.00 extra charge (2) Lenses 18.52
Tinted Lens (1) 8.21
Tinted Lenses (2) 16.42
Prism (1) 8.76
Prisms (2) 17.51
Repairs
Replacement Frame to own lenses 12.16
Replacement Front to own lenses 5.83
Replacement Side (1) to own frame 2.45
Replacement Sides (2) to own frame 4.90
Complete New Frames 90.60 (H)
(H) Denotes fees payable in respect of services under the Health (Amendment) Act 1996 only.
32
32
DETAILED STATISTICAL ANALYSIS 
OF CLAIMS AND PAYMENTS 2009
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Table 1 GMS: Summary of Statistical Information for each of the Five Years 2005-2009
Year ended December:- 2009 2008 2007 2006 2005 Year ended December:- 2009 2008 2007 2006 2005
Number of Eligible 
Persons in December
1,478,560 1,352,120 1,276,178 1,221,695 1,155,727 Number of Doctor 
Contracts
Number of Pharmacist 
Contracts
2,663 2,599 2,347 2,315 2,257
1,630 1,620 1,587 1,530 1,430
DOCTORS (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Total Payments €466,737 €459,476 €427,418 €391,029 €403,071 Total Cost of Stock 
Orders
€14,309 €15,797 €16,231 €15,230 €15,139
Ingredient Cost €11,044 €12,188 €12,559 €11,777 €11,714
Doctors’ Payment per
Person
€337.94 €352.67 €349.03 €314.85 €343.35 Pharmacy Fees
VAT
€2,761
€504
€3,047
€562
€3,140
€532
€2,944
€509
€2,927
€498
PHARMACIES
Total Cost of 
Prescriptions
€1,245,935 €1,129,494 €1,032,178 €924,995 €816,304 Overall Cost of 
Medicines
€1,260,244 €1,145,292 €1,048,409 €940,225 €831,443
Ingredient Cost €962,305 €881,425 €824,323 €743,943 €653,251 *Pharmacy Payment 
per Person
€907.85 €932.63 €856.14 €809.04 €750.04
Dispensing Fee €257,968 €225,697 €188,163 €163,537 €147,860
VAT €25,662 €22,372 €19,692 €17,516 €15,193
Number of Forms 16,333 15,648 14,780 13,932 13,227
Number of Items 50,722 48,212 44,358 40,569 37,428 Overall Payments €1,726,981 €1,604,768 €1,475,827 €1,331,254 €1,234,514
Cost per Form €76.28 €72.18 €69.84 €66.39 €61.71 *Overall Payment 
per Person
€1,245.79 €1,285.30 €1,205.17 €1,123.89 €1,093.39
Cost per Item €24.56 €23.43 €23.27 €22.80 €21.81
Ingredient Cost per Item €18.97 €18.28 €18.58 €18.34 €17.45
Items per Form 3.11 3.08 3.00 2.91 2.83
Note:  Doctors payment per person is exclusive of superannuation paid to retired DMOs.
* These figures are based on the actual number of persons who availed of services.
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Year ended December:- 2009 2008 2007 2006 2005 Year ended December:- 2009 2008 2007 2006 2005
LTI Scheme
Number of Eligible 
Persons in December
127,636 120,407 112,580 106,307 99,280
DP Scheme
Number of Eligible 
Persons in December
1,587,448 1,624,413 1,583,738 1,525,657 1,478,650
*Number of Claimants 65,731 62,934 59,040 53,082 53,006 *Number of Claimants 663,127 687,587 667,782 597,835 526,052
(000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s) (000’s)
Number of Items 2,855 2,643 2,353 2,165 1,929 Number of Items 13,373 13,907 13,430 11,872 10,582
Total Cost €139,759 €137,899 €124,458 €115,461 €100,547 Gross Cost €451,707 €506,806 €491,186 €442,924 €388,021
Cost per Item €48.95 €52.17 €52.90 €53.32 €52.12 Net Cost €259,928 €311,898 €307,334 €283,108 €244,486
*Cost per Claimant €2,126.23 €2,191.17 €2,108.03 €2,175.15 €1,896.89 Gross Cost per Item €33.78 €36.44 €36.57 €37.31 €36.67
*Net Cost per Claimant €391.97 €453.61 €460.23 €473.56 €464.76
* These figures are based on the actual number of persons who availed of services under each Scheme.
Table 1.1  LTI/DP: Summary of Statistical Information for each of the Five Years 2005-2009
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Table 2 Number of Agreements
Health Service 
Executive
Doctors Pharmacists Dentists Optometrists
2009 2008 2009 2008 2009 2008 2009 2008
East Coast Area 283 277 141 136 125 86 41 38
South Western Area 343 330 203 213 189 172 76 75
Northern Area 298 280 189 188 160 130 50 50
Midland 151 152 100 97 76 72 46 43
Mid-Western 234 233 149 148 136 124 45 43
North Eastern 193 180 150 150 103 94 62 60
North Western 159 156 98 96 78 69 33 32
South Eastern 264 268 181 179 152 117 65 61
Southern 452 441 251 244 341 310 70 66
Western 286 282 168 169 210 175 67 67
NATIONAL 2,663 2,599 1,630 1,620 1,570 1,349 555 535
Note: (i) Where Doctors have panel numbers drawn from more than one HSE Area, the Area wherein the majority of such persons reside is deemed to be the Doctors HSE Area.
 (ii) 527 Doctors who do not have agreements under the GMS Scheme and who provide services under the Primary Childhood Immunisation Scheme, the Health (Amendment) Act 1996, 
Heartwatch, Palliative Care and the Methadone Treatment Scheme are included in the above.
 (iii) 188 Dentists (188 – 2008) who are employees of the Health Service Executive and who provide services under the Dental Treatment Services Scheme are included above.
 (iv) 12 Pharmacies who do not hold GMS agreements and who were registered as providing non GMS Schemes at year-end are included above.
 (v) Above figures relate to the position as at 31st December 2009.
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Table 3 GMS: Payments to Doctors
2009 2008
€ €
FEES - Item of Service Contract 769,487 1,064,036
- Capitation 225,954,778 230,862,890
- Special Claims/Services 44,124,618 39,556,736
- Out-of-Hours 49,507,291 46,401,447
- Dispensing 2,285,357 2,323,010
- Asylum Seekers 846,494 1,001,801
- GP Visit Cards 1,383,375 1,665,580
ALLOWANCES - Annual Leave 10,437,384 10,111,378
- Locum and Practice Expenses 12,643 13,696
- Sick Leave 2,223,277 1,804,395
- Maternity Leave/Paternity Leave 1,351,647 1,387,015
- Rural Practice 3,761,836 3,862,778
- Secretarial/Nursing 74,616,329 70,292,878
- Study Leave 1,785,347 1,890,919
- Medical Indemnity Insurance 2,816,513 2,668,269
- Rostering/Out-of-Hours 12,511,152 11,898,090
- Practice Development 4,353,527 4,363,099
- Practice Support Grant 2,671,843 2,667,629
- IMO Agreements:
    One-in-one rotas - -
    Third year Trainees - -
    Trainer Grants - -
SALARIES - Former District Medical Officers 1,696,801 1,548,323
- Benefits to retired DMOs and their dependants 5,537,300 5,727,599
SUPERANNUATION FUND - Contribution 23,627,456 24,092,101
TOTAL €472,274,455 €465,203,669
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Table 4 GMS: Cost of Prescriptions
Health
Service
Executive
Ingredient Cost Dispensing Fee VAT Total
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
East Coast Area 60,233,490 59,039,119 17,422,789 16,095,744 1,613,143 1,523,298 79,269,422 76,658,161
South Western Area 110,468,331 101,636,757 29,933,769 26,417,902 3,075,991 2,705,566 143,478,091 130,760,225
Northern Area 110,257,084 101,677,847 29,238,738 25,432,421 2,900,229 2,560,661 142,396,051 129,670,929
Midland 66,313,109 60,241,590 17,708,193 15,508,514 1,834,861 1,559,590 85,856,163 77,309,694
Mid-Western 88,610,101 80,950,093 23,931,783 20,817,988 2,319,769 2,023,333 114,861,653 103,791,414
North Eastern 82,676,183 75,055,457 22,385,331 19,304,583 2,249,767 1,911,417 107,311,281 96,271,457
North Western 61,038,782 55,745,729 16,259,762 14,134,176 1,592,292 1,363,908 78,890,836 71,243,813
South Eastern 122,874,913 109,403,268 33,699,763 29,069,409 3,396,313 2,896,205 159,970,989 141,368,882
Southern 155,975,463 142,678,310 40,611,288 35,409,200 3,997,631 3,503,316 200,584,382 181,590,826
Western 103,857,704 94,996,907 26,776,671 23,507,378 2,681,780 2,324,559 133,316,155 120,828,844
National €962,305,160 €881,425,077 €257,968,087 €225,697,315 €25,661,776 €22,371,853 €1,245,935,023 €1,129,494,245
Note:  Cost of medicines supplied by pharmacies to Dispensing Doctors is given in Table 5.
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Table 5 GMS: Cost of Stock Order Forms
Health
Service
Executive
Ingredient Cost * Pharmacy Fee VAT Total
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
East Coast Area 111,493 155,246 28,126 38,804 29,898 35,469 169,517 229,519
South Western Area 86,341 102,702 21,594 25,675 23,168 26,880 131,103 155,257
Northern Area 137,431 188,907 34,367 47,226 33,327 44,629 205,125 280,762
Midland 463,139 492,476 115,809 123,117 25,484 27,408 604,432 643,001
Mid-Western 841,912 884,368 210,536 221,089 43,400 46,573 1,095,848 1,152,030
North Eastern 1,063,718 1,235,735 265,943 308,936 51,229 59,548 1,380,890 1,604,219
North Western 1,481,938 1,699,269 370,489 424,821 55,179 59,445 1,907,606 2,183,535
South Eastern 2,579,326 2,974,977 644,769 743,642 96,197 101,842 3,320,292 3,820,461
Southern 358,812 408,970 89,737 102,231 54,488 64,342 503,037 575,543
Western 3,919,974 4,045,697 979,988 1,011,405 91,780 95,958 4,991,742 5,153,060
National €11,044,084 €12,188,347 €2,761,358 €3,046,946 €504,150 €562,094 €14,309,592 €15,797,387
Note: (i) Stock Order Forms are provided by HSE Areas for the use of Dispensing Doctors to obtain Medicines and Appliances from Community Pharmacies for dispensing to persons who are 
entitled to be dispensed to.
 (ii) * Pharmacies are reimbursed for stock order items on the basis of the reimbursement price, with the addition of 25% on cost.
 (iii) The above figures include needles, syringes and dressings which are available for Doctors use.
40
Table 6 DTS: Payments to Dentists
Health Service Executive
Above the Line Below the Line Total
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
Eastern Areas 16,981,125 12,567,717 5,516,151 4,580,574 22,497,276 17,148,291
Midland 3,748,497 2,746,567 1,863,214 1,441,222 5,611,711 4,187,789
Mid-Western 4,980,966 3,876,098 2,452,033 1,864,581 7,432,999 5,740,679
North Eastern 5,502,224 3,981,584 2,488,644 1,983,307 7,990,868 5,964,891
North Western 3,456,832 2,501,120 1,348,171 1,045,002 4,805,003 3,546,122
South Eastern 7,467,429 5,308,001 4,131,261 2,895,519 11,598,690 8,203,520
Southern 10,821,398 8,657,154 4,223,607 3,344,182 15,045,005 12,001,336
Western 7,667,247 5,514,157 4,123,693 3,057,579 11,790,940 8,571,736
National €60,625,718 €45,152,398 €26,146,774 €20,211,966 €86,772,492 €65,364,364
Note:  Dentists were also paid a total €62,114 in 2009 (€56,233 in 2008) in respect of fees under Health (Amendment) Act 1996.
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Health Service Executive
2009 2008
Doctors
€
Pharmacies
€
Total
€
Doctors
€
Pharmacies
€
Total
€
Eastern Areas 334.39 896.72 1,231.11 347.76 910.92 1,258.68
Midland 349.89 943.28 1,293.17 362.76 1,010.94 1,373.70
Mid-Western 331.55 936.25 1,267.80 342.08 954.60 1,296.68
North Eastern 320.18 884.91 1,205.09 343.48 926.64 1,270.12
North Western 319.92 787.19 1,107.11 326.17 779.35 1,105.52
South Eastern 325.38 908.98 1,234.36 347.16 951.02 1,298.18
Southern 371.65 975.65 1,347.30 385.80 993.09 1,378.89
Western 342.17 900.00 1,242.17 356.29 938.34 1,294.63
National €337.94 €907.85 €1,245.79 €352.67 €932.63 €1,285.30
Note: The payment per person is inclusive of total payments to Doctors (Table 3) excluding superannuation benefits to retired DMOs and their dependants and total payments to pharmacies 
(Tables 4 and 5) in respect of the actual cost per person who availed of services.
Table 7 GMS: Payment per Person
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2009 (2008 in brackets)
Number of Doctors with an annual cost per eligible person of:-
Health Service 
Executive Up to €300 €301-€350 €351-€400 €401-€450 €451-€500 €501-€550 €551-€600 €601-€650 €651-€700 €701 & Over
Eastern Areas 156 (62) 3 (6) 3 (3) 4 (7) 5 (8) 11 (10) 18 (13) 12 (8) 13 (15) 540 (516)
Midland 18 (14) - (-) - (1) 1 (1) - (1) 3 (-) - (3) 2 (3) 2 (2) 103 (101)
Mid-Western 21 (11) 1 (1) - (1) 1 (1) 1 (-) 1 (1) 1 (1) 5 (3) 4 (-) 168 (163)
North Eastern 17 (1) - (1) 1 (-) 4 (3) 1 (3) 4 (2) - (3) 5 (7) 13 (3) 128 (126)
North Western 9 (2) - (1) - (1) 2 (-) 2 (3) 6 (3) 3 (3) 2 (3) 6 (5) 115 (112)
South Eastern 27 (5) 2 (2) - (2) 3 (-) 3 (2) 2 (3) 4 (3) 4 (3) 4 (2) 203 (205)
Southern 48 (29) 2 (1) 2 (2) 4 (4) 5 (2) 4 (1) 3 (2) 7 (8) 4 (6) 336 (324)
Western 28 (14) 1 (-) 1 (1) 3 (5) 5 (2) 2 (3) 4 (4) 6 (3) 5 (4) 206 (202)
National 324 (138) 9 (12) 7 (11) 22 (21) 22 (21) 33 (23) 33 (32) 43 (38) 51 (37) 1799 (1749)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from this table.
 (ii) The annual cost per eligible person is the total payment for the Doctor and the total prescribing/dispensing costs in respect of the number of persons on the panel as at December 2009.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
Table 8 GMS: Number of Doctors in Eligible Person Cost Categories
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Table 9 GMS: Number of Eligible Persons
Health Service  
Executive
Number of persons 
(including dependants)
and % of population* 
eligible in
Health Service  
Executive
Number of persons 
(including dependants)
and % of population* 
eligible in
December 2009 December 2009
No. % No. %
HSE DUBLIN MID-LEINSTER HSE WEST
Dublin South 23,102 0.54 Galway 87,377 2.06
Dublin South East 17,156 0.40 Mayo 58,776 1.39
Dublin South City 29,124 0.69 Roscommon 26,606 0.63
Dublin South West 53,260 1.26 Donegal 81,199 1.91
Dublin West 48,258 1.14 Sligo / Leitrim 36,709 0.87
Kildare / West Wicklow 53,325 1.26 Clare 42,563 1.00
Wicklow 34,356 0.81 North Tipperary / East Limerick 26,393 0.62
Laois / Offaly 52,067 1.23 Limerick 62,999 1.49
Longford / Westmeath 43,858 1.03 TOTAL HSE WEST 422,622 9.97
TOTAL HSE DUBLIN MID-LEINSTER 354,506 8.36
HSE SOUTH
HSE DUBLIN NORTH EAST Cork South Lee 51,629 1.22
Dublin North West 52,521 1.24 Cork North Lee 65,050 1.53
North Central Dublin 37,776 0.89 West Cork 20,466 0.48
North Dublin 59,182 1.40 Kerry 51,040 1.20
Cavan / Monaghan 47,645 1.12 North Cork 32,423 0.77
Louth 47,594 1.12 Carlow / Kilkenny 49,599 1.17
Meath 46,261 1.09 Waterford 48,285 1.14
TOTAL HSE DUBLIN NORTH EAST 290,979 6.86 South Tipperary 35,894 0.85
Wexford 56,067 1.32
TOTAL HSE SOUTH 410,453 9.68
NATIONAL 1,478,560 34.87
Note: *The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national 
population as at October 2006 is 4,239,848.
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Table 9.1 GMS: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2009
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 14,544 15,426 29,970 22,006 23,510 45,516 10,206 10,733 20,939 18,760 14,524 33,284 26,253 16,841 43,094 24,033 18,989 43,022
Midland 3,645 3,835 7,480 5,334 5,580 10,914 2,594 2,710 5,304 4,685 3,863 8,548 6,048 4,554 10,602 5,782 5,037 10,819
Mid-Western 4,335 4,548 8,883 6,514 6,645 13,159 3,257 3,357 6,614 6,550 5,752 12,302 8,120 6,364 14,484 7,560 6,652 14,212
North Eastern 5,367 5,598 10,965 7,896 8,271 16,167 3,775 4,034 7,809 7,236 6,213 13,449 9,218 6,972 16,190 8,640 7,668 16,308
North Western 3,897 4,151 8,048 5,829 6,286 12,115 3,033 3,405 6,438 6,231 5,695 11,926 6,875 5,755 12,630 6,958 6,348 13,306
South Eastern 6,306 6,749 13,055 9,329 9,847 19,176 4,652 5,036 9,688 10,043 8,749 18,792 11,783 9,615 21,398 11,028 9,937 20,965
Southern 7,163 7,380 14,543 9,983 10,852 20,835 5,026 5,335 10,361 9,848 8,836 18,684 13,550 10,697 24,247 12,388 11,206 23,594
Western 5,519 5,844 11,363 8,218 8,862 17,080 4,355 4,520 8,875 9,019 7,979 16,998 10,135 8,365 18,500 9,980 9,009 18,989
National 50,776 53,531 104,307 75,109 79,853 154,962 36,898 39,130 76,028 72,372 61,611 133,983 91,982 69,163 161,145 86,369 74,846 161,215
% of Eligible 
Persons 3.43% 3.62% 7.05% 5.08% 5.40% 10.48% 2.50% 2.65% 5.14% 4.89% 4.17% 9.06% 6.22% 4.68% 10.90% 5.84% 5.06% 10.90%
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Health 
Service 
Executive
Age Classification
As at December 2009
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and Over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 17,787 15,532 33,319 19,055 15,434 34,489 11,720 8,010 19,730 19,888 16,303 36,191 42,717 25,789 68,506 226,969 181,091 408,060
Midland 4,428 4,181 8,609 4,736 4,144 8,880 2,601 2,011 4,612 3,524 3,286 6,810 7,674 5,673 13,347 51,051 44,874 95,925
Mid-Western 6,100 5,914 12,014 6,930 6,250 13,180 4,009 3,226 7,235 5,284 4,990 10,274 11,620 7,978 19,598 70,279 61,676 131,955
North Eastern 6,257 5,987 12,244 6,588 6,009 12,597 3,624 2,922 6,546 5,049 4,780 9,829 11,583 7,813 19,396 75,233 66,267 141,500
North Western 5,798 5,653 11,451 6,386 6,144 12,530 3,194 2,978 6,172 3,846 3,790 7,636 9,019 6,637 15,656 61,066 56,842 117,908
South Eastern 9,030 8,675 17,705 9,875 9,026 18,901 5,510 4,617 10,127 7,224 6,793 14,017 15,183 10,838 26,021 99,963 89,882 189,845
Southern 10,572 9,856 20,428 11,640 10,601 22,241 6,960 5,422 12,382 9,529 8,651 18,180 21,178 13,935 35,113 117,837 102,771 220,608
Western 8,468 8,348 16,816 8,927 9,004 17,931 4,839 4,273 9,112 6,006 6,016 12,022 14,576 10,497 25,073 90,042 82,717 172,759
National 68,440 64,146 132,586 74,137 66,612 140,749 42,457 33,459 75,916 60,350 54,609 114,959 133,550 89,160 222,710 792,440 686,120 1,478,560
% of Eligible 
Persons 4.63% 4.34% 8.97% 5.01% 4.51% 9.52% 2.87% 2.26% 5.13% 4.08% 3.69% 7.78% 9.03% 6.03% 15.06% 53.60% 46.40% 100.00%
Table 9.1  GMS: Number of Eligible Persons by Gender within Age Groups continued
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Table 9.2  GMS: Percentage of Eligible Persons by Mileage Allocation
Health Service 
Executive
Mileage Classification
As at December 2009
Up to 3 Miles 3-5 Miles 5-7 Miles 7-10 Miles Over 10 Miles
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 49.37 39.11 88.48 3.29 2.74 6.03 1.78 1.47 3.25 0.68 0.62 1.30 0.49 0.45 0.94
Midland 33.86 29.72 63.58 5.83 5.26 11.09 11.01 9.40 20.41 2.47 2.35 4.82 0.05 0.05 0.10
Mid-Western 35.34 30.96 66.30 6.37 5.56 11.93 10.33 9.13 19.46 0.96 0.84 1.80 0.26 0.25 0.51
North Eastern 34.39 30.15 64.54 7.03 6.25 13.28 10.84 9.69 20.53 0.77 0.63 1.40 0.14 0.11 0.25
North Western 25.95 23.91 49.86 8.85 8.45 17.30 12.52 11.81 24.33 3.32 2.96 6.28 1.16 1.07 2.23
South Eastern 34.56 30.95 65.51 5.83 5.23 11.06 10.91 10.09 21.00 1.12 0.90 2.02 0.23 0.18 0.41
Southern 34.83 30.21 65.04 6.31 5.52 11.83 9.44 8.24 17.68 1.70 1.57 3.27 1.13 1.05 2.18
Western 28.29 25.19 53.48 7.53 7.13 14.66 11.35 10.82 22.17 3.58 3.41 6.99 1.36 1.34 2.70
National 37.28 31.70 68.98 5.80 5.19 10.99 8.30 7.49 15.79 1.59 1.44 3.03 0.63 0.58 1.21
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Health Service  
Executive
Number of persons (including 
dependants) and % of 
population* eligible in Health Service  
Executive
Number of persons (including 
dependants) and % of 
population* eligible in
December 2009 December 2009
No. % No. %
HSE DUBLIN MID-LEINSTER HSE WEST
Dublin South 1,017 0.02 Galway 6,733 0.16
Dublin South East 756 0.02 Mayo 3,355 0.08
Dublin South City 720 0.02 Roscommon 1,730 0.04
Dublin South West 2,307 0.05 Donegal 6,260 0.15
Dublin West 2,959 0.07 Sligo / Leitrim 2,897 0.07
Kildare / West Wicklow 2,927 0.07 Clare 2,287 0.05
Wicklow 2,017 0.05 North Tipperary / East Limerick 1,671 0.04
Laois / Offaly 3,520 0.08 Limerick 3,760 0.09
Longford / Westmeath 3,023 0.07 TOTAL HSE WEST 28,693 0.69
TOTAL HSE DUBLIN MID-LEINSTER 19,246 0.45
HSE SOUTH
HSE DUBLIN NORTH EAST Cork South Lee 4,718 0.11
Dublin North West 2,076 0.05 Cork North Lee 5,840 0.14
North Central Dublin 1,017 0.02 West Cork 1,891 0.04
North Dublin 2,256 0.05 Kerry 3,999 0.09
Cavan / Monaghan 3,828 0.09 North Cork 3,434 0.08
Louth 3,379 0.08 Carlow / Kilkenny 4,033 0.10
Meath 4,159 0.10 Waterford 3,109 0.07
TOTAL HSE DUBLIN NORTH EAST 16,715 0.39 South Tipperary 2,375 0.06
Wexford 4,272 0.10
TOTAL HSE SOUTH 33,671 0.79
NATIONAL 98,325 2.32
Note: * The figures show the number of eligible persons for each Local Health Office. The 2006 Census is used to calculate the percentage. The most recent Official C.S.O. estimate of national 
population as at October 2006 is 4,239,848.
Table 9.3  GPVC: Number of Eligible Persons
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Table 9.4  GPVC: Number of Eligible Persons by Gender within Age Groups
Health 
Service 
Executive
Age Classification
As at December 2009
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 years
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 910 968 1,878 1,416 1,437 2,853 625 634 1,259 945 532 1,477 1,552 854 2,406 1,810 1,469 3,279
Midland 391 397 788 535 541 1,076 273 275 548 324 197 521 654 457 1,111 598 544 1,142
Mid-Western 430 409 839 544 605 1,149 310 294 604 507 346 853 768 499 1,267 688 681 1,369
North Eastern 645 696 1,341 910 967 1,877 365 412 777 582 432 1,014 1,039 685 1,724 1,151 1,024 2,175
North Western 416 425 841 667 672 1,339 386 332 718 604 410 1,014 743 509 1,252 821 711 1,532
South Eastern 702 745 1,447 999 1,031 2,030 504 486 990 841 544 1,385 1,456 889 2,345 1,316 1,125 2,441
Southern 1,088 1,068 2,156 1,435 1,506 2,941 709 726 1,435 1,069 730 1,799 1,876 1,223 3,099 1,888 1,713 3,601
Western 588 656 1,244 855 901 1,756 399 389 788 633 424 1,057 1,148 751 1,899 1,159 1,037 2,196
National 5,170 5,364 10,534 7,361 7,660 15,021 3,571 3,548 7,119 5,505 3,615 9,120 9,236 5,867 15,103 9,431 8,304 17,735
% of Eligible 
Persons 5.26% 5.46% 10.71% 7.49% 7.79% 15.28% 3.63% 3.61% 7.24% 5.60% 3.68% 9.28% 9.39% 5.97% 15.36% 9.59% 8.45% 18.04%
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Health 
Service 
Executive
Age Classification
As at December 2009
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years and over All
Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total Female Male Total
Eastern Areas 1,216 909 2,125 971 749 1,720 474 506 980 27 38 65 5 4 9 9,951 8,100 18,051
Midland 371 369 740 239 224 463 65 83 148 2 3 5 - 1 1 3,452 3,091 6,543
Mid-Western 455 437 892 283 252 535 83 107 190 9 10 19 1 - 1 4,078 3,640 7,718
North Eastern 646 584 1,230 451 405 856 156 193 349 10 13 23 - - - 5,955 5,411 11,366
North Western 628 631 1,259 443 472 915 115 164 279 2 6 8 - - - 4,825 4,332 9,157
South Eastern 931 776 1,707 599 515 1,114 125 200 325 3 2 5 - - - 7,476 6,313 13,789
Southern 1,298 1,088 2,386 987 816 1,803 265 359 624 18 19 37 2 - 2 10,635 9,248 19,883
Western 790 752 1,542 510 467 977 134 196 330 10 15 25 4 - 4 6,230 5,588 11,818
National 6,335 5,546 11,881 4,483 3,900 8,383 1,417 1,808 3,225 81 106 187 12 5 17 52,602 45,723 98,325
% of Eligible 
Persons 6.44% 5.64% 12.08% 4.56% 3.97% 8.53% 1.44% 1.84% 3.28% 0.08% 0.11% 0.19% 0.01% 0.01% 0.02% 53.50% 46.50% 100%
Table 9.4  GPVC: Number of Eligible Persons by Gender within Age Groups continued
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Table 10 GMS: Size of Panels of Doctors
As at December 2009 (2008 in brackets)
Health Service 
Executive
Number of Doctors with panels of:-
Up to 250 251-500 501-1,000 1,001-1,500 1,501-2,000 2,001-2,500
East Coast Area 55 (52) 51 (52) 59 (59) 11 (12) - -
South Western Area 40 (43) 37 (43) 100 (94) 46 (44) 21 (11) 3 (3)
Northern Area 34 (43) 43 (43) 69 (64) 45 (39) 11 (16) 3 (1)
Midland 9 (15) 14 (14) 45 (49) 35 (29) 12 (9) -
Mid-Western 23 (23) 36 (34) 83 (87) 32 (30) 12 (9) 1 (-)
North Eastern 10 (9) 16 (25) 71 (82) 51 (38) 11 (6) 3 (-)
North Western 10 (14) 23 (19) 50 (54) 39 (39) 15 (11) 3 (1)
South Eastern 14 (19) 24 (37) 120 (123) 56 (46) 19 (11) 1 (-)
Southern 84 (81) 61 (69) 155 (153) 63 (51) 10 (6) 3 (2)
Western 30 (27) 45 (51) 108 (105) 51 (50) 9 (3) 1 (-)
National 309 (326) 350 (387) 860 (870) 429 (378) 120 (82) 18 (7)
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Table 11 GMS: Payments to Doctors in each Health Service Executive Area
Health Service Executive 2009€
2008
€
East Coast Area 28,086,765 33,415,983
South Western Area 50,599,550 49,876,623
Northern Area 45,733,538 45,340,172
Midland 30,794,005 29,655,724
Mid-Western 40,618,410 39,960,511
North Eastern 43,156,720 40,648,365
North Western 36,550,156 35,215,976
South Eastern 59,744,270 57,301,388
Southern 76,157,054 74,791,102
Western 55,296,686 53,270,226
National €466,737,154 €459,476,070
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Health Service 
Executive
No. of Temporary 
Resident Claims
No. of EEA Visitor 
Claims
No. of Emergency 
Claims
Second Medical 
Opinion Claims
No. of Out-of-
Hours Claims Total No. of Claims
2009 2008 2009 2008 2009 2008 2009 2008 2009 2008 2009 2008
East Coast Area 6,254 5,171 2,573 2,709 2,797 2,703 6 2 32,706 32,499 44,336 43,084
South Western 
Area 16,546 12,989 5,174 5,624 12,937 5,874 14 5 81,815 76,582 116,486 101,074
Northern Area 11,307 9,548 2,394 2,126 14,092 12,978 - 1 45,482 57,153 73,275 81,806
Midland 17,254 17,144 2,533 2,815 2,388 1,973 9 20 68,574 59,160 90,758 81,112
Mid-Western 14,843 17,824 5,340 5,797 4,540 4,311 644 604 69,117 62,598 94,484 91,134
North Eastern * 11,966 8,127 2,428 2,603 1,904 1,205 19 21 10,169 10,816 26,486 22,772
North Western 5,463 4,994 7,238 7,628 2,084 2,098 70 29 68,358 67,143 83,213 81,892
South Eastern 15,013 13,472 4,676 5,470 2,830 2,677 34 3 135,943 131,423 158,496 153,045
Southern 34,170 30,771 12,277 14,129 5,165 4,716 1,012 1,065 215,184 211,209 267,808 261,890
Western 17,798 16,976 8,381 9,303 7,560 6,415 151 153 109,795 109,108 143,685 141,955
National 150,614 137,016 53,014 58,204 56,297 44,950 1,959 1,903 837,143 817,691 1,099,027 1,059,764
Note:  * HSE North Eastern Area figures do not include statistics from North East Doc.
Table 12 GMS: Number of Special Type Consultations and Out-of-Hours Claims
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Table 12.1  GMS: Payment to Doctors for Special Type Consultations and Out-of-Hours Claims
Health 
Service 
Executive
Cost of Temporary 
Resident Claims
Cost of EEA  
Visitor Claims
Cost of  
Emergency Claims
Cost of Second 
Medical Opinion 
Claims
Cost of Out-of-
Hours Claims
Total Cost  
of Claims
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
East Coast 
Area 312,097 268,168 124,816 131,518 134,897 131,948 192 64 1,610,238 1,609,440 2,182,240 2,141,138
South 
Western Area 865,291 672,489 253,212 273,483 684,341 286,003 457 169 4,104,053 3,906,532 5,907,354 5,138,676
Northern 
Area 553,250 471,211 116,882 103,469 677,326 628,943 - 32 2,223,675 2,805,082 3,571,133 4,008,737
Midland 849,597 845,260 123,449 137,443 115,819 96,749 291 651 3,502,092 3,067,637 4,591,248 4,147,740
Mid-Western 743,035 914,879 259,478 282,457 226,722 212,198 20,883 19,558 3,531,354 3,241,233 4,781,472 4,670,325
North 
Eastern* 594,459 405,081 118,280 126,660 94,913 63,496 610 680 515,104 560,033 1,323,366 1,155,950
North 
Western 271,337 247,296 353,272 371,894 102,791 103,637 2,319 935 3,497,795 3,469,448 4,227,514 4,193,210
South Eastern 737,735 671,017 227,003 266,116 137,081 130,685 1,138 96 6,695,156 6,537,206 7,798,113 7,605,120
Southern 1,793,957 1,692,984 599,846 689,782 278,383 240,269 32,851 34,509 10,821,508 10,769,581 13,526,545 13,427,125
Western 902,781 873,555 408,267 453,281 367,017 314,143 4,989 4,945 5,585,294 5,619,175 7,268,348 7,265,099
National 7,623,539 7,061,940 2,584,505 2,836,103 2,819,290 2,208,071 63,730 61,639 42,086,269 41,585,367 55,177,333 53,753,120
Note:  * HSE North Eastern Area figures do not include statistics from North East Doc.
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Table 13 GMS: Analysis of Special Items of Service
Type of Service Number of Claims Cost of Claims
2009 2008 2009
€
2008
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 103,183 94,419 3,336,932 2,866,090
(ii) Suturing: Cuts and Lacerations 36,416 34,425 1,178,427 1,045,166
(iii) Hydroceles: Draining of 1,378 1,309 43,880 39,760
(iv) Haemorrhages: Dental/Nasal 2,427 2,196 78,640 66,744
(v) Veins: Recognised treatment 4,499 4,287 145,061 130,529
(vi) ECG: Tests and interpretation 76,757 72,249 2,480,452 2,195,068
(vii) Diaphragm: Instruction in the fitting of 1,186 1,157 38,754 35,102
(viii) Eye: Removal of adherent foreign body 9,580 9,790 310,301 296,882
(ix) Ear/Nose/Throat: Removal of foreign body 28,774 27,237 929,154 826,994
(x) Nebuliser: Treatment in the case of acute asthmatic attack 50,945 53,715 2,334,488 2,454,626
(xi) Bladder: Catheterization 6,877 6,366 316,521 290,315
(xii) Case Conference: Convened by HSE 834 631 59,826 48,156
(xiii) Diaphragm: Advice and fitting of 743 722 37,765 36,893
(xiv) IUCD: Counselling and fitting of 10,006 8,638 790,666 706,981
(xv) Pneumococcal: Vaccination 14,588 16,307 625,251 671,109
(xvi) Influenza: Vaccination 349,890 329,030 14,961,300 13,481,357
(xvii) Pneumococcal/Influenza: Vaccination 13,482 17,021 863,658 1,047,577
(xviii) Hepatitis B: Vaccination 2,093 449 122,777 66,096
National 713,658 679,948 €28,653,853 €26,305,445
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Type of Service East Coast Area South Western Area
Number of 
Claims
Cost of 
Claims
€
Number of 
Claims
Cost of 
Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 6,993 226,581 9,553 309,065
(ii) Suturing: Cuts and Lacerations 1,345 43,627 2,321 75,137
(iii) Hydroceles: Draining of 64 2,156 78 2,499
(iv) Haemorrhages: Dental/Nasal 57 1,877 126 4,131
(v) Veins: Recognised treatment 32 942 395 12,796
(vi) ECG: Tests and interpretation 3,758 122,350 4,802 155,872
(vii) Diaphragm: Instruction in the fitting of 19 690 233 7,639
(viii) Eye: Removal of adherent foreign body 225 7,306 937 30,265
(ix) Ear/Nose/Throat: Removal of foreign body 1,521 49,470 2,760 88,707
(x) Nebuliser: Treatment in the case of acute asthmatic attack 1,407 64,770 4,017 183,742
(xi) Bladder: Catheterization 189 8,681 253 11,631
(xii) Case Conference: Convened by HSE 11 778 12 818
(xiii) Diaphragm: Advice and fitting of 27 1,391 88 4,480
(xiv) IUCD: Counselling and fitting of 585 46,174 1,081 85,691
(xv) Pneumococcal: Vaccination 939 40,414 1,611 68,983
(xvi) Influenza: Vaccination 25,556 1,094,091 36,893 1,577,192
(xvii) Pneumococcal/Influenza: Vaccination 1,202 76,983 1,458 93,460
(xviii) Hepatitis B: Vaccination 83 4,668 209 11,766
Total 44,013 €1,792,949 66,827 €2,723,874
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area
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Type of Service Mid-Western North Eastern
Number of 
Claims
Cost of 
Claims
€
Number of 
Claims
Cost of 
Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 6,587 212,833 8,594 277,484
(ii) Suturing: Cuts and Lacerations 2,942 94,776 2,820 90,802
(iii) Hydroceles: Draining of 118 3,773 51 1,611
(iv) Haemorrhages: Dental/Nasal 120 3,886 70 2,281
(v) Veins: Recognised treatment 161 4,981 1,319 42,317
(vi) ECG: Tests and interpretation 5,538 178,697 5,630 181,605
(vii) Diaphragm: Instruction in the fitting of 66 2,089 65 2,210
(viii) Eye: Removal of adherent foreign body 451 14,742 397 12,748
(ix) Ear/Nose/Throat: Removal of foreign body 2,272 73,152 2,318 73,993
(x) Nebuliser: Treatment in the case of acute asthmatic attack 4,213 191,911 3,837 176,082
(xi) Bladder: Catheterization 655 30,031 446 20,467
(xii) Case Conference: Convened by HSE 50 3,589 11 852
(xiii) Diaphragm: Advice and fitting of 114 5,620 68 3,483
(xiv) IUCD: Counselling and fitting of 650 51,260 892 69,764
(xv) Pneumococcal: Vaccination 1,101 47,210 1,131 48,638
(xvi) Influenza: Vaccination 32,701 1,399,339 29,369 1,256,620
(xvii) Pneumococcal/Influenza: Vaccination 1,284 82,164 1,295 82,933
(xviii) Hepatitis B: Vaccination 161 9,700 123 6,936
Total 59,184 €2,409,753 58,436 €2,350,826
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service Northern Area Midland
Number of 
Claims
Cost of 
Claims
€
Number of 
Claims
Cost of 
Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 7,985 259,823 6,625 213,471
(ii) Suturing: Cuts and Lacerations 2,454 79,598 3,462 111,176
(iii) Hydroceles: Draining of 38 1,178 51 1,641
(iv) Haemorrhages: Dental/Nasal 66 2,016 916 29,596
(v) Veins: Recognised treatment 31 988 953 30,542
(vi) ECG: Tests and interpretation 5,231 169,054 6,374 204,432
(vii) Diaphragm: Instruction in the fitting of 44 1,350 39 1,216
(viii) Eye: Removal of adherent foreign body 472 15,633 959 30,965
(ix) Ear/Nose/Throat: Removal of foreign body 2,606 84,701 2,440 78,020
(x) Nebuliser: Treatment in the case of acute asthmatic attack 1,806 82,939 4,584 211,043
(xi) Bladder: Catheterization 137 6,356 593 27,416
(xii) Case Conference: Convened by HSE 15 1,129 13 956
(xiii) Diaphragm: Advice and fitting of 57 2,911 43 2,174
(xiv) IUCD: Counselling and fitting of 1,107 87,537 849 66,821
(xv) Pneumococcal: Vaccination 2,013 86,310 764 32,712
(xvi) Influenza: Vaccination 38,117 1,629,632 20,547 878,946
(xvii) Pneumococcal/Influenza: Vaccination 1,257 80,561 871 55,798
(xviii) Hepatitis B: Vaccination 356 20,632 74 3,802
Total 63,792 €2,612,348 50,157 €1,980,727
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service North Western South Eastern
Number of 
Claims
Cost of 
Claims
€
Number of 
Claims
Cost of 
Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 8,550 276,070 13,072 422,863
(ii) Suturing: Cuts and Lacerations 3,327 108,274 5,671 184,029
(iii) Hydroceles: Draining of 175 5,676 111 3,536
(iv) Haemorrhages: Dental/Nasal 140 4,658 204 6,562
(v) Veins: Recognised treatment 10 307 530 17,802
(vi) ECG: Tests and interpretation 9,920 321,208 12,062 390,182
(vii) Diaphragm: Instruction in the fitting of 248 7,993 104 3,575
(viii) Eye: Removal of adherent foreign body 804 26,034 1,104 34,578
(ix) Ear/Nose/Throat: Removal of foreign body 2,130 68,872 3,314 108,828
(x) Nebuliser: Treatment in the case of acute asthmatic attack 5,328 244,910 6,965 319,135
(xi) Bladder: Catheterization 1,106 50,891 1,037 47,791
(xii) Case Conference: Convened by HSE 35 2,542 74 3,982
(xiii) Diaphragm: Advice and fitting of 42 2,128 113 5,789
(xiv) IUCD: Counselling and fitting of 773 61,100 1,649 130,680
(xv) Pneumococcal: Vaccination 1,033 44,305 1,880 80,472
(xvi) Influenza: Vaccination 25,030 1,070,165 44,727 1,912,169
(xvii) Pneumococcal/Influenza: Vaccination 943 60,437 1,812 116,182
(xviii) Hepatitis B: Vaccination 186 10,511 159 12,462
Total 59,780 €2,366,081 94,588 €3,800,617
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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Type of Service Southern Western
Number of 
Claims
Cost of 
Claims
€
Number of 
Claims
Cost of 
Claims
€
(i) Excisions/Cryotherapy/Diathermy: Skin Lesions 17,565 566,842 17,659 571,900
(ii) Suturing: Cuts and Lacerations 6,504 209,440 5,570 181,568
(iii) Hydroceles: Draining of 358 11,065 334 10,745
(iv) Haemorrhages: Dental/Nasal 283 9,103 445 14,530
(v) Veins: Recognised treatment 629 20,197 439 14,189
(vi) ECG: Tests and interpretation 10,635 343,193 12,807 413,859
(vii) Diaphragm: Instruction in the fitting of 132 4,389 236 7,603
(viii) Eye: Removal of adherent foreign body 2,878 94,049 1,353 43,981
(ix) Ear/Nose/Throat: Removal of foreign body 5,112 165,277 4,301 138,134
(x) Nebuliser: Treatment in the case of acute asthmatic attack 8,118 369,172 10,670 490,784
(xi) Bladder: Catheterization 1,296 59,699 1,165 53,558
(xii) Case Conference: Convened by HSE 56 4,198 557 40,982
(xiii) Diaphragm: Advice and fitting of 84 4,307 107 5,482
(xiv) IUCD: Counselling and fitting of 1,682 132,760 738 58,879
(xv) Pneumococcal: Vaccination 2,119 90,786 1,997 85,421
(xvi) Influenza: Vaccination 57,714 2,467,108 39,236 1,676,038
(xvii) Pneumococcal/Influenza: Vaccination 2,044 131,009 1,316 84,131
(xviii) Hepatitis B: Vaccination 479 27,981 263 14,319
Total 117,688 €4,710,575 99,193 €3,906,103
Table 13.1  GMS: Analysis of Special Items of Service by HSE Area continued
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NATIONAL
2009 (2008 in brackets)
Doctors with 
panels of:-
Visiting Rate:-*
4-4.9 5-5.9 6-6.9 7-7.9 8-8.9 9-9.9 10-10.9 11-11.9 12 and Over
100-249 - - - (1) - - - - - -
250-499 1 (-) - 1 (-) - - - (2) - - -
500-999 - 2 (-) - - (1) - - - - -
1,000-1,499 - - - (1) 1 (-) - - - - - (1)
Over 1,500 - - - - - 1 (-) 1 (1) - -
TOTAL 1 (-) 2 (-) 1 (2) 1 (1) - (-) 1 (2) 1 (1) - (-) - (1)
Note: (i) The overall visiting rate in 2009 of the Doctors who continued on a Fee-Per-Item of service contract was 8.26 (Surgery: 8.13 Domiciliary: 0.13), (2008 – Total: 9.59 Surgery: 9.28 
Domiciliary: 0.31).
 (ii) Only Doctors with panels of 100 persons or over are included in the above table.
 (iii) * Visiting Rate is the total number of consultations divided by the total number of persons on panel.
Table 14 GMS: Visiting Rate Categories for Doctors on Fee-Per-Item of Service
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Health 
Service 
Executive
Age Classification
Under 5 Years 5-11 Years 12-15 Years 16-24 Years 25-34 Years 35-44 Years
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Eastern Areas 97.26 118.45 108.16 72.20 83.12 77.84 90.69 94.02 92.40 255.39 198.33 230.49 363.08 348.43 357.35 541.04 500.30 523.05
Midland 110.25 112.87 111.59 91.47 98.11 94.87 100.62 92.83 96.64 299.80 228.83 267.73 404.35 368.65 389.01 624.06 524.32 577.62
Mid-Western 131.84 137.90 134.94 105.59 126.98 116.39 110.82 168.90 140.30 284.82 234.24 261.17 403.30 391.06 397.92 593.97 561.50 578.77
North Eastern 83.24 103.90 93.79 75.34 83.23 79.38 82.66 89.24 86.06 237.96 176.64 209.63 311.99 291.97 303.37 431.52 403.56 418.38
North Western 72.92 89.30 81.37 63.35 82.84 73.46 74.21 84.81 79.81 191.79 157.58 175.45 294.00 246.18 272.21 414.24 381.97 398.85
South Eastern 101.47 109.31 105.52 76.19 100.09 88.46 92.76 119.01 106.40 260.34 207.21 235.60 349.30 353.35 351.12 544.17 491.94 519.42
Southern 120.13 148.16 134.35 101.97 120.32 111.53 151.61 128.17 138.25 299.18 253.95 277.79 406.38 400.28 403.69 604.81 570.16 588.36
Western 107.08 115.82 111.58 78.27 90.63 84.68 87.52 95.78 91.73 238.56 201.28 221.06 356.50 328.53 343.85 498.68 472.87 486.44
National €102.61 €118.58 €110.80 €81.22 €95.79 €88.73 €95.06 €107.14 €101.28 €258.26 €207.26 €234.81 €362.95 €345.78 €355.58 €534.71 €493.46 €515.56
% of National 
Average 12.04% 13.91% 13.00% 9.53% 11.24% 10.41% 11.15% 12.57% 11.88% 30.30% 24.32% 27.55% 42.58% 40.57% 41.72% 62.73% 57.89% 60.49%
Table 15 GMS: Cost of Medicines by Gender within Age Groups
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Table 15 GMS: Cost of Medicines by Gender within Age Groups continued
Health 
Service 
Executive
Age Classification
45-54 Years 55-64 Years 65-69 Years 70-74 Years 75 Years & Over Total
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Female
€
Male
€
Total
€
Eastern Areas 988.74 903.66 949.08 1,423.46 1,392.79 1,409.74 1,660.55 1,789.16 1,712.77 1,686.90 1,626.12 1,659.52 2,043.28 1,985.41 2,021.50 952.81 831.71 899.07
Midland 1,065.61 968.35 1,018.37 1,637.68 1,544.42 1,594.16 1,747.43 1,907.08 1,817.04 1,915.24 1,869.37 1,893.11 2,347.11 2,218.73 2,292.55 987.05 879.11 936.55
Mid-Western 982.01 910.95 947.03 1,453.12 1,377.72 1,417.36 1,570.64 1,562.60 1,567.06 1,628.68 1,568.85 1,599.63 1,922.20 1,910.95 1,917.62 918.48 838.61 881.15
North Eastern 811.91 760.44 786.74 1,267.30 1,245.87 1,257.08 1,480.21 1,547.98 1,510.46 1,665.63 1,590.14 1,628.92 1,950.04 1,919.43 1,937.71 790.48 709.52 752.56
North Western 650.96 642.06 646.57 1,093.18 1,040.23 1,067.21 1,342.37 1,327.47 1,335.18 1,427.49 1,426.02 1,426.76 1,774.98 1,697.60 1,742.17 712.65 643.27 679.20
South Eastern 975.12 888.37 932.61 1,390.21 1,347.22 1,369.68 1,620.17 1,645.32 1,631.63 1,688.25 1,639.30 1,664.52 2,014.60 1,972.45 1,997.04 887.91 805.47 848.88
Southern 1,018.94 934.93 978.41 1,486.77 1,430.80 1,460.09 1,620.96 1,698.55 1,654.94 1,686.39 1,669.57 1,678.38 1,872.67 1,888.89 1,879.11 963.39 879.19 924.17
Western 827.11 758.71 793.15 1,202.49 1,135.96 1,169.08 1,376.84 1,419.37 1,396.78 1,560.01 1,512.84 1,536.41 1,919.37 1,835.12 1,884.09 822.99 743.72 785.04
National €931.20 €856.00 €894.82 €1,376.49 €1,320.20 €1,349.85 €1,573.99 €1,630.49 €1,598.89 €1,664.28 €1,614.53 €1,640.65 €1,980.27 €1,932.22 €1,961.04 €896.71 €801.11 €852.35
% of National 
Average 109.25% 100.43% 104.98% 161.49% 154.89% 158.37% 184.66% 191.29% 187.59% 195.26% 189.42% 192.49% 232.33% 226.69% 230.07% 105.20% 93.99% 100.00%
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Health Service Executive
Number of Forms Number of Items Items per Form
2009 2008 2009 2008 2009 2008
East Coast Area 993,022 1,017,824 3,252,646 3,313,978 3.28 3.26
South Western Area 1,884,323 1,811,548 5,995,036 5,710,301 3.18 3.15
Northern Area 1,720,016 1,653,006 5,683,891 5,386,385 3.30 3.26
Midland 1,112,330 1,049,184 3,464,279 3,263,230 3.11 3.11
Mid-Western 1,528,655 1,467,904 4,783,532 4,543,217 3.13 3.10
North Eastern 1,438,637 1,357,289 4,423,611 4,151,331 3.07 3.06
North Western 1,145,110 1,101,717 3,211,631 3,051,204 2.80 2.77
South Eastern 2,124,830 1,988,249 6,546,461 6,090,929 3.08 3.06
Southern 2,610,466 2,509,295 8,093,563 7,682,044 3.10 3.06
Western 1,775,985 1,692,464 5,267,269 5,019,244 2.97 2.97
National 16,333,374 15,648,480 50,721,919 48,211,863 3.11 3.08
Table 16 GMS: Number of Prescription Forms and Items
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Table 16.1  GMS: Payment to Pharmacists in Respect of Prescriptions
Health Service 
Executive
Cost Cost per Form Cost per Item Ingredient Cost per Item
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
2009
€
2008
€
East Coast Area 79,269,422 76,658,161 79.83 75.32 24.37 23.13 18.52 17.82
South Western Area 143,478,091 130,760,225 82.79 72.18 25.05 22.90 19.40 17.80
Northern Area 142,396,051 129,670,929 76.14 78.45 23.93 24.07 18.43 18.88
Midland 85,856,163 77,309,694 77.19 73.69 24.78 23.69 19.14 18.46
Mid-Western 114,861,653 103,791,414 75.14 70.71 24.01 22.85 18.52 17.82
North Eastern 107,311,281 96,271,457 74.59 70.93 24.26 23.19 18.69 18.08
North Western 78,890,836 71,243,813 68.89 64.67 24.56 23.35 19.01 18.27
South Eastern 159,970,989 141,368,882 75.29 71.10 24.44 23.21 18.77 17.96
Southern 200,584,382 181,590,826 76.84 72.37 24.78 23.64 19.27 18.57
Western 133,316,155 120,828,844 75.07 71.39 25.31 24.07 19.72 18.93
National €1,245,935,023 €1,129,494,245 €76.28 €72.18 €24.56 €23.43 €18.97 €18.28
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Prescription forms having:-
2009 2008
No. of Forms % of Total No. of Forms % of Total
One Item 6,260,489 38.08 5,906,955 37.71
Two Items 3,133,752 19.06 3,014,358 19.25
Three Items 1,788,810 10.88 1,736,950 11.09
Four Items 1,230,428 7.48 1,200,360 7.66
Five Items 993,697 6.04 965,800 6.17
Six Items 912,282 5.55 889,444 5.68
Seven Items 981,195 5.97 964,431 6.16
Eight or more Items 1,140,953 6.94 984,059 6.28
Table 16.2  GMS: Number of Items on Prescription Forms
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Table 16.3  DP: Number of Items on Claim Forms
Claim forms having:-
2009 2008
No. of Forms % of Total No. of Forms % of Total
One Item 2,004,397 40.84 2,372,535 43.38
Two Items 993,484 20.24 1,155,396 21.13
Three Items 616,005 12.55 680,676 12.44
Four Items 430,221 8.77 447,136 8.18
Five Items 301,242 6.14 297,116 5.43
Six Items 202,985 4.14 192,925 3.53
Seven Items 132,144 2.69 122,229 2.23
Eight or more Items 227,500 4.63 201,026 3.68
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Table 16.4  LTI: Number of Items on Claim Forms
Claim forms having:-
2009 2008
No. of Forms % of Total No. of Forms % of Total
One Item 305,806 33.97 306,096 35.20
Two Items 154,991 17.21 155,502 17.88
Three Items 107,973 11.99 105,346 12.11
Four Items 92,888 10.32 87,855 10.10
Five Items 78,834 8.76 73,169 8.42
Six Items 60,763 6.75 54,981 6.32
Seven Items 41,885 4.65 37,240 4.28
Eight or more Items 57,202 6.35 49,471 5.69
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Table 17 GMS: Number of Dispensing Doctors* and Persons for whom they Dispense
Health Service Executive 2009 2008
No. of Doctors No. of Persons No. of Doctors No. of Persons
Eastern Areas - - - -
Midland 8 4,450 8 4,552
Mid-Western 11 2,572 10 2,844
North Eastern 5 1,414 5 1,350
North Western 31 12,053 31 12,372
South Eastern 19 7,667 20 7,714
Southern 11 1,544 11 1,516
Western 32 15,139 32 14,030
National 117 44,839 117 44,378
Note: * In rural areas where a Doctor has a centre of practice 3 miles or more from the nearest Community Pharmacy the Doctor dispenses for persons served from that centre who opt to 
be dispensed to. The Doctor is paid a dispensing fee for each such person. A Doctor’s medicine requirements are obtained on a Stock Order from a Community Pharmacy – the 
stock ordered is approved in advance by a HSE Area.
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Table 18 GMS: Advance Payments to Pharmacists
Health Service Executive
Amount Advanced to Pharmacists as at 31st December:-
2009
€
2008
€
Eastern 3,362,872 3,384,618
Midland 809,506 816,960
Mid-Western 1,054,886 1,115,195
North Eastern 1,345,799 1,355,407
North Western 1,100,378 1,129,687
South Eastern 1,666,976 1,736,620
Southern 1,920,544 1,969,626
Western 1,592,977 1,690,724
National €12,853,938 €13,198,837
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Table 19 GMS: Notes on Some of the More Commonly Prescribed Products
AMOXICILLIN
AMOXICILLIN AND 
ENZYME INHIBITOR
FUROSEMIDE
FUROSEMIDE WITH 
POTASSIUM SPARING 
DIURETICS
SALBUTAMOL
DICLOFENAC
ATORVASTATIN AND 
PRAVASTATIN
Amoxicillin, alone or potentiated by 
an inhibitor of bacterial enzymes is a 
broad spectrum Penicillin antibiotic 
indicated for the treatment of 
a wide range of infections. 
Salbutamol is a beta-adrenergic 
stimulant used mainly in the treatment 
of chronic asthma and chronic 
bronchitis.
Diclofenac is a Non-Steroidal Anti-
inflammatory Drug (NSAID) mainly 
used to treat pain and inflammation 
associated with muscular conditions 
and rheumatoid arthritis. 
Atorvastatin and Pravastatin are 
indicated, in combination with dietary 
measures, for lowering cholesterol 
levels.
The diuretic Furosemide, alone or in 
combination with potassium – sparing 
diuretics, is used to treat hypertension.
OMEPRAZOLE
LANSOPRAZOLE
BECLOMETASONE
AMLODIPINE
ACETYLSALICYLIC 
ACID - ASPIRIN
ATENOLOL
Beclometasone is a potent steroid 
having an anti-inflammatory action 
within the lungs. It is used mainly 
by inhalation for the treatment of 
bronchial asthma.
Amlodipine is a calcium – channel 
blocker (similar to nifedipine) with 
peripheral and coronary vasodilator 
properties. It is given by mouth in the 
management of hypertension 
and of angina pectoris.
Acetylsalicylic Acid-Aspirin has anti-
inflammatory and additionally analgesic 
and antipyretic (body temperature 
lowering) action. Acetylsalicylic 
Acid-Aspirin also has action against 
thrombosis or clot formation by 
inhibition of platelet cell aggregration 
in the blood.
Atenolol is a beta blocker. Members 
of this class of drugs are used in the 
treatment of hypertension, angina 
pectoris and cardiac arrythmias.
Omeprazole and Lansoprazole are 
proton pump inhibitors which prevent 
secretion of gastric acid. They are used 
in the treatment of reflux oesophagitis 
and peptic ulceration.
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Table 19.1  GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Acetylsalicylic Acid-Aspirin (Antithrombotic) 2,543,938 5.02 5,532,028 0.57
2 Atorvastatin 1,706,372 3.36 70,800,434 7.27
3 Levothyroxine Sodium 974,211 1.92 1,864,262 0.19
4 Calcium, Combinations 898,419 1.77 7,303,320 0.75
5 Paracetamol 869,518 1.71 1,127,559 0.12
6 Bisoprolol 861,809 1.70 6,856,504 0.70
7 Salbutamol (Inhaled) 855,724 1.69 4,582,589 0.47
8 Amlodipine 775,614 1.53 10,303,977 1.06
9 Ramipril 715,103 1.41 7,396,800 0.76
10 Esomeprazole 688,570 1.36 30,645,624 3.15
11 Warfarin 677,398 1.34 1,685,742 0.17
12 Amoxicillin and Enzyme Inhibitor 676,616 1.33 5,808,315 0.60
13 Lansoprazole 668,620 1.32 24,535,582 2.52
14 Omeprazole 613,217 1.21 22,776,338 2.34
15 Furosemide 609,987 1.20 634,260 0.07
16 Clinical Nutritional Products 553,149 1.09 41,382,430 4.25
17 Diclofenac (Systemic) 546,302 1.08 5,647,663 0.58
18 Perindopril 530,925 1.05 10,680,222 1.10
19 Pravastatin 511,563 1.01 14,203,093 1.46
20 Metformin 495,350 0.98 1,738,430 0.18
21 Zopiclone 492,141 0.97 3,500,795 0.36
22 Diazepam 484,814 0.96 496,483 0.05
23 Prednisolone (Systemic) 474,136 0.93 1,747,898 0.18
24 Rosuvastatin 468,619 0.92 13,876,445 1.43
25 Atenolol 461,321 0.91 2,258,362 0.23
26 Salmeterol and other drugs for obstructive airway diseases 440,067 0.87 31,646,309 3.25
27 Pantoprazole 427,325 0.84 13,354,807 1.37
28 Diagnostic Products 425,437 0.84 16,387,335 1.68
29 Alprazolam 399,798 0.79 1,011,278 0.10
30 Bendroflumethiazide 390,063 0.77 613,389 0.06
31 Amoxicillin 381,979 0.75 1,473,515 0.15
32 Zolpidem 375,896 0.74 1,699,259 0.17
33 Escitalopram 368,346 0.73 11,431,492 1.17
34 Paracetamol Combs. excl. Psycholeptics 363,064 0.72 2,401,407 0.25
35 Codeine, Combs excl. Psycholeptics 349,172 0.69 3,065,687 0.31
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Table 19.1  GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Clopidogrel 348,614 0.69 18,998,563 1.95
37 Diclofenac (Topical) 329,475 0.65 2,017,589 0.21
38 Gliclazide 323,960 0.64 3,153,663 0.32
39 Lactulose 321,390 0.63 1,375,688 0.14
40 Alendronic Acid 319,955 0.63 10,708,256 1.10
41 Tramadol 318,039 0.63 3,795,162 0.39
42 Ferrous Fumarate 313,904 0.62 576,014 0.06
43 Carbocisteine 309,255 0.61 1,167,977 0.12
44 Folic Acid 306,310 0.60 294,058 0.03
45 Artificial tears and other indifferent preparations 294,267 0.58 1,706,462 0.18
46 Venlafaxine 288,438 0.57 10,533,483 1.08
47 Doxazosin 288,041 0.57 8,469,086 0.87
48 Tiotropium Bromide 280,345 0.55 14,282,459 1.47
49 Alginic Acid 277,924 0.55 1,605,719 0.16
50 Citalopram 271,792 0.54 5,002,090 0.51
51 Beclometasone (Inhaled) 270,526 0.53 4,989,137 0.51
52 Domperidone 264,949 0.52 1,026,364 0.11
53 Glucosamine 262,931 0.52 6,461,137 0.66
54 Digoxin 255,203 0.50 215,827 0.02
55 Clarithromycin 238,508 0.47 4,206,028 0.43
56 Needles/Syringes/Lancets 230,613 0.45 3,065,677 0.31
57 Macrogol combinations 228,431 0.45 3,726,191 0.38
58 Lisinopril 227,405 0.45 2,499,061 0.26
59 Ibuprofen 219,017 0.43 630,582 0.06
60 Isosorbide Mononitrate 214,132 0.42 2,479,507 0.25
61 Drospirenone and Estrogen 207,599 0.41 1,494,744 0.15
62 Pregabalin 205,776 0.41 18,953,727 1.95
63 Bendroflumethiazide and Potassium 204,434 0.40 724,031 0.07
64 Furosemide and Potassium-Sparing Agents 201,610 0.40 832,892 0.09
65 Temazepam 200,706 0.40 418,493 0.04
66 Valsartan 200,351 0.39 4,784,821 0.49
67 Tamsulosin 196,762 0.39 5,512,832 0.57
68 Allopurinol 195,508 0.39 955,978 0.10
69 Lercanidipine 192,352 0.38 2,992,465 0.31
70 Mirtazapine 186,066 0.37 4,127,061 0.42
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Table 19.1  GMS: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Formoterol and other drugs for obstructive airway diseases 182,896 0.36 10,752,860 1.10
72 Olanzapine 180,955 0.36 20,827,127 2.14
73 Flurazepam 178,165 0.35 778,239 0.08
74 Losartan 177,148 0.35 4,870,209 0.50
75 Simvastatin 175,008 0.35 4,284,057 0.44
76 Nebivolol 170,890 0.34 2,491,412 0.26
77 Amitriptyline 165,518 0.33 149,647 0.02
78 Risedronic Acid 162,789 0.32 5,967,470 0.61
79 Betahistine 162,763 0.32 1,742,642 0.18
80 Sodium Valproate 162,583 0.32 1,794,629 0.18
81 Mefenamic Acid 161,631 0.32 640,915 0.07
82 Betamethasone (Topical) 160,125 0.32 739,493 0.08
83 Flucloxacillin 153,310 0.30 1,268,490 0.13
84 Metoprolol 149,672 0.30 314,966 0.03
85 Tolterodine 149,190 0.29 6,989,654 0.72
86 Quetiapine 148,026 0.29 9,098,226 0.93
87 Glyceryl Trinitrate 147,425 0.29 1,465,935 0.15
88 Other Emollients and Protectives 146,583 0.29 364,014 0.04
89 Latanoprost 144,185 0.28 3,648,466 0.37
90 Valsartan and Diuretics 136,862 0.27 3,642,901 0.37
91 Montelukast 136,287 0.27 5,321,158 0.55
92 Rabeprazole 135,812 0.27 4,337,875 0.45
93 Fluoxetine 135,275 0.27 3,078,761 0.32
94 Levonorgestrel and Estrogen (Fixed Comb. Contraceptive) 135,084 0.27 501,337 0.05
95 Sertraline 134,374 0.26 4,300,656 0.44
96 Cefaclor 131,082 0.26 988,307 0.10
97 Carbamazepine 130,731 0.26 955,261 0.10
98 Risperidone 129,810 0.26 8,482,197 0.87
99 Salbutamol and other drugs for obstructive airway diseases 126,375 0.25 6,576,100 0.68
100 Hypromellose 125,560 0.25 805,471 0.08
Total 36,605,285 72.22% €651,430,932 66.88%
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Table 19.2  GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Atorvastatin 70,800,434 7.27 1,706,372 3.36
2 Clinical Nutritional Products 41,382,430 4.25 553,149 1.09
3 Salmeterol and other drugs for obstructive airway diseases 31,646,309 3.25 440,067 0.87
4 Esomeprazole 30,645,624 3.15 688,570 1.36
5 Lansoprazole 24,535,582 2.52 668,620 1.32
6 Omeprazole 22,776,338 2.34 613,217 1.21
7 Olanzapine 20,827,127 2.14 180,955 0.36
8 Clopidogrel 18,998,563 1.95 348,614 0.69
9 Pregabalin 18,953,727 1.95 205,776 0.41
10 Diagnostic Products 16,387,335 1.68 425,437 0.84
11 Tiotropium Bromide 14,282,459 1.47 280,345 0.55
12 Pravastatin 14,203,093 1.46 511,563 1.01
13 Rosuvastatin 13,876,445 1.43 468,619 0.92
14 Pantoprazole 13,354,807 1.37 427,325 0.84
15 Ostomy Requisites 12,619,818 1.30 122,742 0.24
16 Escitalopram 11,431,492 1.17 368,346 0.73
17 Donepezil 10,860,158 1.12 112,976 0.22
18 Formoterol and other drugs for obstructive airway diseases 10,752,860 1.10 182,896 0.36
19 Alendronic Acid 10,708,256 1.10 319,955 0.63
20 Perindopril 10,680,222 1.10 530,925 1.05
21 Venlafaxine 10,533,483 1.08 288,438 0.57
22 Amlodipine 10,303,977 1.06 775,614 1.53
23 Quetiapine 9,098,226 0.93 148,026 0.29
24 Risperidone 8,482,197 0.87 129,810 0.26
25 Doxazosin 8,469,086 0.87 288,041 0.57
26 Fentanyl 8,402,617 0.86 57,306 0.11
27 Ramipril 7,396,800 0.76 715,103 1.41
28 Calcium, Combinations 7,303,320 0.75 898,419 1.77
29 Tolterodine 6,989,654 0.72 149,190 0.29
30 Bisoprolol 6,856,504 0.70 861,809 1.70
31 Urinary Appliances 6,670,509 0.69 70,783 0.14
32 Salbutamol and other drugs for obstructive airway diseases 6,576,100 0.68 126,375 0.25
33 Glucosamine 6,461,137 0.66 262,931 0.52
34 Lamotrigine 6,230,181 0.64 110,309 0.22
35 Risedronic Acid 5,967,470 0.61 162,789 0.32
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Table 19.2  GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Budesonide (Inhaled) 5,931,549 0.61 73,066 0.14
37 Amoxicillin and Enzyme Inhibitor 5,808,315 0.60 676,616 1.33
38 Diclofenac (Systemic) 5,647,663 0.58 546,302 1.08
39 Acetylsalicylic Acid-Aspirin (Antithrombotic) 5,532,028 0.57 2,543,938 5.02
40 Tamsulosin 5,512,832 0.57 196,762 0.39
41 Montelukast 5,321,158 0.55 136,287 0.27
42 Simvastatin and Ezetimibe 5,123,994 0.53 93,389 0.18
43 Citalopram 5,002,090 0.51 271,792 0.54
44 Beclometasone (Inhaled) 4,989,137 0.51 270,526 0.53
45 Losartan 4,870,209 0.50 177,148 0.35
46 Valsartan 4,784,821 0.49 200,351 0.39
47 Levetiracetam 4,776,320 0.49 50,964 0.10
48 Salbutamol (Inhaled) 4,582,589 0.47 855,724 1.69
49 Memantine 4,516,315 0.46 46,468 0.09
50 Buprenorphine 4,358,311 0.45 72,558 0.14
51 Rabeprazole 4,337,875 0.45 135,812 0.27
52 Sertraline 4,300,656 0.44 134,374 0.26
53 Simvastatin 4,284,057 0.44 175,008 0.35
54 Anastrazole 4,234,429 0.44 39,573 0.08
55 Clarithromycin 4,206,028 0.43 238,508 0.47
56 Mirtazapine 4,127,061 0.42 186,066 0.37
57 Gabapentin 4,111,893 0.42 82,425 0.16
58 Nicotine 4,065,655 0.42 122,746 0.24
59 Insulin Glargine, Long Acting 4,054,967 0.42 51,737 0.10
60 Etoricoxib 4,052,328 0.42 124,928 0.25
61 Aripiprazole 3,807,726 0.39 21,194 0.04
62 Tramadol 3,795,162 0.39 318,039 0.63
63 Macrogol, Combinations 3,726,191 0.38 228,431 0.45
64 Latanoprost 3,648,466 0.37 144,185 0.28
65 Valsartan and Diuretics 3,642,901 0.37 136,862 0.27
66 Varenicline 3,559,612 0.37 45,259 0.09
67 Ezetimibe 3,546,845 0.36 86,139 0.17
68 Zopiclone 3,500,795 0.36 492,141 0.97
69 Mesalazine 3,483,699 0.36 51,240 0.10
70 Alendronic Acid, Combinations 3,452,932 0.35 98,214 0.19
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Table 19.2  GMS: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Duloxetine 3,215,869 0.33 82,609 0.16
72 Gliclazide 3,153,663 0.32 323,960 0.64
73 Insulin Aspart, Fast Acting 3,102,759 0.32 48,529 0.10
74 Fluoxetine 3,078,761 0.32 135,275 0.27
75 Codeine Combs. excl. Psycholeptics 3,065,687 0.31 349,172 0.69
76 Needles/Syringes/Lancets 3,065,677 0.31 230,613 0.45
77 Sildenafil 3,004,298 0.31 92,095 0.18
78 Lercanidipine 2,992,465 0.31 192,352 0.38
79 Telmisartan 2,974,997 0.31 118,818 0.23
80 Oxycodone 2,902,925 0.30 77,612 0.15
81 Fluticasone (Inhaled) 2,843,927 0.29 48,495 0.10
82 Orlistat 2,834,373 0.29 43,534 0.09
83 Ibandronic Acid 2,770,811 0.28 83,638 0.16
84 Solifenacin 2,743,127 0.28 52,998 0.10
85 Calcipotriol, Combinations 2,731,892 0.28 31,399 0.06
86 Insulin Detemir, Long Acting 2,645,764 0.27 30,009 0.06
87 Tinzaparin 2,638,922 0.27 11,194 0.02
88 Timolol, Combinations 2,532,828 0.26 85,647 0.17
89 Lisinopril 2,499,061 0.26 227,405 0.45
90 Nebivolol 2,491,412 0.26 170,890 0.34
91 Isosorbide Mononitrate 2,479,507 0.25 214,132 0.42
92 Ranitidine 2,465,606 0.25 117,116 0.23
93 Paroxetine 2,454,341 0.25 110,091 0.22
94 Omega-3-triglycerides 2,445,312 0.25 87,453 0.17
95 Paracetamol Combs. excl. Psycholeptics 2,401,407 0.25 363,064 0.72
96 Candesartan 2,364,328 0.24 98,037 0.19
97 Alfuzosin 2,299,393 0.24 76,825 0.15
98 Strontium Ranelate 2,269,421 0.23 48,234 0.10
99 Atenolol 2,258,362 0.23 461,321 0.91
100 Losartan and Diuretics 2,230,767 0.23 72,185 0.14
Total €771,118,611 79.19% 27,410,886 54.04%
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Table 19.3  DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Acetylsalicylic Acid-Aspirin (Antithrombotic) 678,884 5.08 1,487,184 0.52
2 Atorvastatin 620,468 4.64 25,690,138 8.96
3 Levothyroxine Sodium 334,499 2.50 649,269 0.23
4 Salbutamol (Inhaled) 281,051 2.10 1,328,871 0.46
5 Esomeprazole 264,083 1.97 11,759,753 4.10
6 Rosuvastatin 262,873 1.97 7,624,316 2.66
7 Bisoprolol 245,196 1.83 1,896,662 0.66
8 Calcium, Combinations 243,582 1.82 2,033,110 0.71
9 Diclofenac (Systemic) 223,253 1.67 2,429,004 0.85
10 Amlodipine 215,177 1.61 2,758,218 0.96
11 Amoxicillin and Enzyme Inhibitor 187,961 1.41 1,628,488 0.57
12 Omeprazole 176,244 1.32 6,579,690 2.29
13 Salmeterol and other drugs for obstructive airway diseases 172,611 1.29 11,559,155 4.03
14 Lansoprazole 170,503 1.28 6,629,745 2.31
15 Ramipril 169,155 1.26 1,747,212 0.61
16 Perindopril 162,989 1.22 3,281,226 1.14
17 Prednisolone (Systemic) 148,635 1.11 621,795 0.22
18 Atenolol 127,115 0.95 600,376 0.21
19 Escitalopram 123,888 0.93 3,952,971 1.38
20 Pravastatin 123,030 0.92 3,425,036 1.19
21 Venlafaxine 117,870 0.88 4,358,108 1.52
22 Clinical Nutritional Products 117,302 0.88 5,119,042 1.78
23 Pantoprazole 112,633 0.84 3,558,223 1.24
24 Warfarin 111,687 0.84 274,048 0.10
25 Zopiclone 104,380 0.78 741,334 0.26
26 Formoterol and other drugs for obstructive airway diseases 103,917 0.78 5,964,413 2.08
27 Clopidogrel 102,952 0.77 5,497,417 1.92
28 Glucosamine 101,475 0.76 2,456,869 0.86
29 Clarithromycin 99,784 0.75 1,862,140 0.65
30 Montelukast 96,152 0.72 3,696,647 1.29
31 Zolpidem 95,823 0.72 449,209 0.16
32 Alprazolam 93,390 0.70 226,441 0.08
33 Bendroflumethiazide 86,502 0.65 131,639 0.05
34 Paracetamol 84,719 0.63 108,461 0.04
35 Codeine Combs. excl. Psycholeptics 79,426 0.59 662,049 0.23
78
Table 19.3  DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Folic Acid 79,245 0.59 75,435 0.03
37 Doxazosin 77,571 0.58 2,265,141 0.79
38 Valsartan 76,586 0.57 1,768,281 0.62
39 Beclometasone (Inhaled) 76,116 0.57 1,327,992 0.46
40 Paracetamol Combs. excl. Psycholeptics 75,786 0.57 543,172 0.19
41 Diazepam 74,493 0.56 53,116 0.02
42 Amoxicillin 73,347 0.55 332,623 0.12
43 Alendronic Acid 72,966 0.55 2,406,296 0.84
44 Citalopram 69,572 0.52 1,300,900 0.45
45 Nebivolol 69,248 0.52 1,007,848 0.35
46 Tramadol 67,601 0.51 790,858 0.28
47 Allopurinol 66,278 0.50 352,572 0.12
48 Valsartan and Diuretics 64,770 0.48 1,674,267 0.58
49 Drospirenone and Estrogen 64,057 0.48 451,762 0.16
50 Diclofenac (Topical) 62,318 0.47 410,667 0.14
51 Pregabalin 62,036 0.46 5,566,197 1.94
52 Losartan 58,977 0.44 1,579,669 0.55
53 Simvastatin and Ezetimibe 58,414 0.44 3,094,750 1.08
54 Lisinopril 57,849 0.43 620,480 0.22
55 Omega-3-triglycerides 56,526 0.42 1,610,900 0.56
56 Domperidone 55,010 0.41 210,270 0.07
57 Etoricoxib 53,536 0.40 1,709,481 0.60
58 Amitriptyline 51,239 0.38 64,877 0.02
59 Alginic Acid 51,165 0.38 308,865 0.11
60 Mometasone 50,916 0.38 777,254 0.27
61 Telmisartan 50,853 0.38 1,234,819 0.43
62 Artificial tears and other indifferent preparations 50,558 0.38 373,034 0.13
63 Ezetimibe 50,402 0.38 1,997,274 0.70
64 Furosemide 49,523 0.37 58,894 0.02
65 Methotrexate 49,092 0.37 431,651 0.15
66 Tiotropium Bromide 48,441 0.36 2,377,466 0.83
67 Fluticasone (Nasal) 48,333 0.36 496,824 0.17
68 Cetirizine 47,989 0.36 317,826 0.11
69 Mefenamic Acid 47,537 0.36 168,102 0.06
70 Lercanidipine 46,826 0.35 719,868 0.25
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Tadalafil 46,685 0.35 1,370,135 0.48
72 Simvastatin 45,707 0.34 1,110,107 0.39
73 Sertraline 45,099 0.34 1,482,479 0.52
74 Risedronic Acid 45,070 0.34 1,582,359 0.55
75 Mesalazine 44,979 0.34 3,604,461 1.26
76 Betamethasone (Topical) 44,740 0.33 216,808 0.08
77 Bendroflumethazide and Potassium 43,918 0.33 149,854 0.05
78 Olmesartan Medoxomil 43,794 0.33 912,730 0.32
79 Fluoxetine 43,174 0.32 1,021,534 0.36
80 Estradiol 42,883 0.32 431,377 0.15
81 Carbocisteine 41,958 0.31 161,248 0.06
82 Olanzapine 40,711 0.30 3,598,191 1.25
83 Sildenafil 38,601 0.29 1,186,917 0.41
84 Ostomy Requisites 38,497 0.29 3,520,075 1.23
85 Tamsulosin 38,375 0.29 1,052,452 0.37
86 Lithium 37,651 0.28 80,991 0.03
87 Candesartan 37,544 0.28 867,418 0.30
88 Paroxetine 36,409 0.27 782,246 0.27
89 Desloratadine 36,020 0.27 400,808 0.14
90 Duloxetine 34,358 0.26 1,363,685 0.48
91 Metformin 34,195 0.26 105,743 0.04
92 Losartan and Diuretics 34,028 0.25 1,009,327 0.35
93 Ibandronic Acid 33,985 0.25 1,071,579 0.37
94 Metoprolol 33,980 0.25 71,415 0.02
95 Ibuprofen 33,688 0.25 124,751 0.04
96 Flucloxacillin 33,578 0.25 283,360 0.10
97 Bromazepam 32,884 0.25 168,499 0.06
98 Cefaclor 32,715 0.24 257,902 0.09
99 Meloxicam 32,368 0.24 311,683 0.11
100 Antifungal Combs. (Topical) 32,292 0.24 111,379 0.04
Total 9,714,271 72.66% €199,679,203 69.66%
Table 19.3  DP: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency continued
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Table 19.4  DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Atorvastatin 25,690,138 8.96 620,468 4.64
2 Esomeprazole 11,759,753 4.10 264,083 1.97
3 Salmeterol and other drugs for obstructive airway diseases 11,559,155 4.03 172,611 1.29
4 Rosuvastatin 7,624,316 2.66 262,873 1.97
5 Lansoprazole 6,629,745 2.31 170,503 1.28
6 Omeprazole 6,579,690 2.29 176,244 1.32
7 Formoterol and other drugs for obstructive airway diseases 5,964,413 2.08 103,917 0.78
8 Pregabalin 5,566,197 1.94 62,036 0.46
9 Clopidogrel 5,497,417 1.92 102,952 0.77
10 Clinical Nutritional Products 5,119,042 1.78 117,302 0.88
11 Venlafaxine 4,358,108 1.52 117,870 0.88
12 Escitalopram 3,952,971 1.38 123,888 0.93
13 Montelukast 3,696,647 1.29 96,152 0.72
14 Mesalazine 3,604,461 1.26 44,979 0.34
15 Olanzapine 3,598,191 1.25 40,711 0.30
16 Pantoprazole 3,558,223 1.24 112,633 0.84
17 Ostomy Requisites 3,520,075 1.23 38,497 0.29
18 Pravastatin 3,425,036 1.19 123,030 0.92
19 Perindopril 3,281,226 1.14 162,989 1.22
20 Simvastatin and Ezetimibe 3,094,750 1.08 58,414 0.44
21 Amlodipine 2,758,218 0.96 215,177 1.61
22 Glucosamine 2,456,869 0.86 101,475 0.76
23 Diclofenac (Systemic) 2,429,004 0.85 223,253 1.67
24 Alendronic Acid 2,406,296 0.84 72,966 0.55
25 Tiotropium Bromide 2,377,466 0.83 48,441 0.36
26 Doxazosin 2,265,141 0.79 77,571 0.58
27 Calcipotriol, Combinations 2,236,169 0.78 22,580 0.17
28 Follitropin Beta 2,178,992 0.76 2,530 0.02
29 Calcium, Combinations 2,033,110 0.71 243,582 1.82
30 Ezetimibe 1,997,274 0.70 50,402 0.38
31 Bisoprolol 1,896,662 0.66 245,196 1.83
32 Clarithromycin 1,862,140 0.65 99,784 0.75
33 Plastic IUCD with Progestogens 1,816,938 0.63 14,771 0.11
34 Valsartan 1,768,281 0.62 76,586 0.57
35 Varenicline 1,767,000 0.62 22,605 0.17
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Ramipril 1,747,212 0.61 169,155 1.26
37 Etoricoxib 1,709,481 0.60 53,536 0.40
38 Valsartan and Diuretics 1,674,267 0.58 64,770 0.48
39 Quetiapine 1,635,068 0.57 25,789 0.19
40 Amoxicillin and Enzyme Inhibitor 1,628,488 0.57 187,961 1.41
41 Omega-3-triglycerides 1,610,900 0.56 56,526 0.42
42 Anastrazole 1,595,470 0.56 15,274 0.11
43 Risedronic Acid 1,582,359 0.55 45,070 0.34
44 Losartan 1,579,669 0.55 58,977 0.44
45 Acetylsalicylic Acid-Aspirin (Antithrombotic) 1,487,184 0.52 678,884 5.08
46 Sertraline 1,482,479 0.52 45,099 0.34
47 Orlistat 1,404,045 0.49 21,948 0.16
48 Tadalafil 1,370,135 0.48 46,685 0.35
49 Duloxetine 1,363,685 0.48 34,358 0.26
50 Salbutamol (Inhaled) 1,328,871 0.46 281,051 2.10
51 Beclometasone (Inhaled) 1,327,992 0.46 76,116 0.57
52 Citalopram 1,300,900 0.45 69,572 0.52
53 Fentanyl 1,279,272 0.45 6,774 0.05
54 Lamotrigine 1,245,751 0.43 27,729 0.21
55 Telmisartan 1,234,819 0.43 50,853 0.38
56 Urinary Requisites 1,219,839 0.43 9,936 0.07
57 Sumatriptan 1,207,104 0.42 20,821 0.16
58 Sibutramine 1,188,996 0.41 18,933 0.14
59 Sildenafil 1,186,917 0.41 38,601 0.29
60 Isotretinoin 1,164,364 0.41 17,643 0.13
61 Famciclovir 1,127,500 0.39 8,255 0.06
62 Gabapentin 1,121,004 0.39 21,025 0.16
63 Simvastatin 1,110,107 0.39 45,707 0.34
64 Fluticasone (Inhaled) 1,108,250 0.39 28,847 0.22
65 Ibandronic Acid 1,071,579 0.37 33,985 0.25
66 Tamsulosin 1,052,452 0.37 38,375 0.29
67 Tolterodine 1,028,220 0.36 22,431 0.17
68 Fluoxetine 1,021,534 0.36 43,174 0.32
69 Alendronic Acid, Combinations 1,015,713 0.35 30,245 0.23
70 Losartan and Diuretics 1,009,327 0.35 34,028 0.25
Table 19.4  DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost  continued
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Table 19.4  DP: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost  continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Nebivolol 1,007,848 0.35 69,248 0.52
72 Rabeprazole 994,835 0.35 31,072 0.23
73 Progesterone 993,908 0.35 10,216 0.08
74 Strontium Ranelate 984,980 0.34 21,445 0.16
75 Proguanil, Combinations 967,015 0.34 13,699 0.10
76 Olmesartan Medoxomil 912,730 0.32 43,794 0.33
77 Budesonide (Inhaled) 905,467 0.32 20,952 0.16
78 Tinzaparin 893,403 0.31 4,924 0.04
79 Candesartan 867,418 0.30 37,544 0.28
80 Tramadol 790,858 0.28 67,601 0.51
81 Paroxetine 782,246 0.27 36,409 0.27
82 Zolmitriptan 780,155 0.27 17,382 0.13
83 Mometasone 777,254 0.27 50,916 0.38
84 Risperidone 763,715 0.27 14,665 0.11
85 Telmisartan and Diuretics 744,515 0.26 28,867 0.22
86 Zopiclone 741,334 0.26 104,380 0.78
87 Fumaric Acid Derivatives, Combinations 740,563 0.26 1,217 0.01
88 Azathioprine 735,032 0.26 26,476 0.20
89 Lercanidipine 719,868 0.25 46,826 0.35
90 Calcipotriol 704,395 0.25 16,081 0.12
91 Solifenacin 687,280 0.24 13,650 0.10
92 Mirtazapine 686,680 0.24 31,377 0.23
93 Diagnostic Products 678,454 0.24 19,379 0.14
94 Terbinafine (Systemic) 677,756 0.24 18,093 0.14
95 Lignocaine (Local Anaesthetic) 671,269 0.23 3,067 0.02
96 Codeine Combs. excl. Psycholeptics 662,049 0.23 79,426 0.59
97 Levothyroxine Sodium 649,269 0.23 334,499 2.50
98 Aripiprazole 642,906 0.22 4,062 0.03
99 Prednisolone (Systemic) 621,795 0.22 148,635 1.11
100 Letrozole 621,283 0.22 7,040 0.05
Total €229,956,347 80.22% 8,240,146 61.63%
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Table 19.5  LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Diagnostic Products 289,982 10.16 13,136,530 15.59
2 Acetylsalicylic Acid-Aspirin (Antithrombotic) 255,278 8.94 565,709 0.67
3 Metformin 245,005 8.58 937,288 1.11
4 Atorvastatin 180,569 6.32 7,342,973 8.71
5 Needles/Syringes/Lancets 158,723 5.56 3,678,602 4.36
6 Gliclazide 130,613 4.57 1,310,664 1.56
7 Ramipril 85,984 3.01 911,882 1.08
8 Insulin Aspart, Fast Acting 84,666 2.97 5,135,135 6.09
9 Perindopril 64,473 2.26 1,368,143 1.62
10 Amlodipine 54,326 1.90 746,739 0.89
11 Insulin Glargine, Long Acting 50,939 1.78 3,882,445 4.61
12 Sodium Valproate 49,614 1.74 602,262 0.71
13 Rosuvastatin 48,265 1.69 1,412,882 1.68
14 Lamotrigine 47,037 1.65 3,156,186 3.74
15 Carbamazepine 42,620 1.49 370,020 0.44
16 Bisoprolol 40,196 1.41 318,581 0.38
17 Clinical Nutritional Products 34,323 1.20 4,287,817 5.09
18 Insulin Detemir, Long Acting 34,231 1.20 2,875,991 3.41
19 Pravastatin 29,043 1.02 814,243 0.97
20 Levetiracetam 25,866 0.91 2,468,283 2.93
21 Doxazosin 24,964 0.87 799,451 0.95
22 Lisinopril 22,841 0.80 261,353 0.31
23 Atenolol 22,270 0.78 111,341 0.13
24 Phenytoin 21,537 0.75 144,250 0.17
25 Levothyroxine Sodium 20,174 0.71 43,081 0.05
26 Losartan 18,770 0.66 537,466 0.64
27 Clopidogrel 16,982 0.59 908,408 1.08
28 Valsartan 16,847 0.59 400,952 0.48
29 Sitagliptin 16,576 0.58 774,885 0.92
30 Folic Acid 16,354 0.57 19,246 0.02
31 Bendrofluazide 13,795 0.48 20,534 0.02
32 Furosemide 12,655 0.44 16,783 0.02
33 Lercanidipine 12,552 0.44 198,009 0.23
34 Insulin Aspart, Comb. Intermediate/Fast Acting 11,997 0.42 853,759 1.01
35 Simvastatin 11,922 0.42 295,018 0.35
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Table 19.5  LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency  continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Nebivolol 11,195 0.39 175,927 0.21
37 Valsartan and Diuretics 10,182 0.36 274,908 0.33
38 Warfarin 10,044 0.35 25,982 0.03
39 Glimepiride 10,027 0.35 81,663 0.10
40 Insulin (Human), Comb. Intermediate/Fast Acting 10,017 0.35 537,061 0.64
41 Metformin and Rosiglitazone 9,798 0.34 539,912 0.64
42 Tadalafil 9,473 0.33 278,048 0.33
43 Telmisartan 9,372 0.33 234,899 0.28
44 Insulin Lispro, Fast Acting 9,356 0.33 558,132 0.66
45 Sildenafil 9,274 0.32 287,304 0.34
46 Insulin (Human), Intermediate Acting 9,273 0.32 338,507 0.40
47 Simvastatin and Ezetimibe 9,046 0.32 490,476 0.58
48 Rosiglitazone 8,683 0.30 492,037 0.58
49 Phenobarbital 8,655 0.30 40,998 0.05
50 Candesartan 8,588 0.30 208,465 0.25
51 Topiramate 8,294 0.29 596,148 0.71
52 Ezetimibe 8,290 0.29 332,489 0.39
53 Pancreatic Enzymes 7,875 0.28 861,894 1.02
54 Glucagon 7,606 0.27 218,679 0.26
55 Levodopa and Decarboxylase Inhibitor 7,514 0.26 133,049 0.16
56 Olmesartan Medoxomil 7,123 0.25 153,773 0.18
57 Omega-3-triglycerides 6,990 0.24 213,503 0.25
58 Urinary Appliances 6,850 0.24 790,351 0.94
59 Indapamide 6,668 0.23 41,200 0.05
60 Metformin and Sitagliptin 6,645 0.23 337,017 0.40
61 Omeprazole 6,524 0.23 257,618 0.31
62 Metoprolol 6,122 0.21 14,025 0.02
63 Calcium, Combinations 6,061 0.21 52,028 0.06
64 Lansoprazole 5,828 0.20 224,329 0.27
65 Lisinopril and Diuretics 5,674 0.20 70,526 0.08
66 Irbesartan 5,631 0.20 144,205 0.17
67 Exenatide 5,582 0.20 603,212 0.72
68 Pioglitazone 5,409 0.19 294,993 0.35
69 Fenofibrate 5,394 0.19 114,144 0.14
70 Esomeprazole 5,367 0.19 234,442 0.28
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Table 19.5  LTI: The Top 100 Most Commonly Prescribed Products in the Order of their Prescribing Frequency  continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Oxcarbazepine 5,340 0.19 170,411 0.20
72 Losartan and Diuretics 5,271 0.18 165,211 0.20
73 Pregabalin 5,230 0.18 522,755 0.62
74 Diltiazem 4,884 0.17 76,845 0.09
75 Gabapentin 4,791 0.17 312,603 0.37
76 Baclofen 4,730 0.17 59,361 0.07
77 Enalapril 4,690 0.16 55,336 0.07
78 Salbutamol (Inhaled) 4,654 0.16 34,969 0.04
79 Insulin (Human), Fast Acting 4,531 0.16 130,922 0.16
80 Bendroflumethazide and potassium 4,525 0.16 14,807 0.02
81 Insulin Glulisine, Fast Acting 4,420 0.15 220,611 0.26
82 Telmisartan and Diuretics 4,011 0.14 106,848 0.13
83 Allopurinol 3,637 0.13 22,009 0.03
84 Evening Primrose Oil (Naudicelle) 3,629 0.13 94,484 0.11
85 Clobazam 3,501 0.12 19,143 0.02
86 Levodopa Decarboxylase Inhibitor and COMT Inhibitor 3,493 0.12 404,604 0.48
87 Isosorbide Mononitrate 3,492 0.12 39,500 0.05
88 Quinapril 3,484 0.12 44,924 0.05
89 Ropinirole 3,401 0.12 421,653 0.50
90 Selegiline 3,276 0.11 106,665 0.13
91 Pramipexole 3,176 0.11 547,224 0.65
92 Diazepam 3,114 0.11 11,043 0.01
93 Atenolol with other Diuretics 3,113 0.11 22,001 0.03
94 Nifedipine 3,106 0.11 44,820 0.05
95 Paracetamol 3,093 0.11 8,725 0.01
96 Clonazepam 3,038 0.11 63,823 0.08
97 Captopril 3,002 0.11 47,463 0.06
98 Amoxicillin and Enzyme Inhibitor 2,995 0.10 31,786 0.04
99 Pantoprazole 2,949 0.10 91,984 0.11
100 Amitriptyline 2,938 0.10 6,233 0.01
Total 2,601,933 91.08% €74,857,618 88.85%
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Table 19.6  LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Diagnostic Products 13,136,530 15.59 289,982 10.16
2 Atorvastatin 7,342,973 8.71 180,569 6.32
3 Insulin Aspart, Fast Acting 5,135,135 6.09 84,666 2.97
4 Clinical Nutritional Products 4,287,817 5.09 34,323 1.20
5 Insulin Glargine, Long Acting 3,882,445 4.61 50,939 1.78
6 Needles/Syringes/Lancets 3,678,602 4.36 158,723 5.56
7 Lamotrigine 3,156,186 3.74 47,037 1.65
8 Insulin Detemir, Long Acting 2,875,991 3.41 34,231 1.20
9 Levetiracetam 2,468,283 2.93 25,866 0.91
10 Rosuvastatin 1,412,882 1.68 48,265 1.69
11 Perindopril 1,368,143 1.62 64,473 2.26
12 Gliclazide 1,310,664 1.56 130,613 4.57
13 Metformin 937,288 1.11 245,005 8.58
14 Ramipril 911,882 1.08 85,984 3.01
15 Clopidogrel 908,408 1.08 16,982 0.59
16 Pancreatic Enzymes 861,894 1.02 7,875 0.28
17 Insulin Aspart, Comb. Intermediate/Fast Acting 853,759 1.01 11,997 0.42
18 Pravastatin 814,243 0.97 29,043 1.02
19 Doxazosin 799,451 0.95 24,964 0.87
20 Urinary Requisites 790,351 0.94 6,850 0.24
21 Sitagliptin 774,885 0.92 16,576 0.58
22 Amlodipine 746,739 0.89 54,326 1.90
23 Apomorphine 690,561 0.82 873 0.03
24 Exenatide 603,212 0.72 5,582 0.20
25 Sodium Valproate 602,262 0.71 49,614 1.74
26 Topiramate 596,148 0.71 8,294 0.29
27 Acetylsalicylic Acid-Aspirin (Antithrombotic) 565,709 0.67 255,278 8.94
28 Insulin Lispro, Fast Acting 558,132 0.66 9,356 0.33
29 Pramipexole 547,224 0.65 3,176 0.11
30 Metformin and Rosiglitazone 539,912 0.64 9,798 0.34
31 Losartan 537,466 0.64 18,770 0.66
32 Insulin (Human), Comb. Intermediate/Fast Acting 537,061 0.64 10,017 0.35
33 Pregabalin 522,755 0.62 5,230 0.18
34 Rosiglitazone 492,037 0.58 8,683 0.30
35 Simvastatin and Ezetimibe 490,476 0.58 9,046 0.32
87
Table 19.6  LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost  continued
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Ropinirole 421,653 0.50 3,401 0.12
37 Levodopa, Decarboxylase Inhibitor and COMT Inhibitor 404,604 0.48 3,493 0.12
38 Valsartan 400,952 0.48 16,847 0.59
39 Carbamazepine 370,020 0.44 42,620 1.49
40 Colistin Parenteral 360,389 0.43 2,343 0.08
41 Insulin (Human), Intermediate Acting 338,507 0.40 9,273 0.32
42 Metformin and Sitagliptin 337,017 0.40 6,645 0.23
43 Ezetimibe 332,489 0.39 8,290 0.29
44 Nutritional/Ancillary Devices 329,525 0.39 2,230 0.08
45 Bisoprolol 318,581 0.38 40,196 1.41
46 Gabapentin 312,603 0.37 4,791 0.17
47 Zonisamide 306,145 0.36 2,802 0.10
48 Simvastatin 295,018 0.35 11,922 0.42
49 Pioglitazone 294,993 0.35 5,409 0.19
50 Sildenafil 287,304 0.34 9,274 0.32
51 Tadalafil 278,048 0.33 9,473 0.33
52 Valsartan and Diuretics 274,908 0.33 10,182 0.36
53 Rasagiline 262,240 0.31 2,515 0.09
54 Lisinopril 261,353 0.31 22,841 0.80
55 Rotigotine 258,031 0.31 1,490 0.05
56 Omeprazole 257,618 0.31 6,524 0.23
57 Telmisartan 234,899 0.28 9,372 0.33
58 Esomeprazole 234,442 0.28 5,367 0.19
59 Other Alimentary Tract/Metabolism Products 234,427 0.28 1,697 0.06
60 Lansoprazole 224,329 0.27 5,828 0.20
61 Insulin Glulisine, Fast Acting 220,611 0.26 4,420 0.15
62 Glucagon 218,679 0.26 7,606 0.27
63 Meropenem 214,727 0.25 124 0.00
64 Omega-3-triglycerides 213,503 0.25 6,990 0.24
65 Candesartan 208,465 0.25 8,588 0.30
66 Lercanidipine 198,009 0.23 12,552 0.44
67 Orlistat 186,029 0.22 2,924 0.10
68 Nebivolol 175,927 0.21 11,195 0.39
69 Oxcarbazepine 170,411 0.20 5,340 0.19
70 Losartan and Diuretics 165,211 0.20 5,271 0.18
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Azithromycin 164,388 0.20 2,564 0.09
72 Modafinil 154,304 0.18 880 0.03
73 Olmesartan Medoxomil 153,773 0.18 7,123 0.25
74 Desmopressin 150,290 0.18 2,161 0.08
75 Phenytoin 144,250 0.17 21,537 0.75
76 Irbesartan 144,205 0.17 5,631 0.20
77 Tizanidine 143,683 0.17 1,421 0.05
78 Levodopa and Decarboxylase Inhibitor 133,049 0.16 7,514 0.26
79 Multivitamins and Trace Elements 131,866 0.16 2,258 0.08
80 Insulin (Human), Fast Acting 130,922 0.16 4,531 0.16
81 Salmeterol and other drugs for obstructive airway diseases 125,368 0.15 1,708 0.06
82 Dressings 115,545 0.14 2,107 0.07
83 Ostomy Requisites 115,441 0.14 1,236 0.04
84 Fenofibrate 114,144 0.14 5,394 0.19
85 Atenolol 111,341 0.13 22,270 0.78
86 Tolterodine 110,896 0.13 2,358 0.08
87 Telmisartan and Diuretics 106,848 0.13 4,011 0.14
88 Selegiline 106,665 0.13 3,276 0.11
89 Metformin and Pioglitazone 101,081 0.12 1,996 0.07
90 Midazolam 96,819 0.11 1,754 0.06
91 Evening Primrose Oil (Naudicelle) 94,484 0.11 3,629 0.13
92 Pantoprazole 91,984 0.11 2,949 0.10
93 Levocarnitine 89,361 0.11 272 0.01
94 Melatonin 87,409 0.10 987 0.03
95 Glimepiride 81,663 0.10 10,027 0.35
96 Candesartan and Diuretics 77,297 0.09 2,660 0.09
97 Diltiazem 76,845 0.09 4,884 0.17
98 Valsartan and Amlodipine 76,612 0.09 2,576 0.09
99 Ceftazidime 74,858 0.09 125 0.00
100 Vardenafil 70,543 0.08 2,254 0.08
Total €78,715,107 93.42% 2,484,934 86.98%
Table 19.6  LTI: The Top 100 Products of Highest Cost in the Order of their Total Ingredient Cost  continued
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
1 Adalimumab 33,726 9.12 46,250,835 16.54
2 Etanercept 33,436 9.05 38,064,481 13.61
3 Tacrolimus 26,352 7.13 7,150,988 2.56
4 Mycophenolic Acid 25,738 6.96 5,512,786 1.97
5 Bicalutamide 23,777 6.43 2,060,709 0.74
6 Ciclosporin 18,599 5.03 2,191,614 0.78
7 Darbepoetin alfa 16,842 4.56 8,047,667 2.88
8 Interferon beta-1a 14,143 3.83 16,380,502 5.86
9 Erythropoietin 13,990 3.78 10,132,560 3.62
10 Triptorelin 13,806 3.73 5,005,534 1.79
11 Leuprorelin 11,504 3.11 5,594,792 2.00
12 Pegfilgrastim 11,005 2.98 13,704,084 4.90
13 Teriparatide 10,390 2.81 4,752,634 1.70
14 Somatropin 8,980 2.43 6,442,636 2.31
15 Interferon beta-1b 8,766 2.37 10,329,522 3.70
16 Goserelin 6,361 1.72 2,180,924 0.78
17 Capecitabine 6,280 1.70 1,587,595 0.57
18 Cinacalcet 5,669 1.53 1,865,312 0.67
19 Glatiramer Acetate 4,906 1.33 5,992,555 2.14
20 Dornase alfa 4,437 1.20 4,286,258 1.53
21 Methoxy Polyethylene Glycol-Epoietin beta 4,312 1.17 975,412 0.35
22 Filgrastim 4,241 1.15 3,093,726 1.11
23 Follitropin beta 3,611 0.98 3,127,510 1.12
24 Choriogonadotropin alfa 3,460 0.94 187,192 0.07
25 Palivizumab 3,252 0.88 3,435,810 1.23
26 Imatinib 2,876 0.78 7,938,190 2.84
27 Octreotide 2,545 0.69 3,001,573 1.07
28 Ribavirin 2,434 0.66 1,449,229 0.52
29 Sildenafil 2,365 0.64 1,836,689 0.66
30 Temozolomide 2,043 0.55 2,286,281 0.82
31 Peginterferon alfa-2a 1,962 0.53 1,953,650 0.70
32 Riluzole 1,950 0.53 633,822 0.23
33 Bosentan 1,805 0.49 5,546,219 1.98
34 Follitropin alfa 1,763 0.48 1,877,592 0.67
35 Tobramycin 1,721 0.47 4,638,011 1.66
Table 19.7  HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
36 Human Menopausal Gonadotrophin 1,674 0.45 1,093,959 0.39
37 Lenalidomide 1,401 0.38 9,766,472 3.49
38 Sirolimus 1,232 0.33 330,455 0.12
39 Linezolid 1,229 0.33 1,804,785 0.65
40 Anagrelide 1,218 0.33 649,717 0.23
41 Parathyroid Hormone 1,182 0.32 489,253 0.18
42 Thalidomide 1,179 0.32 819,342 0.29
43 Fulvestrant 1,130 0.31 591,669 0.21
44 Lamivudine 1,119 0.30 110,508 0.04
45 Erlotinib 1,070 0.29 2,402,891 0.86
46 Valganciclovir 1,025 0.28 1,654,167 0.59
47 Ganirelix 993 0.27 304,038 0.11
48 Paricalcitol 897 0.24 155,960 0.06
49 Peginterferon alfa-2b 890 0.24 538,317 0.19
50 Entecavir 869 0.24 502,035 0.18
51 Lanreotide 812 0.22 886,540 0.32
52 Nafarelin 801 0.22 132,531 0.05
53 Voriconazole 788 0.21 1,987,078 0.71
54 Sunitinib 778 0.21 2,794,283 1.00
55 Deferasirox 777 0.21 764,991 0.27
56 Lutropin alfa 725 0.20 417,424 0.15
57 Adefovir Dipivoxil 716 0.19 393,090 0.14
58 Ibandronic Acid 715 0.19 184,592 0.07
59 Sorafenib 672 0.18 2,313,418 0.83
60 Interferon alfa-2b 651 0.18 459,549 0.16
61 Clodronic Acid 544 0.15 149,392 0.05
62 Lapatinib 455 0.12 1,029,154 0.37
63 Flutamide 439 0.12 58,448 0.02
64 Posaconazole 415 0.11 721,853 0.26
65 Etoposide 410 0.11 40,869 0.01
66 Anakinra 392 0.11 396,072 0.14
67 Vinorelbine 390 0.11 152,846 0.05
68 Interferon alfa-2a 348 0.09 120,639 0.04
69 Sitaxentan 307 0.08 794,701 0.28
70 Dasatinib 298 0.08 1,331,190 0.48
Table 19.7  HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency  continued
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.7  HTD: The Most Commonly Prescribed Products in the Order of their Prescribing Frequency  continued
Name Prescribing Frequency % of Scheme Total Ingredient Cost € % of Scheme Total
71 Vancomycin Oral 273 0.07 55,814 0.02
72 Pegvisomant 234 0.06 980,308 0.35
73 Fludarabine 227 0.06 178,641 0.06
74 Lenograstim 197 0.05 155,452 0.06
75 Nilotinib 182 0.05 841,888 0.30
76 Efalizumab 168 0.05 191,543 0.07
77 Iloprost 122 0.03 582,632 0.21
78 Risedronic Acid 115 0.03 26,999 0.01
79 Cetrorelix 98 0.03 27,448 0.01
80 Bexarotene 94 0.03 254,111 0.09
81 Sodium Oxybate 86 0.02 56,500 0.02
82 Buserelin 77 0.02 16,840 0.01
83 Topotecan 48 0.01 53,850 0.02
84 Idarubicin 31 0.01 20,901 0.01
85 Aldesleukin 30 0.01 26,702 0.01
86 Epoprostenol 29 0.01 231,451 0.08
87 Chorionic Gonadotrophin 18 0.00 149 0.00
88 Degarelix 15 0.00 4,118 0.00
89 Urofollitropin 11 0.00 7,587 0.00
90 Interferon gamma 10 0.00 9,975 0.00
91 Sodium Phenylbutyrate 6 0.00 5,423 0.00
92 Ambrisentan 4 0.00 11,489 0.00
93 Becaplermin 4 0.00 1,955 0.00
94 Follitropin alfa and Lutropin alfa 4 0.00 4,914 0.00
95 Everolimus 2 0.00 8,083 0.00
96 Miglustat 1 0.00 1,136 0.00
Total 369,674 100.00% €279,613,031 100.00%
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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Table 19.8  HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
1 Adalimumab 46,250,835 16.54 33,726 9.12
2 Etanercept 38,064,481 13.61 33,436 9.05
3 Interferon beta-1a 16,380,502 5.86 14,143 3.83
4 Pegfilgrastim 13,704,084 4.90 11,005 2.98
5 Interferon beta-1b 10,329,522 3.70 8,766 2.37
6 Erythropoietin 10,132,560 3.62 13,990 3.78
7 Lenalidomide 9,766,472 3.49 1,401 0.38
8 Darbepoetin alfa 8,047,667 2.88 16,842 4.56
9 Imatinib 7,938,190 2.84 2,876 0.78
10 Tacrolimus 7,150,988 2.56 26,352 7.13
11 Somatropin 6,442,636 2.31 8,980 2.43
12 Glatiramer Acetate 5,992,555 2.14 4,906 1.33
13 Leuprorelin 5,594,792 2.00 11,504 3.11
14 Bosentan 5,546,219 1.98 1,805 0.49
15 Mycophenolic Acid 5,512,786 1.97 25,738 6.96
16 Triptorelin 5,005,534 1.79 13,806 3.73
17 Teriparatide 4,752,634 1.70 10,390 2.81
18 Tobramycin 4,638,011 1.66 1,721 0.47
19 Dornase alfa 4,286,258 1.53 4,437 1.20
20 Palivizumab 3,435,810 1.23 3,252 0.88
21 Follitropin beta 3,127,510 1.12 3,611 0.98
22 Filgrastim 3,093,726 1.11 4,241 1.15
23 Octreotide 3,001,573 1.07 2,545 0.69
24 Sunitinib 2,794,283 1.00 778 0.21
25 Erlotinib 2,402,891 0.86 1,070 0.29
26 Sorafenib 2,313,418 0.83 672 0.18
27 Temozolomide 2,286,281 0.82 2,043 0.55
28 Ciclosporin 2,191,614 0.78 18,599 5.03
29 Goserelin 2,180,924 0.78 6,361 1.72
30 Bicalutamide 2,060,709 0.74 23,777 6.43
31 Voriconazole 1,987,078 0.71 788 0.21
32 Peginterferon alfa-2a 1,953,650 0.70 1,962 0.53
33 Follitropin alfa 1,877,592 0.67 1,763 0.48
34 Cinacalcet 1,865,312 0.67 5,669 1.53
35 Sildenafil 1,836,689 0.66 2,365 0.64
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Table 19.8  HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost  continued
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
36 Linezolid 1,804,785 0.65 1,229 0.33
37 Valganciclovir 1,654,167 0.59 1,025 0.28
38 Capecitabine 1,587,595 0.57 6,280 1.70
39 Ribavirin 1,449,229 0.52 2,434 0.66
40 Dasatinib 1,331,190 0.48 298 0.08
41 Human Menopausal Gonadotrophin 1,093,959 0.39 1,674 0.45
42 Lapatinib 1,029,154 0.37 455 0.12
43 Pegvisomant 980,308 0.35 234 0.06
44 Methoxy Polyethylene Glycol-Epoietin beta 975,412 0.35 4,312 1.17
45 Lanreotide 886,540 0.32 812 0.22
46 Nilotinib 841,888 0.30 182 0.05
47 Thalidomide 819,342 0.29 1,179 0.32
48 Sitaxentan 794,701 0.28 307 0.08
49 Deferasirox 764,991 0.27 777 0.21
50 Posaconazole 721,853 0.26 415 0.11
51 Anagrelide 649,717 0.23 1,218 0.33
52 Riluzole 633,822 0.23 1,950 0.53
53 Fulvestrant 591,669 0.21 1,130 0.31
54 Iloprost 582,632 0.21 122 0.03
55 Peginterferon alfa-2b 538,317 0.19 890 0.24
56 Entecavir 502,035 0.18 869 0.24
57 Parathyroid Hormone 489,253 0.18 1,182 0.32
58 Interferon alfa-2b 459,549 0.16 651 0.18
59 Lutropin alfa 417,424 0.15 725 0.20
60 Anakinra 396,072 0.14 392 0.11
61 Adefovir Dipivoxil 393,090 0.14 716 0.19
62 Sirolimus 330,455 0.12 1,232 0.33
63 Ganirelix 304,038 0.11 993 0.27
64 Bexarotene 254,111 0.09 94 0.03
65 Epoprostenol 231,451 0.08 29 0.01
66 Efalizumab 191,543 0.07 168 0.05
67 Choriogonadotropin alfa 187,192 0.07 3,460 0.94
68 Ibandronic Acid 184,592 0.07 715 0.19
69 Fludarabine 178,641 0.06 227 0.06
70 Paricalcitol 155,960 0.06 897 0.24
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Name Ingredient Cost € % of Scheme Total Prescribing Frequency % of Scheme Total
71 Lenograstim 155,452 0.06 197 0.05
72 Vinorelbine 152,846 0.05 390 0.11
73 Clodronic Acid 149,392 0.05 544 0.15
74 Nafarelin 132,531 0.05 801 0.22
75 Interferon alfa-2a 120,639 0.04 348 0.09
76 Lamivudine 110,508 0.04 1,119 0.30
77 Flutamide 58,448 0.02 439 0.12
78 Sodium Oxybate 56,500 0.02 86 0.02
79 Vancomycin (Oral) 55,814 0.02 273 0.07
80 Topotecan 53,850 0.02 48 0.01
81 Etoposide 40,869 0.01 410 0.11
82 Cetrorelix 27,448 0.01 98 0.03
83 Risedronic Acid 26,999 0.01 115 0.03
84 Aldesleukin 26,702 0.01 30 0.01
85 Idarubicin 20,901 0.01 31 0.01
86 Buserelin 16,840 0.01 77 0.02
87 Ambrisentan 11,489 0.00 4 0.00
88 Interferon gamma 9,975 0.00 10 0.00
89 Everolimus 8,083 0.00 2 0.00
90 Urofollitropin 7,587 0.00 11 0.00
91 Sodium Phenylbutyrate 5,423 0.00 6 0.00
92 Follitropin alfa and Lutropin alfa 4,914 0.00 4 0.00
93 Degarelix 4,118 0.00 15 0.00
94 Becaplermin 1,955 0.00 4 0.00
95 Miglustat 1,136 0.00 1 0.00
96 Chorionic Gonadotrophin 149 0.00 18 0.00
Total €279,613,031 100.00% 369,674 100.00%
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Table 19.8  HTD: The Products of Highest Cost in the Order of their Total Ingredient Cost  continued
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 6,823,109 13.45 156,444,358 16.07
A01 Stomatological Preparations 94,625 0.19 354,012 0.04
A02 Drugs for Acid Related Disorders 2,998,458 5.91 100,396,882 10.31
A03 Drugs for Functional Gastrointestinal Disorders 472,807 0.93 2,385,512 0.25
A04 Anti-emetics and Antinauseants 20,363 0.04 2,306,181 0.24
A05 Bile and Liver Therapy 13,859 0.03 716,000 0.07
A06 Laxatives 713,646 1.41 6,250,788 0.64
A07 Antidiarrheals, Intestinal Anti-inflammatory/ 
Anti-infective Agents
239,558 0.47 5,026,408 0.52
A08 Anti-obesity Preparations, excl. Diet Products 73,417 0.14 4,712,569 0.48
A09 Digestives, incl. Enzymes 13,307 0.03 1,197,653 0.12
A10 Drugs used in Diabetes 1,146,550 2.26 24,430,197 2.51
A11 Vitamins 77,186 0.15 923,022 0.09
A12 Mineral Supplements 959,332 1.89 7,745,125 0.80
A14 Anabolic Agents for Systemic Use 1 0.00 9 0.00
B Blood and Blood Forming Organs 4,432,675 8.74 32,919,001 3.38
B01 Antithrombotic Agents 3,661,585 7.22 31,091,880 3.19
B02 Antihemorrhagics 13,175 0.03 166,926 0.02
B03 Anti-anemic Preparations 757,903 1.49 1,660,105 0.17
B05 Blood Substitutes and Perfusion Solutions 12 0.00 90 0.00
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 12,321,274 24.29 226,213,848 23.24
C01 Cardiac Therapy 789,086 1.55 8,134,343 0.84
C02 Antihypertensives 308,676 0.61 8,623,756 0.89
C03 Diuretics 1,732,681 3.42 5,248,436 0.54
C04 Peripheral Vasodilators 51,957 0.10 846,580 0.09
C05 Vasoprotectives 121,485 0.24 839,740 0.09
C07 Beta Blocking Agents 1,911,958 3.77 14,239,792 1.46
C08 Calcium Channel Blockers 1,275,172 2.51 17,271,187 1.77
C09 Agents Acting on the Renin-Angiotensin System 2,921,226 5.76 54,842,291 5.63
C10 Lipid Modifying Agents 3,209,033 6.33 116,167,723 11.93
D Dermatologicals 1,359,233 2.68 13,257,482 1.36
D01 Antifungals for Dermatological Use 319,460 0.63 2,943,463 0.30
D02 Emollients and Protectives 207,339 0.41 582,987 0.06
D03 Preparations for Treatment of Wounds and Ulcers 662 0.00 16,242 0.00
D05 Antipsoriatics 65,290 0.13 3,688,185 0.38
D06 Antibiotics and Chemotherapeutics for Dermatological Use 134,619 0.27 1,224,789 0.13
D07 Corticosteroids, Dermatological Preparations 563,489 1.11 3,075,790 0.32
D10 Anti-Acne Preparations 52,659 0.10 906,580 0.09
D11 Other Dermatological Preparations 15,715 0.03 819,446 0.08
G Genito Urinary System and Sex Hormones 1,768,748 3.49 38,309,216 3.94
G01 Gynecological Anti-infectives and Antiseptics 24,707 0.05 134,971 0.02
G02 Other Gynecologicals 21,821 0.04 1,681,502 0.17
G03 Sex Hormones and Modulators of the Genital System 892,906 1.76 7,890,023 0.81
G04 Urologicals 829,314 1.64 28,602,720 2.94
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones 
and Insulins
1,604,245 3.16 5,230,939 0.54
H01 Pituitary, Hypothalamic Hormones and Analogues 13,175 0.03 760,126 0.08
H02 Corticosteroids for Systemic Use 549,069 1.08 2,151,208 0.22
H03 Thyroid Therapy 1,035,243 2.04 2,111,145 0.22
H04 Pancreatic Hormones 6,603 0.01 202,008 0.02
H05 Calcium Homeostasis 155 0.00 6,452 0.00
J Anti-infectives for Systemic Use 2,490,998 4.91 27,033,298 2.78
J01 Antibacterials for Systemic Use 2,362,181 4.66 22,344,481 2.30
J02 Antimycotics for Systemic Use 79,573 0.16 1,381,761 0.14
J04 Antimycobacterials 2,900 0.00 73,162 0.01
J05 Antivirals for Systemic Use 46,338 0.09 3,233,830 0.33
J07 Vaccines 6 0.00 64 0.00
L Antineoplastic and Immunomodulating Agents 248,563 0.49 9,967,100 1.03
L01 Antineoplastic Agents 20,479 0.04 668,392 0.07
L02 Endocrine Therapy 95,477 0.19 7,664,951 0.79
L04 Immunosuppressive Agents 132,607 0.26 1,633,757 0.17
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 3,224,421 6.36 55,518,015 5.71
M01 Anti-inflammatory and Antirheumatic Products 1,634,156 3.22 22,026,552 2.26
M02 Topical Products for Joint and Muscular Pain 557,064 1.10 4,349,790 0.45
M03 Muscle Relaxants 43,980 0.09 1,333,210 0.14
M04 Antigout Preparations 195,508 0.39 955,978 0.10
M05 Drugs for treatment of Bone Diseases 735,261 1.44 26,117,973 2.68
M09 Other Drugs for Disorders of the Musculo-Skeletal System 58,452 0.12 734,512 0.08
N Nervous System 9,639,420 19.00 211,746,442 21.76
N01 Anesthetics 3,119 0.01 20,907 0.00
N02 Analgesics 2,377,371 4.69 30,167,025 3.10
N03 Anti-epileptics 930,816 1.83 40,134,381 4.12
N04 Antiparkinson Drugs 241,828 0.48 8,208,274 0.84
N05 Psycholeptics 3,524,727 6.95 55,715,039 5.73
N06 Psychoanaleptics 2,194,696 4.32 67,412,648 6.93
N07 Other Nervous System Drugs 366,863 0.72 10,088,168 1.04
P Antiparasitic Products, Insecticides and Repellents 75,524 0.15 641,448 0.06
P01 Antiprotozoals 54,909 0.11 505,852 0.05
P02 Anthelmintics 8,585 0.02 23,661 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 12,030 0.02 111,935 0.01
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Table 20 GMS: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 3,750,446 7.39 98,264,490 10.10
R01 Nasal Preparations 298,437 0.59 3,340,128 0.34
R02 Throat Preparations 11,595 0.02 26,803 0.00
R03 Drugs for Obstructive Airway Diseases 2,733,416 5.39 90,480,098 9.30
R05 Cough and Cold Preparations 352,058 0.69 1,396,577 0.15
R06 Antihistamines for Systemic Use 354,500 0.70 3,009,095 0.31
R07 Other Respiratory System Products 440 0.00 11,789 0.00
S Sensory Organs 1,214,434 2.40 13,177,562 1.35
S01 Ophthalmologicals 1,128,761 2.23 12,844,628 1.32
S02 Otologicals 39,663 0.08 205,943 0.02
S03 Ophthalmological and Otological Preparations 46,010 0.09 126,991 0.01
V Various 1,768,829 3.49 84,626,045 8.69
V01 Allergens 99 0.00 8,802 0.00
V03 Other Therapeutic Products 14,579 0.03 2,578,263 0.26
V04 Diagnostic Products 425,437 0.84 16,387,335 1.68
V06 Clinical Nutritional Products 553,149 1.09 41,382,430 4.25
V07 All Other Non-Therapeutic Products 775,565 1.53 24,269,215 2.50
        Needles/Syringes/Lancets 231,985 0.46 3,259,767 0.33
        Ostomy Requisites 70,784 0.14 12,619,818 0.69
        Urinary Requisites 25,856 0.05 6,670,509 0.11
        Dressings 122,742 0.24 1,079,813 1.30
        Miscellaneous 324,198 0.64 639,308 0.07
TOTAL 50,721,919 100.00% €973,349,244 100.00%
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 1,559,672 11.66 43,595,868 15.20
A01 Stomatological Preparations 22,687 0.17 84,793 0.03
A02 Drugs for Acid Related Disorders 851,403 6.37 30,592,032 10.66
A03 Drugs for Functional Gastrointestinal Disorders 111,518 0.83 647,285 0.23
A04 Anti-emetics and Antinauseants 9,090 0.07 846,281 0.30
A05 Bile and Liver Therapy 6,533 0.05 405,799 0.14
A06 Laxatives 80,688 0.60 736,273 0.26
A07 Antidiarrheals, Intestinal Anti-inflammatory/Anti-infective Agents 102,717 0.77 4,405,527 1.54
A08 Anti-obesity Preparations, excl. Diet Products 40,992 0.30 2,601,804 0.91
A09 Digestives, incl. Enzymes 2,095 0.01 114,387 0.04
A10 Drugs used in Diabetes 58,613 0.44 787,424 0.27
A11 Vitamins 16,850 0.13 241,199 0.08
A12 Mineral Supplements 256,451 1.92 2,130,409 0.74
A14 Anabolic Agents for Systemic Use 3 0.00 58 0.00
A16 Other Alimentary Tract/Metabolism Products 32 0.00 2,597 0.00
B Blood and Blood Forming Organs 1,037,575 7.76 9,336,007 3.26
B01 Antithrombotic Agents 911,988 6.82 8,997,610 3.14
B02 Antihemorrhagics 4,169 0.03 54,459 0.02
B03 Anti-anemic Preparations 121,413 0.91 283,846 0.10
B05 Blood Substitutes and Perfusion Solutions 5 0.00 92 0.00
Note:  The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 3,601,729 26.94 78,796,091 27.47
C01 Cardiac Therapy 101,663 0.76 1,559,963 0.55
C02 Antihypertensives 81,109 0.61 2,316,295 0.81
C03 Diuretics 259,023 1.94 1,122,128 0.39
C04 Peripheral Vasodilators 3,666 0.03 60,236 0.02
C05 Vasoprotectives 42,434 0.32 295,155 0.10
C07 Beta Blocking Agents 554,996 4.15 4,284,219 1.49
C08 Calcium Channel Blockers 336,512 2.51 4,479,268 1.56
C09 Agents Acting on the Renin-Angiotensin System 973,422 7.28 19,382,914 6.76
C10 Lipid Modifying Agents 1,248,904 9.34 45,295,913 15.79
D Dermatologicals 442,876 3.31 9,199,328 3.21
D01 Antifungals for Dermatological Use 104,088 0.78 1,401,726 0.49
D02 Emollients and Protectives 27,833 0.21 90,140 0.03
D03 Preparations for Treatment of Wounds and Ulcers 428 0.00 60,858 0.02
D04 Antipruritics including Antihistamines, Anesthetics, etc. 588 0.00 35,397 0.01
D05 Antipsoriatics 46,827 0.35 3,813,304 1.33
D06 Antibiotics and Chemotherapeutics for Dermatological Use 35,747 0.27 533,248 0.19
D07 Corticosteroids Dermatological Preparations 166,717 1.25 975,390 0.34
D08 Antiseptics and Disinfectants 11 0.00 38 0.00
D10 Anti-Acne Preparations 48,280 0.36 1,539,238 0.54
D11 Other Dermatological Preparations 12,357 0.09 749,989 0.26
G Genito Urinary System and Sex Hormones 593,570 4.44 16,480,453 5.74
G01 Gynecological Anti-infectives and Antiseptics 6,136 0.05 36,147 0.01
G02 Other Gynecologicals 19,312 0.14 1,949,954 0.68
G03 Sex Hormones and Modulators of the Genital System 345,434 2.58 7,116,609 2.48
G04 Urologicals 222,688 1.67 7,377,743 2.57
Note:  The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.
Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 524,685 3.92 1,923,714 0.67
H01 Pituitary, Hypothalamic Hormones and Analogues 6,368 0.05 470,058 0.17
H02 Corticosteroids for Systemic Use 171,292 1.28 725,638 0.25
H03 Thyroid Therapy 346,784 2.59 719,965 0.25
H04 Pancreatic Hormones 186 0.00 5,679 0.00
H05 Calcium Homeostasis 55 0.00 2,374 0.00
J Anti-infectives for Systemic Use 723,985 5.42 10,441,739 3.64
J01 Antibacterials for Systemic Use 657,941 4.92 7,298,678 2.55
J02 Antimycotics for Systemic Use 35,829 0.27 699,435 0.24
J04 Antimycobacterials 2,450 0.02 85,040 0.03
J05 Antivirals for Systemic Use 27,760 0.21 2,358,548 0.82
J07 Vaccines 5 0.00 38 0.00
L Antineoplastic and Immunomodulating Agents 115,518 0.86 4,342,207 1.51
L01 Antineoplastic Agents 8,342 0.06 423,646 0.15
L02 Endocrine Therapy 32,279 0.24 2,845,698 0.99
L04 Immunosuppressive Agents 74,897 0.56 1,072,863 0.37
Note:  The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 953,952 7.13 17,299,093 6.03
M01 Anti-inflammatory and Antirheumatic Products 559,410 4.18 8,411,887 2.93
M02 Topical Products for Joint and Muscular Pain 98,786 0.74 780,695 0.27
M03 Muscle Relaxants 5,295 0.04 131,692 0.05
M04 Antigout Preparations 68,672 0.51 370,582 0.13
M05 Drugs for treatment of Bone Diseases 212,305 1.59 7,400,175 2.58
M09 Other Drugs for Disorders of the Musculo-Skeletal System 9,484 0.07 204,062 0.07
N Nervous System 2,002,641 14.97 47,020,936 16.39
N01 Anesthetics 3,074 0.02 671,318 0.23
N02 Analgesics 429,273 3.21 7,043,093 2.46
N03 Anti-epileptics 174,170 1.30 9,099,790 3.17
N04 Antiparkinson Drugs 24,207 0.18 963,804 0.34
N05 Psycholeptics 680,876 5.09 9,272,962 3.23
N06 Psychoanaleptics 631,896 4.73 17,633,721 6.15
N07 Other Nervous System Drugs 59,145 0.44 2,336,248 0.81
P Antiparasitic Products, Insecticides and Repellents 39,365 0.30 1,068,892 0.37
P01 Antiprotozoals 37,539 0.28 1,050,625 0.37
P02 Anthelmintics 795 0.01 6,480 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 1,031 0.01 11,787 0.00
Note:  The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.
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Table 20.1  DP: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 1,281,721 9.58 33,158,341 11.56
R01 Nasal Preparations 166,948 1.25 1,979,040 0.69
R02 Throat Preparations 2,825 0.02 6,109 0.00
R03 Drugs for Obstructive Airway Diseases 914,645 6.84 29,618,540 10.33
R05 Cough and Cold Preparations 51,593 0.38 224,557 0.08
R06 Antihistamines for Systemic Use 145,683 1.09 1,329,459 0.46
R07 Other Respiratory System Products 27 0.00 636 0.00
S Sensory Organs 261,519 1.96 2,767,866 0.97
S01 Ophthalmologicals 228,340 1.71 2,654,864 0.93
S02 Otologicals 11,397 0.09 61,522 0.02
S03 Ophthalmological and Otological Preparations 21,782 0.16 51,480 0.02
V Various 233,717 1.75 11,421,362 3.98
V01 Allergens 853 0.01 72,749 0.03
V03 Other Therapeutic Products 2,045 0.02 324,846 0.11
V04 Diagnostic Products 19,386 0.14 678,577 0.24
V06 Clinical Nutritional Products 117,317 0.88 5,119,221 1.78
V07 All Other Non-Therapeutic Products 94,116 0.70 5,225,969 1.82
        Ostomy Requisites 38,497 0.29 3,520,075 1.23
        Needles/Syringes/Lancets 22,325 0.17 131,383 0.05
        Dressings 8,896 0.06 226,846 0.08
        Urinary Requisites 9,937 0.07 1,219,839 0.42
        Miscellaneous 14,461 0.11 127,826 0.04
TOTAL 13,372,525 100.00% 286,851,897 100.00%
Note:  The above costs are inclusive of the monthly payment of €100 payable to the Pharmacy by an individual or family.
105
Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 740,528 25.93 23,252,100 27.59
A01 Stomatological Preparations 589 0.02 3,356 0.00
A02 Drugs for Acid Related Disorders 23,708 0.83 866,735 1.03
A03 Drugs for Functional Gastrointestinal Disorders 1,997 0.07 51,966 0.06
A04 Anti-emetics and Antinauseants 1,436 0.05 56,581 0.07
A05 Bile and Liver Therapy 923 0.03 48,719 0.06
A06 Laxatives 8,062 0.28 78,754 0.09
A07 Antidiarrheals, Intestinal Anti-inflammatory/ 
Anti-infective Agents
1,192 0.04 33,177 0.04
A08 Anti-obesity Preparations, excl. Diet Products 3,975 0.14 251,915 0.30
A09 Digestives, incl. Enzymes 7,896 0.28 867,294 1.03
A10 Drugs Used in Diabetes 668,001 23.40 20,214,746 23.99
A11 Vitamins 13,247 0.46 345,861 0.41
A12 Mineral Supplements 7,419 0.26 67,580 0.08
A13 Tonics 27 0.00 239 0.00
A14 Anabolic Agents for Systemic Use 1 0.00 284 0.00
A16 Other Alimentary Tract and Metabolism Products 2,055 0.07 364,893 0.43
B Blood and Blood Forming Organs 305,410 10.70 1,657,098 1.97
B01 Antithrombotic Agents 284,409 9.96 1,557,092 1.85
B02 Antihemorrhagics 1,063 0.04 13,536 0.02
B03 Anti-anemic Preparations 19,537 0.69 32,625 0.04
B05 Blood Substitutes and Perfusion Solutions 401 0.01 53,845 0.06
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Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
C Cardiovascular System 851,765 29.83 19,641,325 23.30
C01 Cardiac Therapy 12,221 0.43 138,225 0.16
C02 Antihypertensives 25,809 0.90 835,189 0.99
C03 Diuretics 45,970 1.61 206,678 0.24
C04 Peripheral Vasodilators 767 0.03 15,998 0.02
C05 Vasoprotectives 193 0.01 1,508 0.00
C07 Beta Blocking Agents 89,798 3.14 720,866 0.86
C08 Calcium Channel Blockers 77,979 2.73 1,106,558 1.31
C09 Agents Acting on the Renin-Angiotensin System 294,214 10.30 5,469,682 6.49
C10 Lipid Modifying Agents 304,814 10.68 11,146,621 13.23
D Dermatologicals 6,397 0.22 79,430 0.09
D01 Antifungals for Dermatological Use 2,298 0.08 25,274 0.03
D02 Emollients and Protectives 1,221 0.04 7,519 0.01
D03 Preparations for Treatment of Wounds and Ulcers 21 0.00 364 0.00
D04 Antipruritics, incl. Antihistamines, Anesthetics, etc. 80 0.00 2,019 0.00
D05 Antipsoriatics 292 0.01 23,586 0.03
D06 Antibiotics and Chemotherapeutics for Dermatological Use 365 0.01 3,751 0.00
D07 Corticosteroids, Dermatological Preparations 1,263 0.04 7,062 0.01
D08 Antiseptics and Disinfectants 438 0.02 2,930 0.00
D10 Anti-Acne Preparations 140 0.01 1,571 0.00
D11 Other Dermatological Preparations 279 0.01 5,354 0.01
G Genito Urinary System and Sex Hormones 33,446 1.17 1,079,176 1.28
G01 Gynecological Anti-infectives and Antiseptics 98 0.00 18,648 0.02
G02 Other Gynecologicals 93 0.00 6,622 0.01
G03 Sex Hormones and Modulators of the Genital System 2,215 0.08 44,721 0.05
G04 Urologicals 31,040 1.09 1,009,185 1.20
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Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl. Sex Hormones and Insulins 34,015 1.20 437,979 0.52
H01 Pituitary, Hypothalamic Hormones and Analogues 2,162 0.08 150,361 0.18
H02 Corticosteroids for Systemic Use 3,402 0.12 20,462 0.02
H03 Thyroid Therapy 20,828 0.73 47,322 0.06
H04 Pancreatic Hormones 7,606 0.27 218,679 0.26
H05 Calcium Homeostasis 17 0.00 1,155 0.00
J Anti-infectives for Systemic Use 19,046 0.67 1,160,726 1.38
J01 Antibacterials for Systemic Use 17,961 0.63 1,106,848 1.31
J02 Antimycotics for Systemic Use 647 0.02 28,419 0.03
J04 Antimycobacterials 103 0.01 3,565 0.01
J05 Antivirals for Systemic Use 319 0.01 21,735 0.03
J07 Vaccines 16 0.00 159 0.00
L Antineoplastic and Immunomodulating Agents 1,578 0.05 54,774 0.06
L01 Antineoplastic Agents 352 0.01 27,081 0.03
L02 Endocrine Therapy 82 0.00 8,176 0.01
L04 Immunosuppressive Agents 1,144 0.04 19,517 0.02
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 19,798 0.69 413,344 0.49
M01 Anti-inflammatory and Antirheumatic Products 5,751 0.20 77,796 0.09
M02 Topical Products for Joint and Muscular Pain 641 0.02 4,830 0.00
M03 Muscle Relaxants 6,322 0.22 207,493 0.25
M04 Antigout Preparations 3,712 0.13 22,220 0.03
M05 Drugs for treatment of Bone Diseases 2,732 0.10 94,359 0.11
M09 Other Drugs for Disorders of the Musculo-Skeletal System 640 0.02 6,646 0.01
N Nervous System 308,905 10.82 13,236,034 15.71
N01 Anesthetics 285 0.01 25,756 0.03
N02 Analgesics 10,017 0.35 109,124 0.13
N03 Anti-epileptics 229,761 8.05 8,991,184 10.67
N04 Antiparkinson Drugs 29,869 1.05 2,966,229 3.52
N05 Psycholeptics 20,585 0.72 453,011 0.54
N06 Psychoanaleptics 16,606 0.58 586,989 0.70
N07 Other Nervous System Drugs 1,782 0.06 103,741 0.12
P Antiparasitic Products, Insecticides and Repellents 126 0.00 1,377 0.00
P01 Antiprotozoals 118 0.00 1,280 0.00
P02 Anthelmintics 4 0.00 48 0.00
P03 Ectoparasiticides, incl. Scabicides, Insecticides and Repellents 4 0.00 49 0.00
Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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Table 20.2  LTI: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
R Respiratory System 16,074 0.56 443,749 0.53
R01 Nasal Preparations 1,569 0.05 19,107 0.03
R02 Throat Preparations 40 0.00 273 0.00
R03 Drugs for Obstructive Airway Diseases 11,583 0.41 363,755 0.43
R05 Cough and Cold Preparations 1,088 0.04 41,588 0.05
R06 Antihistamines for Systemic Use 1,794 0.06 19,026 0.02
S Sensory Organs 9,568 0.34 154,189 0.18
S01 Ophthalmologicals 9,307 0.33 153,297 0.18
S02 Otologicals 89 0.00 451 0.00
S03 Ophthalmological and Otological Preparations 172 0.01 441 0.00
V Various 508,705 17.82 22,668,344 26.90
V03 Other Therapeutic Products 363 0.01 60,599 0.07
V04 Diagnostic Products 289,993 10.16 13,137,046 15.59
V06 Clinical Nutritional Products 34,323 1.20 4,287,817 5.09
V07 All Other Non-Therapeutic Products 184,026 6.45 5,182,882 6.15
        Needles/Syringes/Lancets/Swabs 158,723 5.56 3,678,601 4.36
        Urinary Requisites 6,850 0.24 790,351 0.94
        Dressings 2,107 0.08 115,545 0.14
        Nutritional/Ancilliary Devices 2,230 0.08 329,525 0.39
        Ostomy Requisites 1,236 0.04 115,441 0.14
        Miscellaneous 12,880 0.45 153,419 0.18
TOTAL 2,855,361 100.00% €84,279,645 100.00%
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Table 20.3  HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification
ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
A Alimentary Tract and Metabolism 1,177 0.32 218,333 0.08
A07A Intestinal Anti-infectives 273 0.08 55,814 0.02
AIICC Vitamin D and Analogues 897 0.24 155,960 0.06
A16AX Other Alimentary Tract and Metabolism Products 7 0.00 6,559 0.00
B Blood and Blood Forming Organs 35,295 9.55 19,969,722 7.14
B01 Antithrombotic Agents 151 0.04 814,083 0.29
B03 Anti-anemic Preparations 35,144 9.51 19,155,639 6.85
C Cardiovascular System 4,481 1.21 8,189,098 2.93
C02 Antihypertensives 4,481 1.21 8,189,098 2.93
D Dermatologicals 4 0.00 1,955 0.00
D03A Cicatrizants 4 0.00 1,955 0.00
G Genito Urinary System and Sex Hormones 11,266 3.05 6,716,327 2.40
G03GA Gonadotropins 11,266 3.05 6,716,327 2.40
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient 
Cost €
% of Scheme 
Total
H Systemic Hormonal Preparations, Excl.Sex Hormones and Insulins 31,704 8.58 18,882,273 6.75
H01 Pituitary and Hypothalamic Hormones and Analogues 14,463 3.91 11,775,074 4.21
H05 Calcium Homeostasis 17,241 4.67 7,107,199 2.54
J Anti-infectives for Systemic Use 13,568 3.67 16,696,567 5.98
J01 Antibacterials for Systemic Use 2,950 0.80 6,442,796 2.31
J02 Antimycotics for Systemic Use 1,203 0.32 2,708,931 0.97
J05 Antivirals for Systemic Use 6,163 1.67 4,109,030 1.47
J06 Immune Sera and Immunoglobulins 3,252 0.88 3,435,810 1.23
L Antineoplastic and Immunomodulating Agents 263,555 71.29 202,836,203 72.54
L01 Antineoplastic Agents 17,074 4.62 23,883,907 8.54
L02 Endocrine Therapy 57,109 15.45 15,513,034 5.55
L03 Immunostimulants 47,149 12.75 52,764,673 18.87
L04 Immunosuppressive Agents 142,223 38.47 110,674,589 39.58
Note:  Based on the data available from claims submitted, the ingredient cost shown is the gross cost before discount.
Table 20.3  HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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ATC 
Class
Product Category Prescribing 
Frequency
% of Scheme 
Total
Ingredient Cost 
€
% of Scheme 
Total
M Musculo-Skeletal System 1,374 0.37 360,983 0.13
M05 Drugs for treatment of Bone Diseases 1,374 0.37 360,983 0.13
N Nervous System 2,036 0.55 690,322 0.25
N07XX Other Nervous System Drugs 2,036 0.55 690,322 0.25
R Respiratory System 4,437 1.20 4,286,257 1.53
R05CB Mucolytics (Inhaled) 4,437 1.20 4,286,257 1.53
V Various 777 0.21 764,991 0.27
V03AC Iron Chelating Agents 777 0.21 764,991 0.27
TOTAL 369,674 100.00% €279,613,031 100.00%
Note:  Based on the data available from the claims submitted, the ingredient cost shown is the gross cost before discount.
Table 20.3  HTD: Distribution of Medicines and Appliances by Anatomical Therapeutic Chemical Classification continued
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Health Service 
Executive
Average Panel Ranges in 2009
0-100 101-250 251-500 501-1,000 1,001-1,500 1,501-2,000 2,001 and 
Over
€ € € € € € €
East Coast Area 15,279 (77) 85,593 (31) 157,384 (51) 234,237 (60) 361,501 (11) - -
South Western Area 15,478 (63) 63,515 (23) 121,898 (36) 227,180 (95) 328,271 (46) 425,877 (21) 483,482 (3)
Northern Area 16,066 (56) 65,371 (22) 122,413 (42) 239,768 (68) 346,588 (45) 459,716 (11) 532,054 (3)
Midland 23,735 (21) 76,830 (3) 109,937 (14) 252,787 (44) 364,918 (34) 448,608 (12) -
Mid-Western 22,823 (35) 57,632 (6) 132,646 (36) 245,785 (81) 338,927 (32) 472,387 (12) 457,692 (1)
North Eastern 6,198 (15) 41,519 (7) 142,990 (16) 220,634 (69) 305,788 (51) 411,289 (11) 467,314 (3)
North Western 6,813 (11) 66,783 (7) 140,139 (21) 227,026 (49) 361,607 (39) 452,381 (15) 582,575 (3)
South Eastern 5,770 (25) 65,410 (8) 117,993 (22) 225,532 (119) 338,593 (56) 460,045 (19) 482,765 (1)
Southern 16,632 (72) 61,304 (49) 134,834 (61) 242,880 (155) 382,304 (63) 450,553 (10) 639,191 (3)
Western 11,961 (38) 62,857 (13) 135,449 (42) 255,667 (106) 364,080 (51) 512,633 (9) 509,750 (1)
National 2009 €15,285 (413) €66,456 (169) €133,757 (341) €237,477 (846) €348,688 (428) €451,852 (120) €531,336 (18)
National 2008 €20,917 (235) €74,466 (173) €145,290 (367) €246,041 (846) €351,858 (375) €465,472 (82) €530,293 (7)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) The number of Doctors in each range is shown in brackets.
 (iii) The average payment to Doctors in each panel range is the gross payments divided by the number of Doctors in that range.
 (iv) Doctors payment is exclusive of superannuation paid to retired DMOs.
Table 21  GMS: Average Payment to Doctors in Panel Ranges
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Table 21.1  GMS: Number of Doctors in Payment Ranges
2009 (2008 in brackets)
Health 
Service 
Executive
Up to 
€30,000
€30,001-
€60,000
€60,001-
€90,000
€90,001-
€120,000
€120,001-
€150,000
€150,001-
€180,000
€180,001-
€210,000
€210,001-
€240,000
€240,001-
€270,000
€270,001-
€370,000
€370,001-
€470,000
€470,001 
and Over
East Coast 
Area 24 (17) 15 (9) 19 (14) 20 (22) 19 (9) 16 (21) 11 (19) 21 (14) 17 (8) 18 (36) 2 (8) 1 (2)
South Western 
Area 21 (29) 21 (18) 16 (19) 13 (20) 25 (17) 18 (20) 22 (18) 17 (12) 20 (19) 47 (48) 20 (25) 5 (8)
Northern Area 21 (28) 11 (8) 21 (23) 14 (12) 11 (12) 17 (21) 15 (13) 18 (13) 22 (13) 40 (41) 13 (21) 6 (11)
Midland 9 (15) 3 (6) 5 (7) 8 (2) 4 (4) 5 (8) 6 (6) 13 (10) 12 (11) 35 (32) 13 (21) 4 (3)
Mid-Western 17 (21) 7 (5) 6 (7) 11 (11) 15 (12) 16 (13) 16 (15) 22 (24) 18 (18) 37 (34) 17 (18) 4 (6)
North Eastern 9 (4) 3 (5) 8 (7) 5 (6) 14 (15) 10 (7) 18 (18) 16 (17) 17 (16) 47 (41) 13 (10) 2 (4)
North 
Western 5 (6) 4 (2) 5 (5) 8 (6) 11 (8) 7 (6) 11 (15) 13 (11) 13 (11) 31 (38) 23 (19) 7 (6)
South Eastern 9 (8) 4 (3) 8 (13) 12 (10) 10 (8) 19 (24) 28 (29) 30 (22) 19 (24) 66 (63) 15 (15) 10 (8)
Southern 33 (45) 30 (32) 30 (28) 24 (21) 22 (19) 27 (28) 28 (23) 38 (34) 35 (34) 63 (75) 33 (28) 9 (11)
Western 20 (19) 8 (13) 14 (13) 17 (10) 15 (20) 15 (16) 19 (15) 24 (18) 21 (20) 53 (59) 24 (25) 9 (10)
National 168 (192) 106 (101) 132 (136) 132 (120) 146 (124) 150 (164) 174 (171) 212 (175) 194 (174) 437 (467) 173 (190) 57 (69)
Note: (i) Doctors not in the GMS Scheme for the full year have been excluded from the above table.
 (ii) Above table relates to the payments listed in Table 3.
 (iii) Doctors payment is exclusive of superannuation paid to retired DMOs.
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Table 22  GMS: Number of Pharmacists in Dispensing Fee Ranges
2009 (2008 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast 
Area 6 (9) 5 (7) 12 (13) 16 (17) 15 (14) 20 (13) 8 (11) 15 (10) 7 (7) 5 (5) 7 (2) 6 (4) 10 (12)
South Western 
Area 5 (17) 13 (21) 20 (16) 15 (16) 22 (24) 17 (16) 17 (19) 15 (8) 8 (12) 18 (9) 7 (11) 7 (6) 36 (25)
Northern Area 6 (6) 9 (18) 17 (12) 17 (19) 16 (15) 13 (13) 15 (12) 18 (14) 12 (13) 8 (5) 6 (4) 7 (7) 38 (30)
Midland - (2) 1 (4) 4 (6) 5 (4) 7 (7) 7 (9) 4 (3) 6 (6) 12 (11) 6 (8) 9 (4) 4 (6) 27 (19)
Mid-Western 2 (3) 5 (9) 12 (15) 9 (4) 5 (15) 12 (16) 14 (16) 14 (10) 11 (11) 10 (7) 10 (10) 13 (9) 25 (20)
North Eastern 3 (8) 8 (13) 11 (8) 11 (9) 7 (11) 15 (16) 14 (14) 13 (17) 14 (10) 11 (5) 8 (8) 4 (1) 26 (19)
North 
Western - (4) 5 (5) 4 (2) 3 (9) 6 (6) 11 (9) 8 (10) 6 (6) 9 (9) 6 (6) 9 (3) 2 (2) 21 (17)
South Eastern 2 (4) 2 (7) 8 (10) 7 (3) 4 (17) 18 (18) 17 (14) 15 (12) 10 (14) 15 (9) 11 (11) 16 (11) 45 (35)
Southern 4 (7) 10 (10) 11 (12) 16 (25) 19 (18) 22 (19) 20 (23) 27 (21) 15 (27) 29 (7) 8 (9) 10 (10) 46 (32)
Western 2 (4) 4 (6) 13 (13) 10 (13) 12 (13) 12 (16) 15 (11) 12 (11) 13 (9) 7 (9) 9 (9) 11 (5) 38 (34)
National 30 (64) 62 (100) 112 (107) 109 (119) 113 (140) 147 (145) 132 (133) 141 (115) 111 (123) 115 (70) 84 (71) 80 (61) 312 (243)
Note:  Pharmacies that entered or left the Scheme during the year are not included in the above table.
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Table 23  DP: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Health Service 
Executive
*Number 
of Persons 
Covered
Unique 
Number of 
Claimants
Number of 
Items
Cost per Item
€
Gross Cost
€
Net Cost per 
Claimant
€
Paid by HSE
€
Eastern Areas 539,188 243,837 5,294,426 34.43 182,280,180 442.50 107,898,970
Midland 101,708 42,258 846,125 32.73 27,689,784 377.56 15,954,793
Mid-Western 159,029 57,404 1,080,867 33.00 35,665,144 349.58 20,067,259
North Eastern 147,811 60,618 1,172,765 32.86 38,537,405 358.62 21,739,038
North Western 63,000 24,967 461,296 33.64 15,520,255 349.37 8,722,729
South Eastern 149,983 69,556 1,421,492 32.21 45,785,782 364.80 25,373,805
Southern 266,122 104,524 2,038,348 34.44 70,198,945 383.07 40,040,494
Western 160,607 59,963 1,057,206 34.08 36,029,819 335.73 20,131,101
National 2009 1,587,448 663,127 13,372,525 €33.78 €451,707,314 €391.97 €259,928,189
National 2008 1,624,413 687,587 13,907,438 €36.44 €506,805,684 €453.61 €311,898,446
Note:  * As at 31st December 2009
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Table 23.1  DP: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
2009 (2008 in brackets)
Health 
Service 
Executive
Up to 
€20,000
€20,001-
€40,000
€40,001-
€60,000
€60,001-
€80,000
€80,001-
€100,000
€100,001-
€120,000
€120,001-
€140,000
€140,001-
€160,000
€160,001-
€180,000
€180,001-
€200,000
€200,001-
€220,000
€220,001-
€240,000
€240,001 
and over
East Coast Area 14 (14) 34 (19) 21 (23) 23 (19) 15 (13) 8 (13) 6 (6) 3 (7) 6 (2) - (2) 2 (2) 1 (3) - (4)
South Western 
Area 27 (19) 47 (44) 37 (23) 25 (29) 13 (17) 15 (15) 16 (10) 10 (8) 3 (7) 1 (10) 2 (7) 1 (3) 3 (8)
Northern Area 29 (21) 42 (26) 33 (21) 11 (21) 23 (14) 16 (12) 5 (11) 5 (16) 6 (6) 5 (1) 1 (8) 1 (3) 5 (10)
Midland 11 (6) 25 (17) 23 (15) 13 (18) 4 (8) 8 (5) 4 (9) 2 (3) 2 (2) - (3) - (1) - - (2)
Mid-Western 24 (20) 47 (28) 36 (32) 19 (23) 7 (17) 4 (10) 2 (5) 2 (4) 1 (1) - (3) - (1) - (1) -
North Eastern 30 (20) 45 (26) 26 (29) 13 (20) 10 (12) 9 (9) 7 (5) 5 (6) - (5) - (3) - (4) - - (1)
North Western 33 (21) 30 (26) 18 (14) 3 (14) 4 (4) 1 (3) - (2) 1 (1) - - - (1) - -
South Eastern 35 (22) 42 (28) 42 (31) 24 (26) 15 (21) 5 (16) 5 (5) 1 (6) - (6) - (2) - 1 (-) - (2)
Southern 28 (16) 66 (39) 58 (45) 40 (36) 17 (34) 11 (17) 7 (7) 3 (6) 3 (7) 3 (3) - (3) - (2) 1 (6)
Western 44 (24) 43 (41) 33 (26) 18 (22) 11 (15) 6 (10) 3 (7) - (5) - (3) - - (1) - -
National 275 (183) 421 (294) 327 (259) 189 (228) 119 (155) 83 (110) 55 (67) 32 (62) 21 (39) 9 (25) 5 (28) 4 (12) 9 (33)
Note: (i) Pharmacies that entered or left the Scheme during the year are not included in the above table.
 (ii) The above figures do not include the monthly co-payment of €100 paid by an individual or family to the Pharmacist.
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Table 24  LTI: Number of Eligible Persons and Number and Cost of Pharmacists Claims
Health Service Executive *Number of 
Eligible Persons
Unique 
Number of 
Claimants
Number of 
Items
Cost per Item
€
Total Cost
€
Cost per 
Claimant
€
Eastern Areas 63,906 27,154 1,211,460 50.29 60,923,738 2,243.64
Midland 7,453 3,981 172,423 46.42 8,003,509 2,010.43
Mid-Western 8,647 4,640 188,257 45.73 8,608,387 1,855.26
North Eastern 10,241 5,956 265,117 48.84 12,947,603 2,173.88
North Western 7,207 4,065 184,643 48.71 8,994,083 2,212.57
South Eastern 13,602 7,014 313,172 45.26 14,174,555 2,020.89
Southern 9,259 7,891 328,991 50.39 16,577,276 2,100.78
Western 7,321 5,030 191,298 49.82 9,530,021 1,894.64
National 2009 127,636 65,731 2,855,361 €48.95 €139,759,172 €2,126.23
National 2008 120,407 62,934 2,643,424 €52.17 €137,898,995 €2,191.17
Note:  * As at 31st December 2009
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Table 24.1  LTI: Number of Pharmacists in Dispensing Fee/Mark-Up Ranges
2009 (2008 in brackets)
Health Service Executive Up to €10,000
€10,001 - 
€20,000
€20,001 - 
€30,000
€30,001 - 
€40,000
€40,001 - 
€50,000
€50,001 - 
€60,000
€60,001 and 
over
East Coast Area 12 (16) 28 (20) 31 (21) 17 (20) 12 (12) 10 (11) 23 (26)
South Western Area 19 (26) 40 (31) 47 (41) 23 (24) 17 (15) 20 (15) 34 (47)
Northern Area 23 (13) 36 (32) 29 (28) 29 (20) 16 (18) 20 (17) 29 (40)
Midland 15 (14) 27 (21) 15 (18) 15 (14) 9 (7) 5 (4) 6 (11)
Mid-Western 42 (37) 46 (39) 37 (38) 7 (15) 5 (4) 2 (6) 3 (6)
North Eastern 31 (30) 33 (24) 32 (34) 12 (16) 15 (11) 5 (9) 17 (15)
North Western 18 (19) 16 (14) 19 (13) 11 (16) 7 (5) 11 (8) 8 (11)
South Eastern 40 (34) 33 (25) 35 (34) 34 (31) 13 (20) 9 (9) 6 (12)
Southern 51 (41) 77 (70) 54 (45) 31 (36) 10 (9) 10 (6) 4 (11)
Western 52 (45) 50 (47) 25 (25) 22 (17) 5 (10) 2 (6) 2 (3)
National 303 (275) 386 (323) 324 (297) 201 (209) 109 (111) 94 (91) 132 (182)
Note:  Pharmacies that entered or left the Scheme during the year are not included in the above table.
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Table 25  EEA: Number and Cost of Pharmacists Claims
Health Service Executive Number of Items Cost per Item €
Total Cost 
€
East Coast Area 3,069 23.49 72,098
South Western Area 5,111 21.98 112,322
Northern Area 3,509 20.92 73,396
Midland 4,609 23.00 106,003
Mid-Western 10,139 22.87 231,847
North Eastern 5,407 25.72 139,049
North Western 10,878 22.29 242,507
South Eastern 8,732 22.90 199,920
Southern 19,539 22.20 433,731
Western 14,527 23.87 346,740
National 2009 85,520 €22.89 €1,957,613
National 2008 91,822 €24.46 €2,245,995
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Table 26  DTS: Number of Treatments
Health Service Executive Above the Line Below the Line Total
Eastern Areas 402,760 29,986 432,746
Midland 89,879 10,060 99,939
Mid-Western 119,984 15,466 135,450
North Eastern 127,435 14,711 142,146
North Western 84,965 6,108 91,073
South Eastern 177,103 23,680 200,783
Southern 258,768 24,635 283,403
Western 178,537 20,521 199,058
National 2009 1,439,431 145,167 1,584,598
National 2008 1,084,517 111,428 1,195,945
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Table 26.1  DTS: Number of Dentists in Payment Ranges
2009 (2008 in brackets)
Health 
Service 
Executive
Up to 
€10,000
€10,001-
€20,000
€20,001-
€30,000
€30,001-
€40,000
€40,001-
€50,000
€50,001-
€60,000
€60,001-
€70,000
€70,001-
€80,000
€80,001-
€90,000
€90,001-
€100,000
€100,001-
€110,000
€110,001-
€120,000
€120,001 
and over
Eastern Areas 14 (15) 17 (22) 23 (17) 16 (16) 21 (21) 10 (7) 20 (12) 7 (12) 14 (14) 12 (16) 19 (6) 10 (3) 51 (40)
Midland 6 (1) - (1) 2 (4) - (1) 3 (2) 1 (2) 3 (5) - (6) 3 (3) 4 (2) 2 (3) 6 (2) 19 (12)
Mid-Western 8 (8) 6 (9) 8 (8) 8 (8) 6 (8) 10 (6) 3 (7) 7 (7) 7 (2) 4 (5) 6 (2) 2 (3) 18 (13)
North Eastern - (4) 3 (6) 3 (5) - (2) 6 (8) 3 (4) 4 (3) 7 (3) 10 (9) 5 (2) 1 (3) 3 (1) 21 (14)
North Western 4 (3) 2 (1) 1 (1) 1 (2) - 1 (1) 3 (1) 1 (-) 2 (4) 2 (2) 1 (4) - (1) 17 (7)
South Eastern 6 (5) 1 (2) 1 (3) 4 (6) 3 (6) 9 (6) 5 (5) 8 (4) 2 (2) 5 (4) 5 (3) 3 (8) 36 (23)
Southern 18 (19) 21 (24) 30 (29) 24 (25) 17 (19) 15 (16) 19 (21) 17 (13) 17 (11) 10 (10) 13 (5) 7 (5) 26 (17)
Western 22 (14) 7 (6) 3 (5) 7 (7) 4 (2) 8 (8) 3 (3) 6 (7) 8 (4) 4 (3) 5 (4) 4 (7) 41 (22)
National 78 (69) 57 (71) 71 (72) 60 (67) 60 (66) 57 (50) 60 (57) 53 (52) 63 (49) 46 (44) 52 (30) 35 (30) 229 (148)
Note:  Dentists who entered or left the Scheme during the year are not included in the above table.
123
Health Service Executive Number of Treatments Cost of Claims€
Eastern Areas 152,370 6,204,743
Midland 40,553 1,647,247
Mid-Western 54,305 2,111,555
North Eastern 40,353 1,553,308
North Western 44,020 1,638,602
South Eastern 85,279 3,247,259
Southern 87,626 3,464,502
Western 60,100 2,317,325
National 2009 564,606 €22,184,541
National 2008 530,282 €20,997,766
Note:  Optometrists/Ophthalmologists were also paid in respect of: Health (Amendment) Act 1996 €72,238; Optical services for Teenagers €195,744; Optical services for Children €1,348,185.
Table 27  HSE-COS: Number of Treatments and Cost of Claims
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Table 27.1  HSE-COS: Number of Optometrists/Ophthalmologists in Payment Ranges
2009 (2008 in brackets)
Health 
Service 
Executive
Up to 
€10,000
€10,001-
€20,000
€20,001-
€30,000
€30,001-
€40,000
€40,001-
€50,000
€50,001-
€60,000
€60,001-
€70,000
€70,001-
€80,000
€80,001-
€90,000
€90,001-
€100,000
€100,001-
€110,000
€110,001-
€120,000
€120,001 
and over
Eastern Areas 52 (48) 29 (28) 17 (20) 12 (13) 6 (6) 3 (5) 7 (4) - (1) 1 (1) 1 (-) 2 (3) - (2) 7 (5)
Midland 9 (12) 5 (2) 2 (3) 2 (5) 7 (6) 1 (2) 2 (1) 1 (-) - (1) - - 1 (-) 1 (1)
Mid-Western 11 (10) 6 (3) 6 (7) 2 (2) 2 (4) 1 (1) 2 (1) - 1 (-) - - - 3 (3)
North Eastern 22 (19) 12 (10) 4 (6) 3 (2) 2 (3) 2 (2) - - (1) 2 (1) - - - -
North Western 6 (5) 4 (6) 5 (3) 1 (4) 5 (5) 3 (3) 1 (2) - 1 (-) - - - 1 (1)
South Eastern 13 (14) 12 (11) 5 (5) 3 (4) 4 (-) 2 (6) 3 (1) 2 (4) 3 (2) 2 (2) - (1) 1 (-) 4 (2)
Southern 11 (13) 16 (19) 11 (9) 3 (6) 7 (6) 5 (4) - (4) 2 (-) - - 1 (-) - 3 (3)
Western 11 (11) 10 (16) 15 (8) 9 (12) 4 (-) - - - - - 1 (-) - 1 (2)
National 135 (132) 94 (95) 65 (61) 35 (48) 37 (30) 17 (23) 15 (13) 5 (6) 8 (5) 3 (2) 4 (4) 2 (2) 20 (17)
Note:  Optometrists/Ophthalmologists who entered or left the Scheme during the year are not included in the above table.
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Health Service Executive 2009
€
2008
€
Eastern Areas 1,285,694 1,816,863
Midland 71,214 303,491
Mid-Western 191,193 347,771
North Eastern 110,980 372,795
*North Western - -
South Eastern 209,684 262,712
Southern 247,531 394,323
Western 767,437 1,127,692
National €2,883,733 €4,625,647
Note: The above are payments from the Indicative Drug Target Savings.
 * No funds available to draw down in 2009.
Table 28  GMS: Investment in General Practice Development

